carbidopa has been researched along with Parkinson Disease in 1262 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 383 (30.35) | 18.7374 |
| 1990's | 235 (18.62) | 18.2507 |
| 2000's | 133 (10.54) | 29.6817 |
| 2010's | 360 (28.53) | 24.3611 |
| 2020's | 151 (11.97) | 2.80 |
| Authors | Studies |
|---|---|
| Adar, L; Arkadir, D; Case, R; Ebersbach, G; Ellenbogen, AL; Espay, AJ; Fuchs Orenbach, S; Giladi, N; Isaacson, SH; Kieburtz, K; LeWitt, P; Olanow, CW; Oren, S; Poewe, W; Rosenfeld, O; Sasson, N; Simuni, T; Stocchi, F; Thomas, A; Yardeni, T; Zlotogorski, A | 1 |
| Ando, R; Hosokawa, Y; Miyaue, N; Nagai, M; Tada, S; Yabe, H; Yamanishi, Y; Yoshida, A | 1 |
| Adar, L; Caraco, Y; Case, R; Djaldetti, R; Giladi, N; Gurevich, T; Leibman-Barak, S; Sasson, N | 1 |
| Eerola-Rautio, J; Koivu, M; Pauls, KAM; Pekkonen, E; Toppila, J; Udd, M | 1 |
| Emanuele, R; Lettieri, M; Minunni, M; Palladino, P; Scarano, S | 1 |
| Bergman, H; Deffains, M; Eitan, R; Fonar, G; Iskhakova, L; Israel, Z; Marmor, O; Paz, R; Rappel, P | 1 |
| Aldred, J; Anca-Herschkovitsch, M; Bergmann, L; Bourgeois, P; Chaudhuri, KR; Cubo, E; Davis, TL; Gao, T; Iansek, R; Kovács, N; Kukreja, P; Pontieri, FE; Siddiqui, MS; Simu, M; Standaert, DG | 1 |
| Bullock, A; El Aidy, S; van Dijk, G; van Kessel, SP | 1 |
| Cubo, E; Miranda, J | 1 |
| Baviera-Muñoz, R; Campins-Romeu, M; Losada-López, M; Martínez-Torres, I; Morata-Martínez, C; Pérez-García, J; Pons-Beltrán, V; Sastre-Bataller, I | 1 |
| Habet, S | 1 |
| Alobaidi, A; Bao, Y; Chaudhuri, KR; Jalundhwala, YJ; Jones, G; Kandukuri, PL; Madin-Warburton, M; Najle-Rahim, S; Oddsdottir, J; Pickard, AS; Ridley, C; Schrag, A; Sus, J; Xu, W | 1 |
| Facheris, MF; Liu, W; Rosebraugh, M; Stodtmann, S | 1 |
| Buskens, E; Moes, HR; van Laar, T | 1 |
| Bianchini, E; Ceriello, F; De Carolis, L; Pontieri, FE; Rinaldi, D | 1 |
| Flisar, D; Kojović, M; Kolmančič, K; Kramberger, MG; Pirtošek, Z; Trošt, M; Zupančič, NK | 1 |
| Baba, Y; Futamura, A; Kinno, R; Nabeshima, Y; Nomoto, S; Osakabe, Y; Shoji, D; Takahashi, S; Yasumoto, T | 1 |
| García-Cano Lizcano, J; Gil Rojas, S; González Martínez, F; López Moreno, MB; Martínez Blanco, P; Olcina Domínguez, P | 1 |
| Baviera-Muñoz, R; Buigues-Lafuente, A; Campins-Romeu, M; Garcés-Sánchez, M; Martinez-Torres, I | 1 |
| Müller, T; Schlegel, E; Thiede, HM; Zingler, S | 1 |
| Ando, M; Hatano, T; Hattori, N; Honda, T; Komatsu, N; Tsutsui, M; Yasuda, H | 1 |
| Alobaidi, A; Bergmann, L; Elibol, B; Fasano, A; Fung, VSC; Onuk, K; Parra, JC; Pirtosek, Z; Seppi, K; Takáts, A | 1 |
| Fernandez, HH; Liao, J; Mata, IF; Salles, PA; Shuaib, U | 1 |
| Artusi, CA; Imbalzano, G; Ledda, C; Lopiano, L; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M | 1 |
| Bahroo, L; Di Maria, G; Jankovic, J; Lamotte, G; Lenka, A | 1 |
| Kubo, M; Miyaue, N; Nagai, M | 1 |
| Jiang, R; Mei, S; Yang, J; Zhao, Z | 1 |
| Blaise, AS; Carrière, N; Cuvelier, E; Defebvre, L; Devos, D; Moreau, F; Mutez, E | 1 |
| Gažová, A; Košutzká, Z; Minár, M; Stanková, S; Straka, I | 1 |
| Lezzi, P; Lezzi, T; Lupo, R; Vitale, E | 1 |
| Antonini, A; Biundo, R; Calandrella, D; Carecchio, M; Carrer, T; Del Sorbo, F; Farinati, F; Garrì, F; Mainardi, M; Pezzoli, G; Pistonesi, F; Russo, FP; Sandre, M; Savarino, E; Soliveri, P; Weis, L; Zecchinelli, AL | 1 |
| Baróti, B; Constantin, V; Forró, T; Frigy, A; Kelemen, K; Metz, J; Mihály, I; Orbán-Kis, K; Szász, JA; Szász, RM; Szatmári, S; Török, Á | 1 |
| Kramberger, MG; Križnar, NZ; Ocepek, L; Pirtošek, Z; Premzl, M; Rajnar, R; Rus, T; Trošt, M | 1 |
| Bloem, BR; Boel, JA; de Bie, RMA; de Haan, RJ; Dijkgraaf, MGW; Munts, A; Post, B; Suwijn, SR; Tissingh, G; van Hilten, JJ; van Laar, T; Verschuur, CVM | 1 |
| Boleková, V; Gmitterová, K; Košutzká, Z; Matejička, P; Minár, M; Valkovič, P | 1 |
| Alobaidi, A; Antonini, A; Bergmann, L; Chaudhuri, KR; Hegde, S; Odin, P; Pahwa, R; Parra, JC; Snedecor, SJ; Standaert, DG; Thakkar, S; Titova, N; Zadikoff, C | 1 |
| Bergmann, L; Fasano, A; Femia, S; Gurevich, T; Kovács, N; Parra, JC; Sanchez-Soliño, O; Svenningsson, P; Szász, J; Vela-Desojo, L | 1 |
| Antonini, A; Ferreira, JJ; Guimarães, B; Moreira, J; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P; Stocchi, F | 1 |
| An, X; Bhutia, YD; Chen, H; Chen, R; Chen, Z; Chu, M; Ganapathy, V; Huang, H; Kim, K; Kou, L; Sun, M; Xia, X; Yao, Q; Zhang, H | 1 |
| Arlt, C; Ebersbach, G; Eggert, K; Fritz, B; Möller, JC; Schwarz, J; Sensken, SC; Weiss, D | 1 |
| Amato, F; Artusi, CA; Calandra-Buonaura, G; Contin, M; Cortelli, P; Giannini, G; Imbalzano, G; Ledda, C; Lopiano, L; Olmo, G; Rinaldi, D; Romagnolo, A; Sambati, L; Zibetti, M | 1 |
| Liu, X; Ming, D; Moussian, B; Pang, M; Peng, R; Su, Y; Wang, P; Wang, Y; Zhu, Y | 1 |
| Adekunle, AO; Alananzeh, WA; Amali, MO; Ayipo, YO; Badeggi, UM; Lawal, BA; Mordi, MN | 1 |
| Aballéa, S; Bebrysz, M; Fujimura, K; Fujioka, S; Migita, H; Mishima, T; Nomoto, M; Tsuboi, Y; Yamaguchi, J; Yamazaki, T | 1 |
| Boura, I; Chaudhuri, KR; Espay, AJ; Jenner, P; Leta, V; Odin, P; Rota, S; Urso, D; van Wamelen, DJ | 1 |
| Bloem, BR; Boel, JA; de Bie, RMA; de Haan, RJ; Deuschl, G; Dijk, JM; Dijkgraaf, MGW; Frequin, HL; Lang, A; Munts, AG; Post, B; Schouten, J; Suwijn, SR; Tissingh, G; van Hilten, JJ; van Laar, T; Verschuur, CVM | 1 |
| Ellmén, J; Kuoppamäki, M; Rouru, J; Sjöstedt, N; Tuunainen, J; Vahteristo, M; Yliperttula, M | 1 |
| Belotti, LMB; Calandra-Buonaura, G; Contin, M; Cortelli, P; Galletti, M; Lopane, G | 1 |
| Fox, SH | 1 |
| Aldred, J; Budur, K; Facheris, MF; Fisseha, N; Fung, VS; Hauser, RA; Jeong, A; Kimber, TE; Klos, K; Litvan, I; O'Neill, D; Robieson, WZ; Soileau, MJ; Spindler, MA; Standaert, DG; Talapala, S; Vaou, EO; Zheng, H | 1 |
| Alobaidi, A; Antonini, A; Bao, Y; Bergmann, L; Chaudhuri, KR; Isaacson, SH; Kandukuri, PL; Merola, A; Odin, P; Pahwa, R; Parra, JC; Wang, L; Yan, CH; Zadikoff, C | 1 |
| Antonoglou, A; Bougea, A; Efthymiopoulou, E; Loupo, B | 1 |
| Baló, B; Botz, K; Györfi, B; Jost, WH | 1 |
| Dulski, J; Piekarski, R; Roszmann, A; Sławek, J | 2 |
| Belozertseva, IV; Dorotenko, A; Efimova, EV; Fesenko, Z; Gainetdinov, RR; Mor, MS; Savchenko, A; Sotnikova, TD; Sukhanov, I | 1 |
| Bergmann, L; Fasano, A; García-Ramos, R; Gurevich, T; Jech, R; Parra, JC; Sanchez-Soliño, O; Simu, M | 1 |
| Duckworth-Mothes, B; Grund, KE; Jost, WH; Zipfel, A | 1 |
| Disilvestro, I; Donzuso, G; Mostile, G; Nicoletti, A; Sciacca, G; Zappia, M | 1 |
| Artusi, CA; Bianchini, E; De Carolis, L; Galli, S; Imbalzano, G; Ledda, C; Lopiano, L; Pontieri, FE; Rinaldi, D; Zibetti, M | 1 |
| Contreras Chicote, A; Grandas Perez, F; Mas Serrano, M; Velilla Alonso, G | 1 |
| Fanciulli, A; Galli, S; Pontieri, FE; Rinaldi, D | 1 |
| Danoudis, M; Iansek, R; Paul, E; Sung, CB | 1 |
| Bauer, MP; Chernova, VO; Contarino, MF; Keller, JJ; Kuijper, EJ; Terveer, EM; van der Meulen-de Jong, AE; van Hilten, JJ; van Prehn, J | 1 |
| Bonno, D; Bouchard, M; Canissario, R; Déry, C; Dupré, N; Lang, AE; Lizarraga, KJ; Logigian, E; McDermott, MP; Modica, JS; Stanton, M | 1 |
| Aldred, J; Anca-Herschkovitsch, M; Ballina, M; Bergmann, L; Bourgeois, P; Chaudhuri, KR; Cubo, E; Davis, TL; Iansek, R; Jia, J; Kovács, N; Kukreja, P; Ladhani, O; Pontieri, FE; Siddiqui, MS; Simu, M; Standaert, DG | 1 |
| Antonini, A; Chaudhuri, KR; Henriksen, T; Trošt, M; van Laar, T | 1 |
| Finsterer, J | 1 |
| Buskens, E; Henriksen, T; Moes, HR; Phokaewvarangkul, O; Sławek, J; van Laar, T | 1 |
| Bar, MR; Borovečki, F; Katzenschlager, R; Kovacs, N; LeWitt, PA; Perković, R | 1 |
| Iwaki, H; Mukai, Y; Nishikawa, N; Takahashi, Y | 1 |
| Furihata, M; Hagiwara, H; Ishino, H; Kitamura, T; Nakatsu, Y; Nishi, S; Noda, K; Nomoto, Y; Ogiwara, S; Okawa, H; Osada, T; Yano, S | 1 |
| Antonini, A; D'Onofrio, V; Guerra, A | 1 |
| Horiba, M; Imamura, A; Kuroyanagi, G; Matsukawa, N; Murakami, H; Sakai, H; Sato, T; Takahashi, A; Ueki, Y; Usami, T | 1 |
| Ce, Z; Jiren, Z; Pinyuan, Z; Tian, W; Ting, L; Wenbo, Z; Zhigang, M | 1 |
| Amouzandeh, A; Barbe, MT; Basheer, AA; Bornmann, S; Csoti, I; Ebersbach, G; Falkenburger, B; Flöel, A; Gruber, D; Gülke, E; Gutsmiedl, PK; Haller, B; Haslinger, B; Herting, B; Hormozi, M; Ip, CW; Jergas, H; Jochim, AM; Jost, WH; Klingelhöfer, L; Kohl, Z; Koschel, J; Krause, P; Kühn, AA; Lingor, P; Liszka, R; Maetzler, W; Paschen, S; Pérez-González, P; Pötter-Nerger, M; Prell, T; Pürner, D; Rijntjes, M; Rozanski, V; Scheller, U; Schröter, N; Schwarz, J; Südmeyer, M; Torka, E; van de Loo, S; van Riesen, C; Weiß, D; Wesbuer, S; Wolff, A; Wolz, M | 1 |
| Jenner, P; Leta, V; Pirtošek, Z; Vérin, M | 1 |
| Bancila, I; Ciocîrlan, M; Cotruta, B; Dobru, D; Drug, V; Dumitru, E; Gheorghe, C; Goldis, A; Jinga, M; Manuc, M; Mercea, VA; Pitigoi, D; Saftoiu, A; Seicean, A; Tanțău, M | 1 |
| Almeida, L; Barabas, M; Eisinger, RS; Elkouzi, A; Malaty, IA; Okun, MS; Ramirez-Zamora, A; Zeilman, P | 1 |
| Hoy, SM | 1 |
| Ares-Pensado, B; Castro, A; Fernandez-Pajarin, G; Rivero-de-Aguilar, A; Sesar, A | 1 |
| Fernández García, J; García Hernández, M; Garrido Durán, C; Khorrami Minaei, S; Legarda Ramírez, I; Sendra Rumbeu, P | 1 |
| Alam, M; Rönnegård, L; Saqlain, M; Westin, J | 1 |
| Chang, FCF; Fung, VSC; Galea, D; Griffith, J; Ha, AD; Kim, SD; Mahant, N; Morales-Briceño, H; Tsui, D | 1 |
| Artusi, CA; Balestrino, R; Bortolani, S; Fabbri, M; Imbalzano, G; Lopiano, L; Montanaro, E; Tuttobene, S; Zibetti, M | 1 |
| Baille, G; Blaise, AS; Carrière, N; Defebvre, L; Devos, D; Dujardin, K; Grolez, G; Kreisler, A; Kyheng, M; Moreau, C; Mutez, E; Seguy, D | 1 |
| Akbostanci, MC; Bilgiç, B; Bora Tokçaer, A; Çakmur, R; Doğu, O; Elibol, B; Erer Özbek, ÇS; Gültekin, M; Hanağasi, H; İnce Günal, D; Kenangil, G; Mirza, M; Tezcan, S; Ulukan, Ç; Yilmaz Küsbeci, Ö | 1 |
| Arca, R; Cossu, G; di Biase, L; Di Lazzaro, V; Di Santo, A; Fasano, A; Marano, M; Marano, P; Naranian, T; Poon, YY | 1 |
| Jalundhwala, YJ; Lakdawalla, DN; Marshall, TS; Sail, KR; Shih, TM; Sullivan, J; van Eijndhoven, E; Zadikoff, C | 1 |
| McFarthing, K; Prakash, N; Simuni, T | 1 |
| Belcaro, G; Cesarone, MR; Cotellese, R; Feragalli, B; Hosoi, M; Hu, S; Ledda, A; Maione, C; Scipione, C; Scipione, V | 1 |
| Stocchi, F; Vacca, L | 1 |
| Armstrong, MJ; Okun, MS | 1 |
| Chen, HJ; He, JC; Jiang, ZY; Wu, K; Xie, CL; Zhang, XR; Zhang, ZR | 1 |
| Li, K; Li, S; Liao, X; Liu, D; Shuai, B; Wu, N | 1 |
| Fung, VSC; Griffith, J; Mahant, N; Martin, AJ; Morales-Briceño, H; Tsui, D | 1 |
| Artusi, CA; Fabbri, M; Imbalzano, G; Lopiano, L; Pongmala, C; Romagnolo, A; Zibetti, M | 1 |
| Abbruzzese, G; Antonini, A; Bentivoglio, AR; Berardelli, A; Comi, C; Cossu, G; Fabbrini, G; Lopiano, L; Mancini, F; Martino, T; Melchionda, D; Minafra, B; Modugno, N; Pontieri, FE; Riboldazzi, G; Sensi, M; Solla, P; Stefani, A; Stroppa, I; Tambasco, N; Tamma, F; Tessitore, A | 1 |
| Cerroni, R; Imbriani, P; Liguori, C; Mercuri, NB; Pierantozzi, M; Pisani, A; Scalise, S; Stefani, A | 1 |
| Paik, J | 1 |
| Antonini, A; Bergmann, L; Gusmaroli, G; Lopiano, L; Marano, P; Melzi, G; Modugno, N; Pacchetti, C; Sensi, M; Zibetti, M | 1 |
| Baumann, CR; Oertel, MF; Stieglitz, LH | 1 |
| Antonini, A; Chaudhuri, KR; Leta, V; Teo, J | 1 |
| Ehlers, C; Honig, H; Odin, P; Timpka, J | 1 |
| Bloem, BR; Nonnekes, J | 1 |
| Ebersbach, G; Jost, WH; Kassubek, J; Klebe, S; Tönges, L | 1 |
| Bonno, D; Lizarraga, KJ; Modica, JS | 1 |
| Barone, P; Canoro, V; Cicarelli, G; Erro, R; Picillo, M | 1 |
| D'Souza, R; Fisher, S; Hauser, RA; Zeitlin, L | 2 |
| Chaudhuri, KR; Jones, S; Leta, V; Parry, M; Rizos, A; Sauerbier, A; van Wamelen, DJ | 1 |
| Aracil-Bolaños, I; Bejr-Kasem, H; Calopa, M; Campolongo, A; Crespo-Cuevas, A; de Fàbregues, O; Horta-Barba, A; Izquierdo-Barrionuevo, C; Kulisevsky, J; Marín-Lahoz, J; Martinez-Horta, S; Pagonabarraga, J; Pascual-Sedano, B; Pérez-Pérez, J; Puente, V | 1 |
| Boettcher, L; Edinger, G; Erickson, LO; Gardner, J; Kitzmann, R; Nance, MA; Wichmann, R; Wielinski, CL | 1 |
| de Bie, RMA; Dijk, JM; Espay, AJ; Katzenschlager, R | 1 |
| Adnan, M; Nyholm, D; Senek, M | 1 |
| Borovič, M; Dugonik, J; Flisar, D; Novak, D; Verber, D | 1 |
| Drent, M; Groenendal-Laurensse, JWMJ; Moes, HR; Tissingh, G; van Laar, T | 1 |
| Al-Hashel, JY; Kamel, WA | 1 |
| Ahmed-Farid, OA; Lashin, FM; Re, L; Rizk, HA; Saber, SM; Shehata, AM | 1 |
| Altiparmak, E; Erdoğan Küçükdağli, F; Köseoğlu, HT; Öztürk, Ö; Saltoğlu, T; Sücüllü Karadağ, Y | 1 |
| Aradi, SD; Hauser, RA | 1 |
| Arnold, AC; De Jesus, S; Delnomdedieu, M; Duvvuri, S; Eslinger, PJ; Fernandez-Mendoza, J; Gray, DL; Harrington, W; Huang, X; Kong, L; Lewis, MM; Mahoney, SE; Mailman, RB; Miller, AJ; Snyder, B; Sun, D; Van Scoy, LJ; Wang, X | 1 |
| Nielsen, EI; Nyholm, D; Senek, M | 3 |
| Adar, L; Case, RJ; Ellenbogen, AL; Espay, AJ; Leinonen, M; Olanow, CW; Oren, S; Orenbach, SF; Poewe, W; Stocchi, F; Yardeni, T | 1 |
| Leucuta, DC; Perju-Dumbrava, L; Popa, LC; Popa, SL; Tohanean, N | 1 |
| Atzori, L; Contu, P; Cossu, G; Cusano, R; Fabbri, M; Lopiano, L; Madau, V; Manzin, A; Melis, M; Mereu, A; Morelli, M; Murgia, D; Oppo, V; Palmas, V; Perra, D; Pisanu, S; Santoru, ML; Sarchioto, M; Serra, A; Uva, P; Vascellari, S; Zibetti, M | 1 |
| Barrajón Masa, AJ; Colmenares Bulgheroni, M; Moralejo Lozano, Ó | 1 |
| Carroll, DG; Halli-Tierney, AD; Luker, J | 1 |
| Bonvegna, S; Cilia, R; Colucci, F; Cossu, G; De Micco, R; Eleopra, R; Elia, AE; Fabbri, M; Ielo, GC; Lopiano, L; Modugno, N; Morgante, F; Novelli, A; Olivola, E; Oppo, V; Pilleri, M; Ricciardi, L; Sensi, M; Sorbera, C; Tessitore, A; Zibetti, M | 1 |
| Gillespie, A; Jones, E; Pappert, E; Pike, J; Thach, A; Wright, J | 1 |
| Bologna, M; Colosimo, C; Marsili, L; Miyasaki, JM | 1 |
| Guillén Climent, S; Monteagudo, C; Pinazo Canales, MI; Porcar Saura, S | 1 |
| Athanasakis, E; Avgoustaki, A; Boura, I; Chlouverakis, G; Giakoumakis, E; Giannopoulou, IA; Koulentaki, M; Orfanoudaki, E; Spanaki, C | 1 |
| Carr, RA; Enright, BP; Facheris, MF; Jameel, F; Kym, PR; Liu, W; Lou, X; Mayer, PT; Moussa, EM; Rosebraugh, M; Stolarik, D; Voight, EA; Zhang, GGZ | 1 |
| Bloem, BR; de Bie, RMA; Esselink, R; Groenewoud, H; Meinders, MJ; Nijhuis, FAP; Post, B | 1 |
| Arai, A; Hanabata, N; Katagai, A; Okudera, R; Tomiyama, M; Ueno, T | 1 |
| Babu, S; Chang, FC; Dal, S; Fletcher, N; Fung, VSC; Mahant, N; Martin, AJ; Morales-Briceno, H; Nankervis, J; Ong, TL; Robbie, M; Williams, LJ | 1 |
| Fukae, J; Hatano, T; Hattori, N; Oyama, G; Saiki, S; Shimo, Y; Tsunemi, T | 1 |
| Khurana, N; Muthuraman, A; Sharma, N; Utreja, P | 1 |
| Bergmann, L; Fasano, A; Gurevich, T; Jech, R; Johnson, A; Kovács, N; Parra, JC; Sanchez-Soliño, O; Svenningsson, P; Szász, J; Tang, Z; Vela-Desojo, L | 1 |
| Benner, J; Jalundhwala, YJ; Lakdawalla, DN; Marshall, TS; Sail, KR; Shih, TM; Sullivan, J; van Eijndhoven, E; Zadikoff, C | 1 |
| Ganguly, J; Jog, M; Tuesta Bernaola, M | 1 |
| Fujioka, S; Komorita, S; Mishima, T; Nishida, A; Okajima, M; Tsuboi, Y | 1 |
| Aldred, J; Alobaidi, A; Antonini, A; Bao, Y; Bergmann, L; Chaudhuri, KR; Inguva, S; Jalundhwala, YJ; Kukreja, P; Odin, P; Pahwa, R | 1 |
| Comella, CL; Hauser, RA; LeWitt, PA | 1 |
| Davis, RL; Holmes, AJ; Lubomski, M; Sue, CM; Xu, X; Yang, JYH | 1 |
| Barange, K; Barthélémy, C; Brefel-Courbon, C; Dupouy, J; Fabre-Delcros, MH; Fernández-Rodríguez, B; Harroch, E; Loubière, P; Ory-Magne, F; Rascol, O | 1 |
| Fujioka, S; Fukuchi, T; Furukawa, K; Furune, S; Ikeda, Y; Jin, X; Kato, M; Koike, T; Kubota, E; Murakami, H; Sato, Y; Suzuki, T; Tsuboi, Y; Uehara, T; Yamashita, K; Yamazaki, Y; Yube, Y | 1 |
| Baig, F; Boca, M; Cheminais, L; Collin, N; Mooney, L; Rolinski, M; Selikhova, M; Szewczyk-Krolikowski, K; Whone, A | 1 |
| Barbato, LM; Freire-Alvarez, E; Kurča, E; Liu, Y; Lopez Manzanares, L; Pekkonen, E; Sánchez-Soliño, O; Spanaki, C; Vanni, P | 1 |
| Ashok, A; Balaraman, S; Bellettini, JR; Cardinal-David, B; Chan, VS; Ghosh, S; Hill, DR; Huters, AD; Ji, J; Klix, RC; Kotecki, BJ; Matulenko, MA; Reddy, RE; Shou, M; Simanis, J; Stambuli, J; Towne, TB; Voight, EA | 1 |
| Ruiz Pardo, J; Sánchez Fuentes, PA; Vidaña Márquez, E | 1 |
| Ammendolia, A; de Sire, A; Demeco, A; Marinaro, C; Moggio, L; Petraroli, A; Pino, I | 1 |
| Corti, EJ; Egan, SJ; Gasson, N; Loftus, AM; Nielsen, C; Starkstein, S | 1 |
| Facheris, MF; Liu, W; Neenan, M; Rosebraugh, M | 1 |
| Fasano, A; Naranian, T; Poon, YY; Rohani, M | 1 |
| Aasly, J; Dietrichs, E; Egge, A; Ezat, B; Pihlstrøm, L; Tysnes, OB | 1 |
| Ehm, G; Jeon, B; Kim, A; Kim, HJ; Kim, YE; Lee, WW; Yang, HJ; Yun, JY | 1 |
| Chorbadzhieva, E; Dressler, D; Kleimann, A; Loens, S; Schrader, C | 1 |
| Capone, JG; Golfrè Andreasi, N; Preda, F; Rispoli, V; Sensi, M; Sette, E; Simioni, V; Tugnoli, V | 1 |
| Antonini, A; Danielsen, EH; de Fabregues, O; Doskas, T; Henselmans, JML; Krüger, R; Lingor, P; Onuk, K; Parra, JC; Sensken, SC; Stefani, A; Yegin, A | 1 |
| Bove, F; Di Iorio, R; Fasano, A; Gallicchio, L; Luigetti, M; Petruzzellis, A; Recchia, V; Tamma, F | 1 |
| Durando, M; Kim, JS; Tiu, H | 1 |
| Bentivoglio, AR; Bove, F; Fasano, A; Naranian, T | 1 |
| Eerola-Rautio, J; Kenttämies, A; Kylänpää, L; Lindström, O; Lyytinen, J; Pekkonen, E; Udd, M | 1 |
| Ando, R; Miyaue, N; Nagai, M; Nishikawa, N; Nomoto, M; Tada, S; Yabe, H | 1 |
| Mundt-Petersen, U; Odin, P | 1 |
| Abu-Suboh, M; Alvarez-Sabín, J; Armengol, JR; De Fabregues, O; Dot, J; Ferré, A; Gómez, MR; Hernández-Vara, J; Ibarria, M; Puiggros, C; Quintana, M; Raguer, N; Romero, O; Seoane, JL | 1 |
| D'Elia, A; Imbriani, P; Pisani, A; Schirinzi, T | 1 |
| Baj, R; Chaudhuri, KR; Jalundhwala, YJ; Konwea, H; Lowin, J; Marshall, TS; Sail, K | 1 |
| Dizdar, N; Grenholm, P; Groth, K; Kjellander, S; Larsson, J; Nyholm, D; Permert, J; Schmiauke, U; Urbom, A; Widner, H; Willows, T | 1 |
| Antonini, A; Barch, D; Bergmann, L; Chaudhuri, KR; Jech, R; Odin, P; Onuk, K; Pickut, B; Pirtošek, Z; Poewe, W; Szasz, J; Valldeoriola, F; Winkler, C; Yegin, A | 1 |
| Fasano, A; Jog, M; Kumar, N; Murgai, A; Naranian, T | 1 |
| Hoon, M; Petzer, A; Petzer, JP; Viljoen, F | 1 |
| Compta, Y; Martí, MJ; Muñoz, JE; Ríos, J; Rumià, J; Santacruz, P; Tolosa, E; Valldeoriola, F | 1 |
| Fairchild, A; Hass, S; Marshall, T; Pugh, A | 1 |
| Bring, PP; Diggle, JL; Lau, ACW | 1 |
| Catalán, MJ; Grandas, F; Matías-Arbelo, J; Mir, P; Parra, JC; Puente, V; Regidor, I; Santos-García, D; Valldeoriola, F | 1 |
| Barichella, M; Cassani, E; Cereda, E; Cilia, R; Laguna, J; Pezzoli, G; Raspini, B | 1 |
| Angrisano, S; Artusi, CA; Dematteis, F; Lopiano, L; Merola, A; Romagnolo, A; Zibetti, M | 1 |
| Esqueda-Liquidano, M; García-Gomar, MG; Velasco, AL; Velasco, F | 1 |
| Bakis, G; Nutt, J; Staisch, J | 1 |
| Antonini, A; Canesi, M; Costanzo, AM; Defazio, G; di Luzio Paparatti, U; Gualberti, G; Latorre, A; Lopiano, L; Marano, P; Melzi, G; Modugno, N; Pontieri, FE; Quatrale, R; Sensi, M; Solla, P; Tambasco, N; Tessitore, A | 1 |
| Kundt, FS; Lex, KM; Lorenzl, S | 1 |
| Arbelo, JM; Catalan, MJ; Cubo, E; Martinez-Martin, P; Mir, P; Molina-Arjona, JA | 1 |
| Eklund, M; Henriksen, T; Nyholm, D; Odin, P; Sahlström, T; Timpka, J | 1 |
| Benesh, J; Boyd, JT; Chatamra, K; Eaton, S; Espay, AJ; Facheris, MF; Fernandez, HH; Fung, VSC; Hall, C; Lew, MF; Robieson, WZ; Rodriguez, RL; Slevin, JT; Standaert, DG; Vanagunas, AD; Zadikoff, C | 1 |
| Andrisani, G; di Biase, L; Di Lazzaro, V; Di Matteo, FM; Di Santo, A; Marano, M; Martino, M; Pandolfi, M; Pizzicannella, M; Rea, R | 1 |
| Bertram, KL; Hewer, S; Lee, W; Ligtermoet, M; Paul, E; Varley, S; Vijiaratnam, N; Williams, DR | 1 |
| Sue, CM; Vijiaratnam, N | 1 |
| Antonini, A; Bergmann, L; Poewe, W; Robieson, WZ; Yegin, A | 1 |
| Bergquist, F; Ericsson, A; Johansson, A; Johansson, D; Medvedev, A; Nyholm, D; Ohlsson, F; Senek, M; Spira, J; Thomas, I; Westin, J | 1 |
| Fujioka, S; Fukae, J; Hasegawa, S; Hayashi, Y; Mishima, T; Nose, K; Shiwaku, H; Tsuboi, Y; Umemoto, G; Yamashita, K | 1 |
| Baek, JS; Ho, HK; Lim, KL; Loo, SCJ; Pang, YY; Tan, EY; Tee, JK | 1 |
| Ares-Pensado, B; Castro, A; Fernandez-Pajarin, G; Iglesias-Canle, J; Masa-Vazquez, L; Sesar, A | 1 |
| Allone, C; Bonanno, L; Bramanti, P; Ciurleo, R; Corallo, F; Di Lorenzo, G; Lo Buono, V; Marino, S; Palmeri, R; Versaci, R | 1 |
| Antonini, A; Kleinman, LS; Marshall, TS; Odin, PLA; Onuk, K; Sail, KR; Skalicky, AM; Stoessl, AJ | 1 |
| Anang, JBM | 1 |
| Hirozawa, D; Ikenaka, K; Mochizuki, H; Nakano, T; Sasaki, T; Shimamura, M | 1 |
| Memedi, M; Nyholm, D; Thomas, I; Westin, J | 1 |
| Cowie, F; Grosset, DG; Watson-Fargie, T; White, J | 1 |
| Dinh, P | 1 |
| Fabbri, M; Ferreira, JJ; Rosa, MM | 1 |
| Beccaria, L; Fabbri, M; Ferreira, JJ; Lopiano, L; Merola, A; Montanaro, E; Palermo, S; Romagnolo, A; Zibetti, M | 1 |
| Antonini, A; Bergmann, L; Poewe, W; Ray Chaudhuri, K; Robieson, WZ; Sanchez-Soliño, O | 1 |
| Hirata, Y; Ishikawa, H; Kato, N; Matsuura, K; Matsuyama, H; Narita, Y; Niwa, A; Tomimoto, H | 1 |
| Baik, JS; Cho, J; Jeon, B; Kim, HT; Kim, JM; Kim, JW; Koh, SB; Kwon, OD; Lee, HW; Lee, JY; Ma, HI; Yoon, WT | 1 |
| Christie, M; Coss, P; Ondo, W; Pascual, B | 1 |
| Duvvuri, S; Gray, DL; Liu, W; Papapetropoulos, S; Thayer, K | 1 |
| Belsey, J; Kalabina, S; Mohamed, B; Paterson, B; Pivonka, D; Thomas, C | 1 |
| Antonini, A; Bergmann, L; Chaudhuri, KR; Poewe, W | 1 |
| Arbelo, JM; Catalán, MIJ; Grandas, F; Mir, P; Parra, JC; Puente, V; Regidor, I; Santos-García, D; Valldeoriola, F | 1 |
| Grassini, P; Heller, A; Heller, E; Kieburtz, K; Leinonen, M; Stocchi, F; Torti, M; Vacca, L; Warren Olanow, C | 1 |
| Alam, M; Bergquist, F; Johansson, D; Memedi, M; Nyholm, D; Thomas, I; Westin, J | 1 |
| Bloem, BR; Boel, JA; de Bie, RMA; de Haan, RJ; Deuschl, G; Dijkgraaf, MGW; Lang, AE; Munts, AG; Post, B; Suwijn, SR; Tissingh, G; van Hilten, JJ; van Laar, T; Verschuur, CVM | 1 |
| Lees, AJ; Moro, A; Munhoz, RP; Pessoa, RR; Teive, HAG | 1 |
| Aschermann, Z; Harmat, M; Janszky, J; Juhász, A; Kovács, N; Pintér, D | 1 |
| Hideshima, M; Hirozawa, D; Ikenaka, K; Ishikura, T; Kitano, T; Konaka, K; Mochizuki, H; Nakano, T; Shimamura, M; Shinzaki, S; Takehara, T | 1 |
| Metzer, WS; Rodrigues, FB | 1 |
| Bloem, BR; Boers, I; Muilwijk, EW; Radder, DLM; Tiel Groenestege, AT | 1 |
| Cabreira, V; Massano, J; Soares-da-Silva, P | 1 |
| Mukai, Y; Murata, M; Nishikawa, N; Takahashi, Y | 1 |
| Barbagallo, G; Quattrone, A | 1 |
| Ellenbogen, A; Hauser, RA; Isaacson, SH; Kegler-Ebo, DM; Komjathy, SF; Oh, C; Safirstein, BE; Truong, DD; Zhao, P | 1 |
| Artusi, CA; Fabbri, M; Lopiano, L; Pongmala, C; Rizzone, MG; Romagnolo, A; Zibetti, M | 1 |
| Di Vico, IA; Novelli, A; Ramat, S; Sorbi, S; Terenzi, F | 1 |
| Januário, C; Morgadinho, A; Reis Carneiro, D; Sousa, M | 1 |
| Centonze, D; Fasano, A; Femiano, C; Lena, F; Modugno, N; Olivola, E; Santilli, M; Varanese, S | 1 |
| Egawa, H; Fukunaga, T; Hatano, T; Hattori, N; Ishibashi, Y; Kaji, S; Kanda, S; Kohira, Y; Oka, S; Oyama, G; Shimo, Y; Yube, Y | 1 |
| Antonini, A; Bentivoglio, A; Eleopra, R; Gualberti, G; Gusmaroli, G; Lopiano, L; Mancini, F; Marano, P; Meco, G; Melzi, G; Modugno, N; Quatrale, R; Sensi, M; Solla, P; Tamma, F; Zangaglia, R | 1 |
| Giladi, N; LeWitt, PA; Navon, N | 1 |
| Navon, N | 1 |
| Duma, S; Fung, VS; Griffith, J; Mahant, N; Martin, A; Morales-Briceño, H; Tsui, D | 1 |
| Bartig, D; Gold, R; Jörges, C; Jost, W; Krogias, C; Richter, D; Stumpe, B; Tönges, L | 1 |
| Amjad, F; Bhatti, D; Davis, TL; Kukreja, P; Metman, LV; Oguh, O; Pahwa, R; Zamudio, J | 1 |
| Antonini, A; Bergmann, L; Kukreja, P; Poewe, W; Robieson, WZ | 1 |
| Zesiewicz, TA | 1 |
| Holiga, Š; Jech, R; Möller, HE; Mueller, K; Růžička, E; Schroeter, ML; Sieger, T; Vymazal, J | 1 |
| Gupta, S; Hsu, A; Mao, Z; Modi, NB | 1 |
| de Jong, MH; Van Gool, AR; Zemel, D | 1 |
| Hernández, B; Martínez-Martín, P; Ricart, J | 1 |
| Sheehan, J; Thorpe, M; Wilson, L | 1 |
| Ossig, C; Reichmann, H | 1 |
| Rascol, O | 2 |
| Espay, AJ; Gupta, S; Hauser, RA; Hsu, A; Kell, S; O'Connell, M; Ondo, W; Sethi, K; Stacy, M | 1 |
| Worth, PF | 1 |
| Agarwal, P; Burdick, DJ; Griffith, A | 1 |
| Durso, R; Josephs, E; Modak, A; Rosen, D | 1 |
| Best, CM; Ifedi, BO; Reichel, LM | 2 |
| Aschermann, Z; Komoly, S; Kovács, N | 1 |
| Namazi, H | 1 |
| Levin, OS; Liashchenko, EA; Skripkina, NA | 1 |
| Hernández-Vara, J; Salvado, M | 1 |
| Filipek, B; Pytka, K; Zygmunt, M | 1 |
| Galazky, I; Heinze, HJ; Kluge, C; Kupsch, A; Schoof, J; Stallforth, S | 1 |
| Fahn, S; Gupta, S; Hauser, RA; Hsu, A; Jankovic, J; Kell, S; Lyons, KE; O'Connell, M; Pahwa, R; Pourcher, E | 1 |
| Hernández, B; Kulisevsky, J; Linazasoro, G; López-Lozano, JJ; Marey, J; Mir, P; Tolosa, E | 1 |
| Angrisano, S; Artusi, CA; De Angelis, C; Lopiano, L; Merola, A; Reggio, D; Rizzi, L; Rizzone, M; Zibetti, M | 1 |
| Baumann, CR; Waldvogel, D | 1 |
| Chen, D; Cundy, KC; Hauser, RA; Huff, FJ; LeWitt, PA; Lissin, D; Zomorodi, K | 1 |
| Antonini, A; Benesh, J; Chatamra, K; Espay, AJ; Fernandez, HH; Kieburtz, K; Lenz, RA; Odin, P; Olanow, CW; Othman, AA; Pritchett, Y; Robieson, WZ; Standaert, DG; Vanagunas, A; Widnell, KL | 1 |
| de Beyl, DZ; Dethy, S; Pickut, BA; Van De Maele, H; van der Linden, C | 1 |
| Bhidayasiri, R; Boonrod, N; Jitkritsadakul, O; Rerknimitr, R | 1 |
| Muhlack, S; Müller, T | 4 |
| Capone, JG; Contini, E; Golfre-Andreasi, N; Gragnaniello, D; Preda, F; Quatrale, R; Sensi, M; Sette, E; Tola, MR; Trevisani, L; Tugnoli, V | 1 |
| Fedorova, NV; Kulua, TK | 1 |
| Dutta, S; Othman, AA | 1 |
| Cáceres-Redondo, MT; Carballo, M; Carrillo, F; Huertas-Fernández, I; Lama, MJ; Mir, P; Vargas-González, L | 1 |
| Katzenschlager, R; Poewe, W | 1 |
| Nagy, H; Radics, P; Takáts, A; Tamás, G; Tóth, A | 1 |
| Aglan, H; Ahmed, H; Atta, H; Ghazy, M; Salem, A | 1 |
| Chowdhury, JH; Chowdhury, TI; Rahman, MM; Uddin, MJ | 1 |
| Jost, WH | 1 |
| Klivényi, P; Vécsei, L | 3 |
| Ceballos-Baumann, AO; Fietzek, UM; Lehnerer, SM; Messner, M | 1 |
| Kimber, TE; Schoeman, M | 1 |
| Herrmann, L; Muhlack, S; Müller, T; Salmen, S | 1 |
| Carpintero, P; de Deus, T; de la Fuente-Fernandez, R; Echarri-Piudo, A; Llaneza-Gonzalez, MA; Lopez-Pazos, E; Macias-Arribi, M; Santos-Garcia, D | 1 |
| Fregly, BJ; Hass, CJ; Roemmich, RT | 1 |
| Argyris, P; Barla, G; Maltezou, M; Stathis, P; Tzias, V | 1 |
| Ahlskog, JE | 4 |
| Cardoso, MA; de Carvalho, KA; Marson, BM; Pontarolo, R; Pontes, FL; Ribeiro, RP; Vilhena, Rde O | 1 |
| Epstein, J; Hayes, MT; Lai, L; Madiedo, CJ | 1 |
| Ondo, W | 1 |
| Eleopra, R; Onofrj, M; Uncini, A | 1 |
| Giladi, N; Goldstein, S; Gurevich, T; Hilel, A; Shapira, Y; Zlotnik, Y | 1 |
| Guthikonda, LN; Lyons, KE; Pahwa, R | 1 |
| Dillmann, U; Ellenbogen, A; Gupta, S; Hsu, A; Kell, S; Khanna, S; Liang, G; Mahler, A; Rubens, R; Stocchi, F | 1 |
| Odin, P; Walter, E | 1 |
| Ceci, R; Colamartino, M; Cozzi, R; Duranti, G; Padua, L; Sabatini, S; Santoro, M; Testa, A | 1 |
| Merello, M; Rossi, M | 1 |
| Alexiou, A; Psiha, M; Vlamos, P | 1 |
| Katunina, EA; Titova, NV | 2 |
| Antonini, A; Poewe, W | 1 |
| Ács, P; Aschermann, Z; Bosnyák, E; Deli, G; Janszky, J; Komoly, S; Kovács, N | 1 |
| Bell, B; Buyan-Dent, L; Christian, BT; Gallagher, CL; Harding, SJ; Holden, JE; Johnson, SC; Nickles, RJ; Oh, J; Okonkwo, O; Palotti, M; Sojkova, J; Stone, CK | 1 |
| Benesh, JA; Chatamra, K; Chouinard, S; Dubow, J; Espay, AJ; Fernandez, HH; Fung, VS; Hall, CM; Hauser, RA; Klostermann, F; Lang, AE; Lew, MF; Odin, P; Robieson, WZ; Standaert, DG; Steiger, M; Suchowersky, O; Yakupov, EZ | 1 |
| Chang, FC; Drury, M; Fung, VS; Griffith, JM; Ha, AD; Kim, SD; Mahant, N; Tsui, DS; Wolfe, N | 1 |
| Antonini, A; Bergmann, L; Poewe, W; Preda, C; Yegin, A | 1 |
| Benesh, J; Chatamra, K; Dubow, J; Eaton, S; Fernandez, HH; Hall, C; Slevin, JT; Zadikoff, C | 1 |
| Kretova, AS; Lyubimov, AV | 1 |
| di Biase, L; Di Lazzaro, V; Marano, M; Melgari, JM; Salomone, G; Scrascia, F | 1 |
| Rudakova, AV; Yakupov, EZ | 1 |
| Timofeeva, AA | 1 |
| Falcão, A; Ferreira, JJ; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P | 1 |
| Fahn, S; Kestenbaum, M | 1 |
| Aschermann, Z; Bereczki, D; Dézsi, L; Dibó, G; Klivényi, P; Komoly, S; Kovács, N; Nagy, H; Takáts, A; Tóth, A; Valikovics, A; Varannai, L; Vécsei, L; Zemlényi, G | 1 |
| Nutt, JG | 1 |
| Fasano, A; Lang, AE; Liu, LW; Poon, YY | 1 |
| Fung, VS | 1 |
| Chen, C; Cowles, VE; Stover, N; Sweeney, M; Verhagen Metman, L | 1 |
| Bankiewicz, K; Beyer, J; Ciesielska, A; Forsayeth, J; Sharma, N | 1 |
| Benesh, J; Chatamra, K; Dutta, S; Mohamed, ME; Nagai, M; Othman, AA; Yanagawa, M | 1 |
| Gambini, O; Islam, L; Piacentini, S; Scarone, S; Soliveri, P | 1 |
| Dzyak, L; Gupta, S; Hsu, A; Kell, S; Khanna, S; Nausieda, P; Rudzinska, M; Silver, DE; Spiegel, J; Tsurkalenko, ES; Waters, CH | 1 |
| Antonini, A; Cossu, G; Mancini, F; Melis, M; Mereu, A; Murgia, D; Pilleri, M; Ricchi, V; Ricchieri, G | 1 |
| Barrios-Barrios, A; Bustamante-Balén, M; del-Hoyo-Francisco, J; Martínez-Torres, I; Pons-Beltrán, V; Satorres-Paniagua, C | 1 |
| Johnson, KE | 1 |
| Antonelli, F; Buongiorno, M; Calopa, M; Cámara, A; Campolongo, A; de Fabregues-Nebot, O; Hernandez-Vara, J; Kulisevsky, J; Martí, MJ; Pascual-Sedano, B; Puente, V; Tolosa, E; Valldeoriola, F | 1 |
| Benedetti, A; Gros, P; Kaminska, M; Kimoff, RJ; Lafontaine, AL; Mery, VP; Robinson, A | 1 |
| Cannas, A; Fasano, A; Lang, AE; Marrosu, F; Marrosu, MG; Mulas, CS; Solla, P | 1 |
| Dam-Larsen, S; Darkahi, B; Glad, A; Gleditsch, D; Gustavsson, L; Halttunen, J; Johansson, KE; Pischel, A; Reiertsen, O; Törnqvist, B; Zebski, H | 1 |
| Bellante, F; Dethy, S; Zegers de Beyl, D | 1 |
| Bruno, E; Cicero, CE; Contrafatto, D; Dibilio, V; Giuliano, L; Luca, A; Mostile, G; Nicoletti, A; Pappalardo, I; Raciti, L; Sciacca, G; Sofia, V; Zappia, M | 1 |
| Bonuccelli, U; Ceravolo, R; Frosini, D; Mazzucchi, S | 1 |
| Benesh, JA; Chatamra, K; Fernandez, HH; Standaert, DG | 1 |
| Flisar, D; Kojovic, M; Kramberger, MG; Pirtosek, Z; Zorko, N | 1 |
| Nyholm, D; Nyman, R; van Laar, T | 1 |
| di Biase, L; Di Lazzaro, V; Marano, M; Melgari, JM; Salomone, G | 2 |
| Kuoppamäki, M; Leinonen, M; Poewe, W | 1 |
| Antonini, A; Chaudhuri, KR; Fox, K; Fox, T; Honig, H; Martinez-Martin, P; Odin, P; Timpka, J | 1 |
| Mick, D; Resan, B; Segec, I; Skelac, D; Soldo, SB; Tomic, S | 1 |
| Elmer, L; Gil, RA; Gupta, S; Hsu, A; Kell, S; Khanna, S; Modi, NB; Nausieda, PA; Rubens, R; Singer, C; Spiegel, J | 1 |
| Cannas, A; Fasano, A; Marrosu, F; Solla, P | 1 |
| Cannas, A; Marrosu, F; Marrosu, MG; Solla, P | 1 |
| Bernardini, A; Cocito, D; Lopiano, L; Merola, A; Romagnolo, A; Zibetti, M | 1 |
| Bloem, BR; de Bie, RM; de Haan, RJ; Deuschl, G; Dijkgraaf, M; Lang, AE; Post, B; Suwijn, SR; Tissingh, G; van Hilten, JJ; van Laar, T; Verschuur, CV | 1 |
| Hauser, RA; Seeberger, LC | 2 |
| Abou Al-Shaar, H; Al-Ajlan, F; Alkahtani, K; Alkhairallah, T; Bohlega, S; Hasan, N | 1 |
| Mao, ZL; Modi, NB | 1 |
| Greig, SL; McKeage, K | 1 |
| Benesh, JA; Boyd, JT; Chatamra, K; Chouinard, S; Draganov, PV; Dubow, J; Eaton, S; Espay, AJ; Fasano, A; Fernandez, HH; Fung, VS; Klostermann, F; Lang, AE; Lew, MF; Odin, P; Robieson, WZ; Rodriguez, RL; Schmulewitz, N; Slevin, JT; Stein, DA; Zadikoff, C | 1 |
| Băjenaru, O; Buraga, I; Constantinescu, A; Ene, A; Mureşan, DF; Perju-Dumbrava, L; Popescu, BO; Popescu, CD; Sabău, M; Simu, M; Szász, JA | 1 |
| Hattori, N | 1 |
| Dagher, A; Fellows, LK; Simioni, AC | 1 |
| Bereczki, D; Nagy, H; Takáts, A; Toth, A; Wacha, J | 1 |
| Chang, FC; Fung, VS; Griffith, JM; Ha, AD; Kim, SD; Kwan, V; Mahant, N; Tsui, D; van der Poorten, D; Wolfe, N | 1 |
| Ito, H; Koh, J; Kondo, T; Nagashima, Y; Sakata, M | 1 |
| Antonini, A; Benesh, JA; Boyd, JT; Chatamra, K; Eaton, S; Fung, VS; Hall, C; Slevin, JT | 1 |
| Jankovic, J; Lotia, M | 1 |
| Atlas, D | 1 |
| Mueller, BK; Muhlack, S; Müller, T; Trommer, I | 1 |
| Cicero, CE; Mostile, G; Nicoletti, A; Zappia, M | 1 |
| Bove, F; Espay, AJ; Espay, KJ; Fasano, A; Krikorian, R; Lena, F; Modugno, N; Poon, YY; Ricciardi, L | 1 |
| Dhall, R; Kreitzman, DL | 1 |
| Silver, DE; Trosch, RM | 1 |
| Benita León, V; Campolongo Perillo, A; Fernández Díez, S; Mariscal Pérez, N; Martínez Castrillo, JC; Puente Périz, V; Santos García, D; Seoane Urgorri, A; Udaeta Baldivieso, B | 1 |
| Nyholm, D; Odin, P; Wirdefeldt, K | 2 |
| Almeida, L; Falcão, A; Ferreira, JJ; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P | 1 |
| Bernardini, A; Espay, AJ; Espay, KJ; Lanotte, M; Lopiano, L; Merola, A; Rizzi, L; Romagnolo, A; Rosso, M; Zibetti, M | 1 |
| Jog, MS; Kumar, N; Rizek, P | 1 |
| Lyons, KE; Pahwa, R | 1 |
| Abreu, L; Bernardo, C; López Gómez, M; Magaz Martínez, M; Martínez Porras, JL; Santiago, J | 1 |
| Baek, JS; Choo, CC; Loo, SC; Qian, C; Shen, Z; Tan, NS | 1 |
| Mundt-Petersen, U; Odin, P; Timpka, J | 1 |
| Bergmann, L; Dizdar, N; Hauge, T; Holmberg, B; Jansson, R; Johansson, A; Kjellander, S; Linder, J; Marshall, TS; Nyholm, D; Pålhagen, SE; Sydow, O; Widner, H | 1 |
| Amato, MR; De Micco, R; Del Prete, A; Esposito, P; Ferraro, F; Sica, M; Tessitore, A; Zulli, C | 1 |
| Durso, R; McNamara, P; Morgan, J; Smart, K | 1 |
| Cubo, E; Giuffrida, JP; Heldman, DA | 1 |
| Antonini, A; Cannas, A; Costanzo, AM; di Luzio Paparatti, U; Gualberti, G; Gusmaroli, G; Lopiano, L; Mancini, F; Marano, P; Meco, G; Melzi, G; Modugno, N; Quatrale, R; Sensi, M; Tamma, F | 1 |
| Cannas, A; Marrosu, F; Meloni, M; Solla, P | 1 |
| Carpenter, MG; Inglis, JT; McKeown, MD; McKeown, MJ; Pasman, EP; Peters, RM | 1 |
| Arbelo, JM; Catalán, MJ; Grandas, F; Mir, P; Parra, JC; Puente, V; Regidor, I; Santos-García, D; Valldeoriola, F | 1 |
| Ebersbach, G; Holtmann, M; Jost, W; Odin, P; Schrader, C; Südmeyer, M; Winkler, C | 1 |
| Bloem, BR; Faber, MJ; Nijhuis, FA; Post, B; van Heek, J | 1 |
| Devigili, G; Eleopra, R; Lettieri, C; Rinaldo, S | 1 |
| Lambarth, AT | 1 |
| Avolio, C; De Francesco, V; Lalla, A; Martino, T; Melchionda, D; Specchio, LM; Tonti, P | 1 |
| Bilic, B; Markos, P; Miletic, V; Rustemovic, N | 1 |
| Fox, SH; Freitas, ME; Ruiz-Lopez, M | 1 |
| Cataldo, BO; Cury, RG; de Campos Duprat, A; Fonoff, E; Noffs, G; Zarzur, AP | 1 |
| Bojarski, C; Ehlen, F; Klostermann, F; Maier, A; Marzinzik, F; Schindlbeck, KA | 1 |
| Abreu, L; Magaz Martínez, M; Martínez Porras, JL; Oliva, B | 1 |
| Borgemeester, R; van Laar, T | 1 |
| Altamura, C; Basile, S; Calcagno, M; Garibaldi, S; Pinelli, S; Salerno, MG | 1 |
| Cannas, A; Marrosu, F; Mascia, MM; Meloni, M; Solla, P | 1 |
| Aquilonius, SM; Askmark, H; Bergquist, F; Constantinescu, R; Ericsson, A; Lycke, S; Medvedev, A; Memedi, M; Nyholm, D; Ohlsson, F; Senek, M; Spira, J; Westin, J | 1 |
| Alonso-Frech, F; Catalán, MJ; Escribano, PM | 1 |
| Duker, AP; Ellenbogen, A; Farbman, ES; Gupta, S; Hauser, RA; Hsu, A; Kell, S; Khanna, S; Kreitzman, D; Liang, GS; Nausieda, P; Nieves, A; Rubens, R; Tetrud, J | 1 |
| Dietrichs, E; Odin, P | 1 |
| Ács, P; Annus, Á; Aschermann, Z; Dézsi, L; Dibó, G; Harmat, M; Janszky, J; Juhász, A; Karádi, K; Klivényi, P; Komoly, S; Kovács, M; Kovács, N; Makkos, A; Nagy, H; Takáts, A; Tényi, D; Tóth, A; Varannai, L; Vécsei, L; Zádori, D | 1 |
| Debelius, JW; Factor, SA; Hill-Burns, EM; Knight, R; Lewis, MR; Molho, E; Morton, JT; Payami, H; Peddada, SD; Wallen, ZD; Wissemann, WT; Zabetian, CP | 1 |
| Evans, AH; Fung, VSC; Hayes, M; Iansek, R; Kimber, T; O'Sullivan, JD; Sue, CM; Williams, DR | 1 |
| Chatamra, K; Dutta, S; Locke, C; Othman, AA; Rosebraugh, M | 1 |
| Buhmann, C; Hilker, R; Lingor, P; Reichmann, H; Schrader, C; Schwarz, J; Wolz, M | 1 |
| Gupta, S; Mittur, A; Modi, NB | 1 |
| Antonini, A; Cossu, G; Mancini, F; Modugno, N; Pilleri, M; Quatrale, R; Sensi, M; Tamma, F; Zibetti, M | 1 |
| Artusi, CA; Comi, C; Duker, AP; Espay, AJ; Lanotte, M; Lopiano, L; Maule, S; Merola, A; Romagnolo, A; Rosso, M; Zibetti, M | 1 |
| Aquilonius, SM; Nyholm, D | 1 |
| Albo, J; Hellström, M; Nyholm, D; Senek, M; Svenningsson, P | 1 |
| Erdmann, C; Goetze, O; Müller, T; Woitalla, D | 1 |
| Hsu, A; Khor, SP | 1 |
| Doan, JB; Melvin, KG; Suchowersky, O; Whishaw, IQ | 1 |
| Comella, CL; Fahn, S; Friedman, JH; Marek, K; Oakes, D; Schifitto, G; Shulman, L | 1 |
| Aste, R; Cannas, A; Congia, S; Floris, G; Marrosu, MG; Solla, P; Tacconi, P | 1 |
| Chigir', IP; Dokadina, LV; Fedorova, NV; Levin, OS; Makhnev, SO; Smolentseva, IG | 1 |
| Fung, VS; Herawati, L; Wan, Y | 1 |
| Babina, LA; Batysheva, TT; Boiko, AN; Khozova, AA; Kostenko, EV; Malykhina, EA; Minaeva, NG; Shikhkerimov, RK; Vdovichenko, TV; Zaitsev, KA; Zhuravleva, EY | 1 |
| Abbruzzese, G; Dronamraju, N; Hauser, RA; Kakarieka, A; Mancione, L; Panisset, M | 1 |
| Arai, H; Hatta, K; Hattori, N; Ishikawa, K; Kamigaichi, R; Kubo, S; Mochizuki, H; Ogaki, K; Usui, C; Yokoyama, K | 1 |
| Litvinenko, IV; Mogil'naia, VI; Odinak, MM; Sakharovskaia, AA; Sologub, OS | 1 |
| Bono, G; Garavaglia, P; Guidotti, M; Leva, S; Pianezzola, C; Raudino, F; Riboldazzi, G | 1 |
| Frei, K; Truong, DD; Wolters, E | 1 |
| Lundgren, D; Nyholm, D; Nyman, R | 1 |
| Cannas, A; Floris, G; Marrosu, F; Marrosu, MG; Piga, M; Serra, A; Solla, P; Tacconi, P | 1 |
| Ahlskog, JE; Bostwick, JM; Bower, JH; Hecksel, KA; Stevens, SR | 1 |
| Silver, DE | 2 |
| Guarnieri, M; Hubble, JP; Jennings, D; LeWitt, PA; Lyons, KE; Murck, H; Pahwa, R; Rabinowicz, AL; Wang, J | 1 |
| Addy, C; Assaid, C; Ellenbogen, A; Gottesdiener, K; Herring, WJ; Hreniuk, D; Jinnah, HA; Kirby, L; Leibowitz, MT; Stewart, RM; Stoch, SA; Stroh, M; Tarsy, D; Tetrud, J; Wagner, J; Xu, Y | 1 |
| Bloem, BR; Gerschlager, W | 1 |
| Gold, MS; Graham, NA; Hammond, CJ | 1 |
| Kroenke, K; Murck, H; Stacy, MA | 1 |
| Amar, K; Eggert, K; Kuoppamäki, M; Leinonen, M; Luotonen, L; Nissinen, H; Oertel, W; Skogar, O | 1 |
| Jurjevic, A; Kovacevic, M; Ljubicic, D; Mrsic-Pelcic, J; Perkovic, O; Rudez, J; Vitezic, D; Vitezic, M | 1 |
| Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E | 1 |
| Goldstein, DS; Holmes, C; Kopin, IJ; Pechnik, S; Sewell, L | 1 |
| Asanuma, M; Diaz-Corrales, FJ; Kikkawa, Y; Kimoto, N; Miyazaki, I; Miyoshi, K; Murata, M; Takeshima, M | 1 |
| Marconi, S; Stocchi, F | 1 |
| Delea, TE; Hagiwara, M; Mancione, L; Thomas, SK | 1 |
| Eggert, K; Eichhorn, T; Oertel, WH; Ries, V; Selzer, R | 1 |
| Cámara, A; Valldeoriola, F | 1 |
| Müller, T | 1 |
| Barone, P; Jankovic, J; Kieburtz, K; Lang, AE; Olanow, CW; Poewe, W; Rascol, O; Stocchi, F; Tolosa, E | 1 |
| Cetas, JS; Fields, JD | 1 |
| Bonnici, A; Hornstein, D; Ruiner, CE; St-Laurent, L | 1 |
| Almeida, L; Ferreira, JJ; Nunes, T; Poewe, W; Rascol, O; Rocha, JF; Sampaio, C; Soares-da-Silva, P | 1 |
| Dall'Armi, V; Kulisevsky, J; Lamberti, P; Obeso, JA; Stocchi, F; Zappia, M | 1 |
| Barrero, FJ; Duran, R; Luna, JD; Morales, B; Ramirez, M; Vives, F | 1 |
| Bokor, M; Szentesi, A | 1 |
| Khadem, NR; Nirenberg, MJ | 1 |
| Armand, C; Groenendaal, H; Tarrants, ML | 1 |
| Deuschl, G; Herzog, J; Volkmann, J; Wailke, S; Witt, K | 1 |
| Bugalho, P; Lampreia, T; Santos, L; Soares, P | 1 |
| Moore, S; Ondo, WG; Shinawi, L | 1 |
| Drent, M; Leenders, KL; Meppelink, AM; Nyman, R; Prins, T; van Laar, T | 1 |
| Gradl, B; Persson, U; Willis, M; Zoellner, Y | 1 |
| Ferreira, JJ; Sampaio, C | 1 |
| Delea, TE; Hagiwara, M; Thomas, SK | 1 |
| Bogdanov, RR; Kotov, SV; Kunitsyna, AN; Turbina, LG | 1 |
| Auclair-Ouellet, N; Cantin, L; Chantal, S; Langlois, M; Macoir, J; Prud'homme, M | 1 |
| Ivanov, AK; Levin, OS; Shindriaeva, NN | 1 |
| Fernandez, HH; Odin, P | 1 |
| Bengel, G; Ebersbach, G; Ehret, R; Jugel, C; Klostermann, F; Muhlack, S; Müller, T | 1 |
| Arai, M | 3 |
| Dotchin, C; Jusabani, A; Walker, R | 1 |
| Angrisano, S; Lanotte, M; Lopiano, L; Merola, A; Rizzi, L; Zibetti, M | 1 |
| Muhlack, S; Müller, T; Woitalla, D | 1 |
| Abbs, JH; Bendlin, BB; Brooks, BR; Brown, WD; Chung, MK; Dejesus, OT; Dogan, S; Gallagher, CL; Holden, JE; Johnson, SC; Konopacki, RA; Nickles, RJ; Oakes, TR; Pyzalski, RW; Xu, G | 1 |
| Fonseca-Ornelas, L; Hernández-Vargas, R; López-González, I; Reynaud, E; Riesgo-Escovar, J; Zurita, M | 1 |
| Hazan, D; Siegert, S; Szyper-Kravitz, M | 1 |
| Chen, C; Cowles, VE; Illarioshkin, SN; Stolyarov, ID; Sweeney, M | 1 |
| Carpintero, P; de la Fuente-Fernández, R; Llaneza, M; Macías, M; Sanjurjo, LF; Santos-García, D | 1 |
| Belcastro, V; Calabresi, P; Castrioto, A; Gallina, A; Rossi, A; Tambasco, N | 1 |
| Agarwal, P; Alcalay, R; Black, KJ; Chou, KL; Cote, L; Dayalu, P; Frank, S; Friedman, JH; Hartlein, J; Hauser, RA; Lang, AE; Marsh, L; Marshall, F; Moskowitz, C; Ravina, B; Riley, D; Sanchez-Ramos, J; Simon, DK; Simuni, T; Sutton, J; Tuite, P; Weintraub, D; Zesiewicz, T | 1 |
| Bel'gusheva, ME; Fedorova, NV; Iablonskaia, AIu | 1 |
| Adam, JJ; Duits, A; Scholtissen, B; van Houdt, H; Visser-Vandewalle, V; Winogrodzka, A | 1 |
| Kishi, M; Ogawa, E; Sakakibara, R; Takahashi, O; Tateno, F; Uchiyama, T; Yamamoto, T; Yamanishi, T; Yokoi, Y | 1 |
| Bergman, A; Chaudhuri, KR; Findley, LJ; Lowin, J; Morris, S; Roeder, C; Schifflers, M; Wood, E | 1 |
| Ellenbogen, AL; Gupta, SK; Hauser, RA; Hsu, A; Kell, SH; Metman, LV; Modi, NB; O'Connell, MJ; Yao, HM | 1 |
| Jugel, C; Klostermann, F; Marzinzik, F; Müller, T | 1 |
| Lew, MF; McCague, K; Somogyi, M; Welsh, M | 1 |
| Almer, Z; Gerstenhaber, M; Klein, KS; Marsh, L; Repka, MX | 1 |
| Babiuc, RD; Bajenaru, OA; Ene, A; Negreanu, L; Popescu, BO; Smarandache, GC | 1 |
| Buttarelli, FR; Campanelli, D; Fanciulli, A; Misasi, R; Pontieri, FR | 1 |
| Fedorova, NV; Kulua, TK; Popovkina, OA | 1 |
| Becker, N; Munhoz, RP; Teive, HA | 1 |
| Ishihara, A; Kihira, K; Kimura, Y; Matsumoto, M; Miyachi, T; Nakamura, T; Ohtsuki, T; Yamawaki, T | 1 |
| Okun, MS | 1 |
| Grice, T; Stagg, P | 1 |
| Boskovic, R; Clark, M; Houle, S; Kish, SJ; Meyer, JH; Rabiner, EA; Rusjan, P; Sacher, J; Soliman, A; Wilson, AA | 1 |
| Askmark, H; Munro Neville, A; Nyholm, D; Parsons, RW | 1 |
| Añón, MJ; de la Fuente-Fernández, R; Fuster-Sanjurjo, L; Santos-García, D | 1 |
| Ehret, R; Haas, T; Lütge, S; Marg, M; Müller, T | 1 |
| Emre, M; Reichmann, H | 1 |
| Hauser, RA | 2 |
| Benko, R; Jain, L; Safranek, S | 1 |
| Coon, EA; Laughlin, RS | 1 |
| Danoudis, M; Iansek, R | 1 |
| Johansson, A; Klangemo, K; Nyholm, D | 1 |
| Aldred, JL; Brod, LS; Nutt, JG | 1 |
| Bhatia, KP; Dayan, P; Dolan, RJ; Hill, C; Seymour, B; Shiner, T; Wunderlich, K | 1 |
| Bini, V; Bortolato, M; Cannas, A; Marrosu, F; Puligheddu, M; Solla, P | 1 |
| Busk, K; Nyholm, D | 1 |
| Nishijima, K; Saito, S; Shioda, K | 1 |
| Dizdar, N; Hauge, T; Holmberg, B; Jansson, R; Johansson, A; Linder, J; Nyholm, D; Pålhagen, SE; Sydow, O; Wainwright, M; Widner, H | 1 |
| Tarsy, D | 1 |
| Belavic, J | 1 |
| Derkinderen, P; Lebouvier, T; Pouclet, H | 1 |
| Artusi, CA; De Angelis, C; Lopiano, L; Marchisio, A; Merola, A; Montanaro, E; Reggio, D; Ricchi, V; Rizzi, L; Rizzone, M; Zibetti, M | 1 |
| Müller, T; Skodda, S | 1 |
| Nyholm, D | 2 |
| Fedotova, EIu; Illarioshkin, SN; Ivanova-Smolenskaia, IA; Karabanov, AV; Mirkasimov, AF; Poleshchuk, VV; Polevaia, EV; Zagorovskaia, TB | 1 |
| Foote, KD; Hassan, A; Iyer, S; McFarland, NR; Okun, MS; Rodriguez, RL; Sriram, A; Ward, HE | 1 |
| Puig-Junoy, J; Puig-Peiró, R; Valldeoriola, F | 1 |
| Fortuna, G; Pollio, A | 1 |
| Burguera, JA; Martínez-Castrillo, JC | 1 |
| Grandas, FJ; Sesar-Ignacio, Á | 1 |
| Bömelburg, M; Ebersbach, G; Jugel, C; Klostermann, F; Marzinzik, F; Müller, T | 1 |
| Chatamra, K; Dutta, S; Johansson, A; Locke, C; Nyholm, D; Odin, P; Othman, AA | 1 |
| Anderson, LC; Fagerlund, K; Gurvich, O | 1 |
| Datieva, VK; Levin, OS; Makotrova, TA | 1 |
| Benesh, J; Chatamra, K; Espay, AJ; Fernandez, HH; Hass, SL; Hauser, RA; Lenz, RA; Odin, P; Pritchett, Y; Standaert, DG; Vanagunas, A | 1 |
| Albanese, A; Antonini, A; Chaudhuri, KR; Clarke, CE; de Bie, RM; Deuschl, G; Eggert, K; Houeto, JL; Kulisevsky, J; Nyholm, D; Odin, P; Oertel, W; Poewe, W; Pollak, P; Rabey, JM; Rascol, O; Ruzicka, E; Samuel, M; Speelman, H; Sydow, O; Valldeoriola, F; van der Linden, C; Volkmann, J; Østergaard, K | 1 |
| Angrisano, S; Cicolin, A; Lopiano, L; Merola, A; Montanaro, E; Rizzi, L; Rizzone, M; Zibetti, M | 1 |
| Ghika, J; Solida, A; Vingerhoets, F | 1 |
| Kapustina, MT; Karaban', IN; Karasevich, NV; Lukhanina, EP | 1 |
| Montgomery, EB | 1 |
| Schölzel-Dorenbos, CJ | 1 |
| Hauser, RA; Holford, NH | 1 |
| Borra, S; Hauser, RA; Zesiewicz, TA | 1 |
| Eng, JJ; Inkster, LM; MacIntyre, DL; Stoessl, AJ | 1 |
| Bhattacharya, KF; Kaufmann, H; Nouri, S; Olanow, CW; Yahr, MD | 1 |
| Blomgren, M; Goberman, AM | 1 |
| Bakay, RA; Barnhart, H; Chockkan, V; DeLong, MR; Evatt, M; Freeman, A; Green, J; Haber, M; McDonald, W; Mewes, K; Triche, S; Vitek, JL; Wahlay, N; Zhang, JY | 1 |
| Black, KJ; Carl, JL; Hartlein, JM; Hershey, T; Perlmutter, JS; Warren, SL | 1 |
| Apetauerova, D; Norregaard, T; Ryan, P; Tarsy, D | 1 |
| Decker, PA; Dousa, MK; Muenter, MD; Offord, KP; Tyce, GM; Weinshilboum, RM | 1 |
| Bara-Jimenez, W; Bibbiani, F; Chase, TN; Dimitrova, T; Favit, A; Gillespie, M; Morris, MJ; Mouradian, MM; Sherzai, A | 1 |
| Karaban', IM; Kolesnikova, IeE; Serebrovs'ka, TV | 1 |
| Chaná, P; Fierro, A; Reyes-Parada, M; Sáez-Briones, P | 1 |
| Krahn, M; Lang, A; Marras, C; Naglie, G; Tomlinson, G | 1 |
| Barbato, L; Bolner, A; Caraceni, T; Nordera, G; Stocchi, F | 1 |
| Hurka, MR; Leopold, NA; Polansky, M | 1 |
| Gluck, MR; Granson, H; Santana, LA; Yahr, MD | 1 |
| Burkhard, PR; Flachsbart, KD; Fross, RD; Horvath, J; Kleiner-Fisman, G; Lang, AE; Lerch, R; Liaudat, S; Pache, JC; Rakowski, H; Raskoff, WJ; Stalder, H | 1 |
| Bassi, A; Brusa, L; Fedele, E; Giacomini, P; Lunardi, G; Pierantozzi, M; Stanzione, P | 1 |
| Berezetskaia, NM; Burenok, IuA; Karaban', IN; Lukhanina, EP; Mel'nik, NA | 1 |
| Bassi, A; Brusa, L; Fedele, E; Lunardi, G; Pasqualetti, P; Peppe, A; Pierantozzi, M; Stanzione, P; Stefani, A | 1 |
| Bara-Jimenez, W; Chase, TN; Dimitrova, T; Favit, A; Mouradian, MM; Sherzai, A | 1 |
| de Freitas, RM; dos Santos Souza, MP; Fricke, D; Rieder, CR | 1 |
| Cullen, EI; Hahne, WA; Kirby, L; Kumar, D; Okereke, CS; Pratt, RD | 1 |
| Guarnieri, M; Hubble, J; Koller, W; Rabinowicz, AL; Silver, D | 1 |
| Jung, SK | 1 |
| Delville, Y; Fleming, SM; Schallert, T | 1 |
| Fahn, S; Kieburtz, K; Lang, A; Marek, K; Oakes, D; Olanow, CW; Rudolph, A; Shoulson, I; Tanner, C | 1 |
| Antenor, JA; Kotagal, V; McGee-Minnich, L; Moerlein, SM; Perlmutter, JS; Racette, BA; Videen, TO | 1 |
| Aquilonius, SM; Askmark, H; Constantinescu, R; Dizdar, N; Holmberg, B; Jansson, R; Nilsson Remahl, AI; Nyholm, D | 1 |
| Goberman, AM | 1 |
| DeRoche, C; Kastenholz, KV; Nausieda, PA; Pfeiffer, RF; Slevin, JT; Tagliati, M | 1 |
| Artemova, IIu; Batysheva, TT; Boĭko, AN; Chikina, ES; Ganzhula, PA; Ismailov, AM; Khozova, AA; Lisenker, LN; Obydenova, NA; Rotor, LD; Vdovichenko, TV; Vinetskiĭ, IaIa | 1 |
| Alvarez, L; Castro, A; Gimenez-Roldan, S; Grandas, F; Hernandez, B; Jenner, P; Linazasoro, G; Luquin, MR; Macias, R; Marin, C; Obeso, JA; Pavon, N; Rodriguez, M; Rodriguez-Oroz, MC; Stochi, F; Tolosa, E; Vaamonde, J; Valldeoriola, F | 1 |
| Agid, Y; Brooks, DJ; Eggert, K; Holopainen, A; Ostergaard, K; Widner, H | 1 |
| Apajasalo, M; Findley, LJ; Lees, A; Pitkänen, A; Turunen, H | 1 |
| Oberpichler-Schwenk, H | 1 |
| Bakay, RA; Corcos, DM; Metman, LV; Prodoehl, J; Sturman, MM; Vaillancourt, DE | 1 |
| Arthur, K; Foley, SR; Kelly, BD | 1 |
| Bremen, D; Erdmann, C; Muhlack, S; Müller, T; Przuntek, H; Woitalla, D | 1 |
| Beiske, AG; Grotli, R; Lundqvist, C; Nystedt, T; Reiertsen, O | 1 |
| Fahn, S | 3 |
| Cercy, SP; Walker, RH; Warwick, R | 1 |
| Iyer, SS; Morgan, JC; Sethi, KD | 1 |
| Chan, PL; Holford, NH; Nutt, JG | 1 |
| Brown, LA; Doan, J; Pellis, SM; Suchowersky, O; Whishaw, IQ | 1 |
| Bremen, D; Erdmann, C; Goetze, O; Muhlack, S; Müller, T; Przuntek, H; Woitalla, D | 1 |
| Brodsky, MA; Hogarth, P; Nutt, JG | 1 |
| Imamura, A; Uitti, RJ; Wszolek, ZK | 1 |
| Dougherty, MS; Groth, T; Nyholm, D; Palhagen, SE; Westin, J; Yerramsetty, PK | 1 |
| Stocchi, F | 1 |
| Chigir', IP; Fedorova, NV | 1 |
| Haapaniemi, T; Hartikainen, P; Heikkinen, H; Jolma, T; Kaakkola, S; Kinnunen, E; Kuopio, AM; Myllylä, V; Nuutinen, J; Rissanen, A; Satomaa, O | 1 |
| Herkes, GK; McKay, D; Meagher, LJ; Needham, M | 1 |
| Weiner, WJ | 1 |
| Fedorova, NV; Kulua, TK; Levin, OS; Smolentseva, IG | 1 |
| Ludin, HP; Surber, Ch | 1 |
| Chou, KL; Stacy, MA | 1 |
| Alonso-Navarro, H; Jiménez-Jiménez, FJ | 1 |
| Brusa, L; Finazzi-Agrò, E; Iani, C; Miano, R; Moschella, V; Petta, F; Pisani, A; Stanzione, P | 1 |
| Bliwise, DL; Rye, DB; Trotti, LM | 1 |
| Ander, L; Kolf, K; Muhlack, S; Müller, T; Woitalla, D | 1 |
| Aimi, Y; Arai, R; Kudo, M; Nagatsu, I; Taki, K; Yamada, H | 1 |
| Antonini, A; Canesi, M; Dal Fante, M; Isaias, IU; Lopiano, L; Mancini, F; Manfredi, L; Pezzoli, G; Zibetti, M | 1 |
| Hauser, RA; Schapira, AH; Simonson, W | 1 |
| Adeva-Bartolomé, T; Alonso-Navarro, H; Jiménez-Jiménez, FJ; Ruiz-Ezquerro, JJ | 1 |
| Duggal, HS; Singh, I | 1 |
| Hernández, B; Kulisevsky, J; Linazasoro, G | 1 |
| Crucian, GP; Drago, V; Foster, PS; Heilman, KM; Skidmore, F; Skoblar, BM | 1 |
| Babina, LA; Batysheva, TT; Boĭko, AN; Khozova, AA; Kostenko, EV; Malykhina, EA; Minaeva, NG; Shikhkerimov, RK; Vdovichenko, TV; Zaĭtsev, KA; Zhuravleva, EIu | 1 |
| Enna, SJ; Lake, CR; Teychenné, PF; Ziegler, MG | 1 |
| Marsden, CD; Parkes, JD; Quinn, N | 1 |
| Bodis-Wollner, I; Mylin, L; Thornton, J; Yahr, MD | 1 |
| Bergmann, KJ; Clough, CG; Yahr, MD | 1 |
| Shoulson, I | 1 |
| Calne, DB; Ebert, MH; Eisler, T; Kopin, IJ; Krebs, H; Lake, CR; Murphy, DL; Nelson, R; Teräväinen, H; Weise, V; Whetzel, N | 1 |
| Gunder, M; Miller, S; Stewart, RM | 1 |
| Iadgarov, IS | 1 |
| Hadjikonstantinou, M; Markianos, M | 1 |
| Bianchine, JR; Dippel, RL; Hutton, JT; Meyer, PG; Strahlendorf, HK | 1 |
| Coffey, CE; Massey, EW; Olanow, CW; Ross, DR | 1 |
| Gerstenbrand, F; Poewe, W; Ransmayr, G | 1 |
| Alonso, RJ; Covington, TR; Mancall, EL | 1 |
| Hayashi, A; Kishimoto, S; Kondo, T; Narabayashi, H; Sakoda, S; Suzuki, T; Ueji, M | 1 |
| Da Prada, M; Haefely, WE; Keller, HH; Kettler, R; Pieri, L | 1 |
| Beers, MF; Hurtig, H; Melvin, G; Scarpa, A; Stern, M | 1 |
| Albizzati, MG; Bassi, S; Frattola, L; Spano, PF; Trabucchi, M | 1 |
| Indo, T | 1 |
| Spencer, SE; Wooten, GF | 1 |
| Friedrich, FJ; Posner, MI; Rafal, RD; Walker, JA | 1 |
| Calne, DB; Kopin, IJ; Trombley, IK; Ward, CD | 1 |
| Goldstein, M; Gopinathan, G; Hiesiger, E; Lieberman, AN; Nelson, J; Neophytides, A; Walker, R | 1 |
| Calne, DB; Larsen, TA; LeWitt, P; Newman, R | 1 |
| Agid, Y; Barroche, G; de Smet, Y; Lhermitte, F; Mear, JY; Weber, M | 1 |
| Glover, V; Lees, AJ; Sandler, M; Stern, GM; Ward, C | 1 |
| Maier Hoehn, MM | 1 |
| Rondot, P; Ziegler, M | 1 |
| Ballard, P; Langston, JW | 1 |
| Diamond, SG; Markham, CH | 1 |
| Gerdes, U; Lehmann, K; Ulm, G | 1 |
| Callieco, R; Cosi, V; Romani, A; Zerbi, F | 1 |
| Bermejo Pareja, F; Martínez-Martín, P | 1 |
| Klawans, HL | 1 |
| Agnoli, A; Baldassarre, M; D'Urso, R; Del Roscio, S; Falaschi, P; Frajese, G; Mearelli, S; Rocco, A; Ruggieri, S | 1 |
| Lawton, NF; MacDermot, J | 1 |
| Alaghband-Zadeh, J; Das, PK; Gawel, MJ; Lavin, PJ; Rose, FC | 1 |
| Anderson, GM; Chouinard, G; Gauthier, S; Purdy, WC; Young, SN | 1 |
| Calne, DB; Chuang, LW; Eisler, T; Karoum, F; Klein, DF; Liebowitz, MR; Quitkin, FM; Wyatt, RJ | 1 |
| Vartanian, KZ | 1 |
| Caraceni, T; Cocchi, D; Giovannini, P; Martinez-Campos, A; Müller, EE; Novelli, A | 1 |
| Calne, DB; Eisler, T; Kaiser, DL; MacLeod, RM; Thorner, MO | 1 |
| Gopinathan, G; Hiesiger, E; Leibowitz, M; Lieberman, AN; Neophytides, A; Walker, R | 1 |
| Shapiro, MB; Yaar, I | 1 |
| Lees, AJ; Stern, GM | 1 |
| Lang, AE; Marsden, CD; Parkes, JD; Quinn, NP; Toone, B | 1 |
| Glantz, RH; Glatt, SL; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Goldstein, M; Gopinathan, G; Hiesiger, E; Leibowitz, M; Lieberman, AN; Nelson, J; Neophytides, A; Walker, R | 1 |
| Guttridge, D | 1 |
| Mintz, M; Myslobodsky, MS; Radwan, H; Tomer, R | 1 |
| Baker, H; Gauthier, S; Magnussen, I; Osterland, CK; Sternberg, EM; Van Woert, MH; Young, SN | 1 |
| Boshes, B | 1 |
| Calne, DB; Le Witt, PA | 1 |
| Goetz, CG; Nausieda, PA; Tanner, CM | 1 |
| Agnoli, A; Baldassarre, M; D'Urso, R; De Giorgio, G; Falaschi, P; Rocco, A; Ruggieri, S | 1 |
| Manyam, BV | 1 |
| Nausieda, PA; Weiner, WJ | 2 |
| Hildick-Smith, M | 2 |
| Duvoisin, RC | 2 |
| Muenter, MD | 2 |
| Edwards, M | 1 |
| Kaplan, LR; Klawans, HL; Nausieda, PA; Weber, S; Weiner, WJ | 1 |
| Agnoli, A; Bruno, G; Denaro, A; Ruggieri, S | 1 |
| Klawans, HL; Koller, WC; Nausieda, PA; Perlik, S; Weiner, WJ | 1 |
| Berger, JR; Kelley, RE | 1 |
| Koller, WC | 3 |
| Glantz, R; Goetz, CG; Klawans, HL; Nausieda, PA; Weiner, WJ | 1 |
| Gilden, ER; Hansch, EC; Hirsch, SB; Potvin, AR; Potvin, JH; Syndulko, K; Tourtellotte, WW | 1 |
| Sandyk, R | 3 |
| Lieberman, AN; Plasse, HM | 1 |
| Grimes, JD; Hassan, MN | 1 |
| Stewart, RM | 1 |
| Agnoli, A; Baldassarre, M; Falaschi, P; Rocco, A; Ruggieri, S; Urso, RD | 1 |
| Agostini, L; Piccinin, GL; Piccirilli, M | 1 |
| Clough, CG; Mendoza, M; Yahr, MD | 1 |
| La Medica, A; Piccinin, GL; Piccirilli, M | 1 |
| Klawans, HL; Nausieda, PA; Weiner, WJ | 1 |
| Hoehn, MM | 3 |
| Bellizzi, J; Hale, MS | 1 |
| Barrett, RE; Côté, LJ; Fahn, S; Snider, SR | 1 |
| Lander, CM; Lees, AJ; Shaw, KM; Stern, GM | 1 |
| Duvoisin, RC; Mendoza, MM; Yahr, MD | 1 |
| Hirsch, SB; Potvin, AR; Potvin, JH; Syndulko, K; Tourtellotte, WW | 1 |
| Gulliver, PA; Hagan, RM; Raxworthy, MJ | 1 |
| Boomsma, F; Man in 't Veld, A; Schalekamp, M; van den Meiracker, A | 1 |
| Bushenbark, K; Esterlitz, J; Gauger, L; Hauser, RA; Hubble, J; Koller, W; Lilienfeld, D; Malapira, T; Olanow, CW | 1 |
| Abe, T; Saheki, M; Takahashi, S; Tohgi, H; Tsukamoto, Y; Yamazaki, K | 1 |
| Fitzpatrick, AJ | 1 |
| Heerschap, A; Hinshaw, DB; Holshouser, BA; Kolem, H; Komu, M; Masur, H; Möller, HE; Sonninen, P; Vermathen, P; Zijlmans, J | 1 |
| Kuno, S; Mizuta, E; Nakatake, M; Yamasaki, S | 1 |
| Aceves, J; Flores, G; Ondarza, R; Velasco, F; Velasco, M | 1 |
| D'Costa, DF; Moore-Smith, B; Phillips, PA; Sheehan, LJ | 1 |
| Chirakal, R; Firnau, G; Garnett, ES; Nahmias, C; Wahl, L | 1 |
| Carter, JH; Maricle, RA; Nutt, JG | 1 |
| Burns, RS; Davis, TL; Roznoski, M | 2 |
| Greene, P | 1 |
| Fukuuchi, Y; Kobari, M; Nogawa, S; Obara, K; Shinohara, T | 1 |
| Bentlage, C; Björklund, A; Nikkhah, G; Olsson, M | 1 |
| Iacono, RP; Lonser, RR; Yamada, S | 1 |
| Huszonek, JJ | 1 |
| Camicioli, R; Joseph, CL; McWhorter, K; Siple, J | 1 |
| Kawai, H; Mitsui, T; Miyata, M; Saito, S; Sakoda, S | 1 |
| Brannan, T; Yahr, MD | 1 |
| Marsh, CB; Mazzaferri, EL | 1 |
| Korczyn, AD; Kuritzky, A; Nisipeanu, P | 1 |
| Linazasoro, G | 1 |
| Haas, RH; Hill, LR; Nakano, K; Nasirian, F; Pay, M; Shults, CW; Ward, DM | 1 |
| Bennett, KM; Castiello, U | 1 |
| Factor, SA; Schneider, AS | 1 |
| Caligiuri, MP | 1 |
| Mahler, ME; Scharre, DW | 1 |
| Chase, TN; Hoff, J; Metman, LV; Mouradian, MM | 1 |
| Achiron, A; Djaldetti, R; Melamed, E; Ziv, I | 1 |
| Friedman, JH | 1 |
| Brooks, DJ; Burn, DJ; Lammertsma, AA; Luthra, S; Morrish, PK; Osman, S; Sawle, GV; Snow, BJ | 1 |
| Fahn, S; Lew, MF; Moskowitz, CB; Shindo, M; Waters, CH; Wilhelmsen, KC | 1 |
| Paulson, GW | 1 |
| Broe, GA; Hely, MA; Margrie, S; Morris, JG; O'Sullivan, DJ; Rail, D; Reid, WG; Williamson, PM | 1 |
| Abe, T; Kikuchi, T; Nozaki, Y; Takahashi, J; Takahashi, S; Tohgi, H; Ueno, M | 1 |
| Ahlskog, JE; Imke, S; Lieberman, A; Maraganore, DM; Matsumoto, JY; Muenter, M; Schoenfelder, J; Wheeler, K; Wright, KF | 1 |
| Illi, A; Keränen, T; Myllylä, VV; Sotaniemi, KA; Suominen, K | 1 |
| Calne, DB; Duvoisin, RC; Koller, WC | 1 |
| Fahn, S; Grimes, JD; Hurtig, H; Jankovic, J; Klawans, H; Kurlan, R; Muenter, M; Olanow, CW; Shoulson, I; Stern, M | 1 |
| Lang, AE; Mark, MH; Sage, JI; Zimmerman, TR | 1 |
| George, A; Gray, P; Grimes, JD; Mendis, T; Mohr, E; Rusk, IN | 1 |
| Lauterbach, EC | 1 |
| Aquilonius, SM; Bredberg, E; Johansson, K; Johnels, B; Nilsson, D; Nyström, C; Paalzow, L | 1 |
| Fukumura, T; Ichiya, Y; Kuwabara, Y; Masuda, K; Otsuka, M; Sasaki, M | 1 |
| Comella, CL; Ristanovic, RK; Tanner, CM | 1 |
| Breimer, DD; Roos, RA; Tijssen, MA; van der Velde, EA | 1 |
| Lieberman, A | 3 |
| Hossain, MA; Weiner, N | 1 |
| Bergen, M; Fowler, SB | 1 |
| Fullerton, T | 1 |
| Cumming, P; Gjedde, A; Kuwabara, H; Léger, GC | 1 |
| Atchison, PR; Frackowiak, RS; Marsden, CD; Thompson, PD | 1 |
| Bennett, JP; Schuh, LA | 1 |
| Chase, TN; Davis, TL; Giuffra, ME; Mouradian, MM; Sethy, VH | 1 |
| Ahlskog, JE; Atkinson, EJ; Cha, RH; Maraganore, DM; Muenter, MD; O'Brien, PC; Uitti, RJ | 1 |
| Bravi, D; Chase, TN; Davis, TL; Mouradian, MM; Roberts, JW | 1 |
| Goetz, CG; Irwin, I; Kurth, MC; Langston, JW; Stebbins, GT; Tanner, CM; Tetrud, JW | 1 |
| Imai, H; Kondo, T; Nakamura, T; Narabayashi, H | 1 |
| Horstink, MW; Jansen, EN; Roos, RA; Wolters, EC | 2 |
| Graff, E; Harsat, A; Korczyn, AD; Rabey, JM; Shabtai, H; Vered, Y | 1 |
| Chase, TN; Dambrosia, JM; Peppe, A | 1 |
| Cote, L; Fahn, S; Greene, P | 1 |
| Durso, R; Feldman, RG; Isaac, K; Perry, L; Saint-Hilaire, M | 1 |
| Abe, T; Takahashi, S; Tohgi, H | 1 |
| Baraldo, M; Benetello, P; Furlanut, M; Hassan, E; Zara, G | 1 |
| Busenbark, K; Hubble, JP; Huber, SJ; Koller, WC; Michalek, D; Pahwa, R | 1 |
| Carter, JH; Gancher, ST; Hammerstad, JP; Nutt, JG; Woodward, W | 1 |
| Linazasoro, G; Martí Massó, JF; Suárez, JA | 1 |
| Factor, SA | 1 |
| Caraceni, T; Fetoni, V; Geminiani, GC; Genitrini, S; Giovannini, P; Girotti, F; Parati, EA; Soliveri, P; Testa, D | 1 |
| Bowes, SG; Charlett, A; Dobbs, RJ; Dobbs, SM; Nicholson, PW; O'Neill, CJ; Purkiss, A; Weller, C | 1 |
| Cashaw, JL | 1 |
| Irwin, I; Kurth, MC; Langston, JW; Lyness, WH; Tetrud, JW | 1 |
| Cohen, G; DiRocco, A; Merchant, CA; Molinari, S; Moros, D; Mytilineou, C; Yahr, MD | 1 |
| Ahlskog, JE; Kokmen, E; Low, PA; Nickander, KK; Petersen, RC; Tyce, GM; Uitti, RJ | 1 |
| Artem'ev, DV; Damulin, IV; Iakhno, NN | 1 |
| Olanow, CW | 1 |
| Koller, WC; Pahwa, R | 1 |
| Durso, R; Folkerth, RD | 1 |
| Colosimo, C; Hughes, AJ; Lees, AJ; Merello, M; Sieradzan, K | 1 |
| Cabello López, J; Galvañ Berenguer, B; Gómez García, J; Leiva Santana, C | 1 |
| Blanchet, PJ; Chase, TN; de Jong, D; Metman, LV; Mouradian, MM | 1 |
| Carreras, MC; Fernandez Pardal, MM; Gatto, EM; Llesuy, S; Pargament, GA; Poderoso, JJ; Reides, C; Repetto, M; Riobo, NA | 1 |
| Arnold, G; Eichhorn, TE; Gasser, T; Mai, N; Marquardt, C; Oertel, WH; Schwarz, J | 1 |
| Facca, A; Sanchez-Ramos, J | 1 |
| Ahlskog, JE; Dewey, RB; Maraganore, DM; Matsumoto, JY | 1 |
| Buhrfiend, C; Carvey, PM; Goetz, CG; Lipton, JW; Pappert, EJ; Stebbins, GT | 1 |
| Pfeiffer, RF | 1 |
| Revell, SP; Shulman, LM; von Graevenitz, KS | 1 |
| Dubinsky, R; Hubble, JP; Koller, WC; Lyons, K; McGuire, D; Pahwa, R | 1 |
| Hasegawa, T; Mizutani, Y; Nabeshima, T; Ogawa, M; Okada, Y | 1 |
| Bowes, SG; Charlett, A; Dobbs, RJ; Dobbs, SM; Hunt, WB; Kirollos, C; Kosik, R; Mozol, K; Nicholson, PW; O'Neill, CJ; Purkiss, AG; Weller, C | 1 |
| Koller, WC; Lyons, K; Marjama, J; McGuire, D; Pahwa, R; Silverstein, P; Ward, R; Zwiebel, F | 1 |
| Muilenburg, ND | 1 |
| Tesselaar, HJ; Wolters, EC | 1 |
| Block, G; Irr, J; Liss, C; Nibbelink, D; Reines, S | 1 |
| Dike, GL | 1 |
| Lanska, DJ | 1 |
| Amyot, D; Demong, C; Duff, J; Gray, P; Murphy, D; Watson, J; Wilson, W | 1 |
| Calne, DB; Lee, CS; Schulzer, M; Shinotoh, H; Tsui, J; Uitti, RJ; Vingerhoets, FJ | 1 |
| Carter, JH; Lea, ES; Nutt, JG; Woodward, WR | 1 |
| Damhaut, P; Dethy, S; Goldman, S; Hildebrand, J; Laute, MA; Van Blercom, N | 1 |
| Chacón, J; Cordero, M; García de Yébenes, J; Giménez Roldán, S; Mateo, D; Mena, MA; Morales, B; Pastor, M; Pino, MA; Sánchez, V | 1 |
| Carvey, PM; Goetz, CG; Ling, ZD; Lipton, JW; Pappert, EJ; Stebbins, GT | 1 |
| Block, GA; Cyhan, G; Gancher, ST; Hammerstad, JP; Nutt, JG; Woodward, WR | 1 |
| Barbato, L; Berardelli, A; Bonamartini, A; Manfredi, M; Patsalos, PN; Ruggieri, S; Stocchi, F | 1 |
| Koller, WC; Lyons, K; McGuire, D; Pahwa, R; Robischon, M; Silverstein, P; Zwiebel, F | 1 |
| Sakajiri, K; Takamori, M | 1 |
| McCallum, RW; Sarosiek, I; Shifflett, J; Soykan, I; Wooten, GF | 1 |
| Kumar, R; Lang, AE | 1 |
| Gerritsen, JJ; Lammers, GJ; Meinders, AE; Roos, RA; van Laar, T | 1 |
| Aquilonius, SM; Hansson, LE; Johansson, K; Nilsson, D; Nyström, C; Paalzow, L | 1 |
| Chase, TN; Lenz, FA; van den Munckhof, P | 1 |
| Alberts, JL; Stelmach, GE; Tresilian, JR | 1 |
| Aitken, J; Fotteler, B; Jorga, K; Nielsen, T; Sedek, G | 1 |
| Goetz, CG | 1 |
| Blanchet, PJ; Chase, TN; Del Dotto, P; Natté, R; van den Munckhof, P; Verhagen Metman, L | 1 |
| Durso, R; Fernandez, HH | 1 |
| Koller, WC; Wasielewski, PG | 1 |
| Grandas, F; Linazasoro, G; Martínez-Martín, P | 1 |
| Capildeo, R | 1 |
| Ruggieri, S; Silver, DE | 1 |
| Carter, JH; Nutt, JG; Thulin, PC; Woodward, WR | 1 |
| Albani, F; Baruzzi, A; Contin, M; Martinelli, P; Riva, R | 1 |
| Adler, CH; Deptula, D; Dorflinger, E; Hauser, RA; Lew, MF; Marek, KL; O'Brien, C; Pedder, S; Singer, C; Yoo, K | 1 |
| Amano, K; Takakura, K | 1 |
| Goetz, CG; Stebbins, GT; Tanner, CM; Vogel, C | 1 |
| Black, KJ; Carl, JL; Hershey, T; McGee-Minnich, LA; Perlmutter, JS; Stambuk, MK | 1 |
| Hempel, AG; Maaty, MA; Sage, JI; Wagner, ML | 1 |
| Beerahee, A; Burns, E; Citerone, DR; Cyronak, MJ; Fitzpatrick, KL; Leigh, TJ; Lennox, G; Lopez-Gil, A; Taylor, AC; Vakil, SD | 1 |
| Avraham, M; Dabby, R; Djaldetti, R; Melamed, E; Ziv, I; Zoldan, J | 1 |
| Boronat, A; Herreros, R; Serrat, I | 1 |
| Castronuovo, J; Feigin, A; Innis, RB; Marek, KL; Seibyl, JP; Sheff, K; Zoghbi, S | 1 |
| Arnold, G; Kupsch, A | 1 |
| Capilldeo, R; Hutton, JT; Koller, WC; Tolosa, E | 1 |
| Jorga, KM; Nicholl, DJ | 1 |
| Stacy, M | 1 |
| Chen, JJ; Chirakal, R; Nahmias, C; Thompson, M; Wahl, LM | 1 |
| Scheife, RT | 1 |
| Ahlskog, JE; Burnett, OL; Maraganore, DM; Matsumoto, JY; O'Connor, MK; Stark, KF; Turk, MF; Uitti, RJ | 1 |
| Brousolle, E; Dentresangle, C; Froment, JC; Guerin, J; Lavenne, F; Le Bars, D; Pierre, C; Pollak, P; Veyre, L | 1 |
| Banken, L; Fotteler, B; Jorga, K; Snell, P; Steimer, JL | 1 |
| Bennett, KM; Bonfiglioli, C; Castiello, U; Peppard, RF | 1 |
| Minagar, A; Shulman, LM; Weiner, WJ | 1 |
| Brooks, DJ; Gordin, A; Karlsson, M; Korpela, K; Pavese, N; Piccini, P | 1 |
| Bosco, D; Branca, D; Caracciolo, M; Gambardella, A; Napoli, ID; Nicoletti, G; Oliveri, RL; Quattrone, A; Zappia, M | 1 |
| Busenbark, K; Hauser, RA; Hubble, JP; Koller, WC; Malapira, T; Olanow, CW | 1 |
| Chernik, D; Dorflinger, E; Waters, C; Welsh, MD | 1 |
| Bressman, SB; Ford, B; Greene, PE; Hyland, K | 1 |
| Schiess, MC; Van Horn, G | 1 |
| Mark, LP; Mueller, WR; Prieto, TE; Reynolds, NC; Terry, LC | 1 |
| Kesler, S; Niehaus, DJ; Seedat, S; Stein, DJ | 1 |
| Calmes, J; Hendersen, N; Jankovic, J; Olson, S; Ondo, W; Overby, A; Warrior, D | 1 |
| Black, KJ; Carl, JL; Hershey, T; Perlmutter, JS | 1 |
| Cooper, SD; Frank, C; Ismail, HA | 1 |
| Iwata, S; Kaseda, S; Nomoto, M | 1 |
| Haapaniemi, TH; Korpelainen, JT; Myllylä, VV; Sotaniemi, KA; Suominen, K; Tolonen, U | 1 |
| Ebinger, G; Jonkers, N; Michotte, Y; Sarre, S | 1 |
| Borri-Voltattorni, C; Burkhard, P; Dominici, P; Jansonius, JN; Malashkevich, VN | 1 |
| Anderson, VC; Burchiel, KJ; Carter, JH; Hammerstad, JP; Nutt, JG; Pahwa, R; Rufener, SL | 1 |
| Cutler, NR; Dockens, RC; Frackiewicz, EJ; Jhee, SS; Salazar, DE; Shiovitz, TM; Topham, C; Webster, J; Whigan, D | 1 |
| Hironishi, M; Kondo, T; Miwa, H | 1 |
| Danisi, F | 1 |
| Aquilonius, SM; Nilsson, D; Nyholm, D | 1 |
| Ahuja, M; Srivastava, M; Srivastava, T; Trivedi, A | 1 |
| Brenninkmeijer, JH; Freijzer, PL | 1 |
| Bilbao Garay, J; Castilla Castellano, V; Dhimes Tejada, P; Mesa Plaza, N | 1 |
| Adler, CH; Blasucci, L; Carvey, P; Caviness, JN; Chase, WM; Ferry, JJ; Goetz, CG; Kompoliti, K; Leibowitz, MT; Leurgans, S; Pincus, JH; Raman, R; Tan, E; Yones, LC | 1 |
| Steur, EN | 1 |
| Walker, E | 1 |
| Greer, M | 1 |
| Agnoli, A; Carolei, A; Casacchia, M; Fazio, C; Zamponi, A | 1 |
| Morley, JB | 1 |
| Winkelman, AC | 1 |
| Rinne, UK | 1 |
| Bell, RD; Boyar, RM; Carruth, A; Rosenberg, RN | 1 |
| Leibowitz, M; Lieberman, A | 1 |
| Calne, DB; Gielen, AC; Gillespie, MM; Kartzinel, R; Perlow, M; Sadowsky, DA; TEYCHENNE, P | 1 |
| Lipper, S | 1 |
| Elsworth, JD; Kohout, LJ; Lees, AJ; Sandler, M; Shaw, KM; Stern, GM; Youdim, MB | 1 |
| Gilbert, GJ | 1 |
| Coxon, A; Greenacre, JK; Petrie, A; Reid, JL | 1 |
| Klawans, HL; Lupton, MD; Moskovitz, C; Sharf, B | 1 |
| Sears, ES | 1 |
| Ishimitsu, H; Nakasone, S; Namba, S | 1 |
| Ogawa, M; Tohgi, H | 1 |
| Savery, F | 2 |
| Bedard, P; Marsden, CD; Parkes, JD | 1 |
| Estey, E; Goldstein, M; Gopinathan, G; Kupersmith, M; Lieberman, A | 1 |
| Battistin, L; Meneghetti, G; Rigotti, S; Saia, A | 1 |
| Diamond, SG; Markham, CH; Treciokas, LJ | 2 |
| Cotzias, GC; Miller, ST; Papavasiliou, PS; Rosal, VL | 1 |
| Dorner, A; Wajsbort, E; Wajsbort, J | 1 |
| Hokkanen, E; Myllylä, VV; Saarinen, A; Tokola, O | 1 |
| Calne, DB; Eng, N; Nutt, J; Plotkin, C; Williams, A; Ziegler, M | 1 |
| Gilligan, B; O'Halloran, M; Stark, R; Wodak, J | 1 |
| Green, J; Haycook, W; Kilgore, M; Stephens, R | 1 |
| Birkmayer, W; Mentasti, M; Podiwinsky, F; Riederer, P | 1 |
| Barone, DA; Martin, HL | 1 |
| Bernstein, RM | 1 |
| Bender, DA; Earl, CJ; Lees, AJ | 1 |
| Martinelli, P; Montagna, P | 1 |
| Barthal, JS; Garrett, G; Schultz, DR | 1 |
| Estey, E; Goldstein, M; Gopinathan, G; Lieberman, A; Ohashi, T; Sauter, A | 1 |
| Johnson, JC; Maeder, MC; Mazzaferri, EL; Spagna, VA | 1 |
| Jotkowitz, S | 1 |
| McDowell, FH; Miller, ST; Papavasiliou, PS; Rosal, V; Wang, YY | 1 |
| Estey, E; Goldstein, M; Goodgold, A; Gopinathan, G; Kupersmith, M; Lieberman, AN | 1 |
| Hershman, JM; Wingert, TD | 1 |
| Mölsä, P; Rinne, UK | 1 |
| Fahn, S; Hutt, CS; Snider, SR | 1 |
| Davidson, DL; Mawdsley, C; Pullar, IA; Wilson, H; Yates, CM | 1 |
| Feuerstein, C; Gavend, M; Pellat, J; Perret, J; Serre, F; Tanche, M | 2 |
| Cotzias, GC; McDowell, FH; Papavasilliou, PS; Rosal, VL; Sheehan, PJ | 1 |
| Coscia, CJ; Mitchell, J | 1 |
| Bern, SM; Calne, DB; McInturff, D; Pfeiffer, RF; Teychenne, PF | 1 |
| Klawans, HL; Kramer, J; Nausieda, PA; Wiener, WJ | 1 |
| Haddad, S; Kohout, LJ; Lees, AJ; Shaw, KM; Stern, GM | 1 |
| Choi, CR | 1 |
| Dessi'-Fulgheri, P; Glorioso, N; Monaco, F; Rappelli, A; Tedde, R | 1 |
| Bentin, S; Cooper, G; Lavy, S; Melamed, E | 1 |
| Bodis-Wollner, I; Yahr, MD | 1 |
| Fisher, MA; Milner-Brown, HS; Weiner, WJ | 1 |
| Clemens, R | 1 |
| Chase, TN; Shoulson, I | 1 |
| Deze, J; Völler, GW | 1 |
| Marsden, CD; Mindham, RH; Parkes, JD | 1 |
| Avery, GS; Brogden, RN; Pinder, RM; Sawyer, PR; Speight, TM | 1 |
| Bissessur, S; De Man, JJ; Lakke, JP; Moll, L; Seegers, J; Wesseling, H; Witt, FG | 1 |
| Hanzal, F | 2 |
| Kishikawa, H; Namba, S; Omoto, T | 1 |
| Lee, MC; Lippert, DM; Loewenson, RB; Martin, WE; Resch, JA; Tolosa, ES | 1 |
| Bianchine, JR | 1 |
| McKinney, AS | 1 |
| Anderson, F; Joynt, R; Rivera-Calimlim, L; Tandon, D | 1 |
| Hayek, J | 1 |
| Celesia, GG; Quaglieri, CE | 1 |
| Rampton, DS | 1 |
| De la Garza, R; Lombardo, L | 1 |
| Burke, W; Coscia, CJ; Jamroz, G; Lasala, JM; McFarlane, J; Mitchell, J; O'Toole, MM; Wilson, ML | 1 |
| Calne, DB; Pfeiffer, RF; Teychenne, PF | 1 |
| Lin, JT; Ziegler, DK | 1 |
| True, AC | 1 |
| Goodwin, BL; Johnson, RD; Ruthven, CR; Sandler, M | 1 |
| Carrera, N; Marti-Masso, JF; Martínez-Lage, JM | 1 |
| Bowers, MB; Extein, I; Roth, RH; Van Woert, M | 1 |
| Mizuno, Y; Obayashi, T; Ueki, A; Yoshida, M | 1 |
| Londoõ, R | 1 |
| Omoto, T | 1 |
| Martocci, RJ | 1 |
| Gabreëls, FJ; Joosten, EM; Keyser, A; Korten, JJ | 1 |
| Marsden, CD; Parkes, JD; Tarsy, D | 1 |
| Jaatoul, N; Kertesz, A; McInnis, W; Paty, DW | 1 |
| Goodgold, A; Jonas, S; Leibowitz, M; Lieberman, A | 1 |
| Baker, AB; Lee, MC; Loewenson, RB; Martin, WE; Resch, JA; Tolosa, ES | 1 |
| Critchley, E | 1 |
| Bell-Midura, M; Cotzias, GC; Mendez, JS; Papavasiliou, PS; Tolosa, ES | 1 |
| Barbeau, A | 1 |
| Muenter, MD; Sharpless, NS; Tyce, GM | 1 |
| McDowell, FH; Stern, PH; Sweet, RD; Wasterlain, CG | 1 |
| Kishikawa, H; Ohmoto, T | 1 |
| Calne, DB; Findley, LJ; Lewis, PJ; Teychenne, PF | 1 |
| McDowell, FH; Sweet, RD | 1 |
| Cohen, HP; Jacobson, RL; Martin, WE; Tolosa, ES | 1 |
| Cerone, G; Nurzia, A; Pirro, R; Vacca, U | 1 |
| Celesia, GG; Wanamaker, WM | 1 |
| Birket-Smith, E; Dupont, E; Hansen, E; Mikkelsen, B; Pakkenberg, H; Presthus, J; Rautakorpi, I; Riman, E; Rinne, UK | 1 |
| Calne, DB; Fermaglich, J | 1 |
| Reid, WG | 1 |
| Ashford, JW; Hargrave, R | 1 |
| Manji, HK; Potter, WZ; Rudorfer, MV | 1 |
| Bramante, L; Quinn, NP; Ruggieri, S; Steiger, MJ; Stocchi, F | 1 |
| Bowes, SG; Charlett, A; Dobbs, RJ; Dobbs, SM; Henley, M; Nicholson, PW; O'Neill, CJ; Purkiss, AG; Weller, C | 1 |
| Collin, C; Eckernäs, SA; Grahnén, A; Ling-Andersson, A; Nilsson, M; Tiger, G | 1 |
| Fenton, ML; Harnett, DS; Rosenthal, SH | 1 |
| Furukawa, Y; Kondo, T; Mizuno, Y; Narabayashi, H; Nishi, K | 1 |
| Graff, E; Korczyn, AD; Rabey, JM; Shabtai, H; Vered, Y | 1 |
| Hildebrand, J; Moussa, Z; Przedborski, S; Raftopoulos, C | 1 |
| Caligiuri, MP; Heindel, WC; Lohr, JB | 1 |
| Anderson, TJ; Donaldson, IM; Ewer, TC; Gilchrist, NL | 1 |
| Rodnitzky, RL | 1 |
| Hutton, JT; Morris, JL | 2 |
| Marsden, CD; Pires, M; Quinn, NP; Scaravilli, F; Steiger, MJ | 1 |
| Kleedorfer, B; Poewe, W | 1 |
| Gancher, ST; Grandas, F; Lera, G; Nutt, JG; Obeso, JA; Rodriguez, M | 1 |
| Ahlskog, JE; Bailey, PA; Muenter, MD; Stevens, PM | 1 |
| Anderson, JJ; Bravi, D; Chase, TN; Dagani, F; Davis, TL; Ferrari, R; Gillespie, M | 1 |
| Baruzzi, A; Contin, M; Martinelli, P; Riva, R | 1 |
| Cutlip, WD; Makela, EH | 1 |
| Ahlskog, JE; Bailey, PA; Miller, PM; Muenter, MD | 1 |
| Pleet, AB | 1 |
| Karstaedt, PJ; Pincus, JH | 1 |
| Mark, MH; Sage, JI | 2 |
| Deleu, D; Ebinger, G; Michotte, Y | 1 |
| Bowes, SG; Deshmukh, AA; Dobbs, RJ; Dobbs, SM; Leeman, AL; Nicholson, PW; O'Neill, CJ | 1 |
| Ashwood, TJ; Bateman, DN; Tulloch, JA; Woodhouse, KW | 1 |
| Abe, T; Kikuchi, T; Nozaki, Y; Takahashi, S; Tohgi, H | 1 |
| Jiménez, F; Jurado, J; Olvera, J; Rodríguez Cuevas, H; Velasco, F; Velasco, M | 1 |
| Cedarbaum, JM; Gauger, LL; Olanow, CW | 1 |
| Fritz, VU; Ming, A; Temlett, JA | 1 |
| Findley, L; Prasher, D | 1 |
| Carey, RJ | 1 |
| Blunt, S; Jenner, P; Marsden, CD | 1 |
| Jacobs, MB; Varon, J | 1 |
| Cedarbaum, JM; Green-Parsons, A; Toy, LH | 1 |
| Azevedo, MS; Coelho, MH; Manso, CF; Silva, IJ | 1 |
| Joly, P; Lampert, A; Lauret, P; Thomine, E | 1 |
| Cedarbaum, JM; Olanow, CW | 1 |
| Bulling, MT; Burns, RJ; Wing, LM | 1 |
| Ahlskog, JE; Wilkinson, JM | 1 |
| Cedarbaum, JM; Clark, M; Green-Parsons, A; Toy, LH | 1 |
| Bhatti, AR; Devlin, AJ; Ramsden, DB; Williams, AC | 1 |
| Glaeske, CS; Hofman, R; Pfeiffer, RF; Wilken, KE | 1 |
| Marsden, CD; Quinn, NP; Steiger, MJ; Toone, B | 1 |
| Lefeber, EJ; Rainer, C; Scheinost, NA | 1 |
| Coughlin, SS; Karstaedt, PJ; Pincus, JH | 1 |
| Altus, P; Hencey, MA; Weissman, MS | 1 |
| Bowes, SG; Charlett, A; Clark, PK; Deshmukh, AA; Dobbs, RJ; Dobbs, SM; Leeman, AL; Nicholson, PW; O'Neill, CJ; Weller, C | 1 |
| Driver, PS | 1 |
| Block, G; Bush, D; Last, B; Liss, C; Manyam, B; Nakano, K; Nausieda, P; Olanow, CW; Tetrud, JA | 1 |
| Duvoisin, RC; Heikkila, RE; McHale, DM; Sage, JI; Sonsalla, PK | 2 |
| Bodian, CA; Elizan, TS; Mendoza, MR; Moros, DA; Pang, S; Yahr, MD | 1 |
| Korczyn, AD; Rabey, JM; Streifler, M; Treves, T | 1 |
| Blunt, SB; Jenner, P; Marsden, CD | 1 |
| Hodges, LC; Rapp, CG | 1 |
| Sanchez-Ramos, J; Singer, C; Weiner, WJ | 1 |
| Appley, AJ; Apuzzo, ML; Boyd, SD; Couldwell, WT; Neal, JH; Waters, CH; Weiner, LP; Wheelock, VH | 1 |
| Bowes, SG; Clark, PK; Deshmukh, AA; Dobbs, RJ; Dobbs, SM; Leeman, AL; Nicholson, PW; O'Neill, CJ; Weller, C | 1 |
| Cowan, A | 1 |
| Calne, DB; Chu, NS; Lu, CS; Martin, WR; Peppard, RF; Teal, P | 1 |
| Hamaguchi, K; Iwasaki, A; Iwasaki, S; Narabayashi, Y; Takakusagi, M | 1 |
| Belliardo, F; Betto, P; Corradini, C; Giambenedetti, M; Lucarelli, C; Ricciarello, G; Stocchi, F | 1 |
| Abascal, J; Bravo, G; Lopez-Lozano, JJ | 2 |
| Cedarbaum, JM; Clark, M; Green-Parsons, A; Harts, A; McDowell, FH; Silvestri, M; Toy, L | 1 |
| Abe, T; Nozaki, Y; Takahashi, J; Takahashi, S; Tohgi, H; Ueno, M | 1 |
| Frankel, JP; Kempster, PA; Lees, AJ; Stern, GM | 1 |
| Bovingdon, M; Frankel, JP; Kempster, PA; Lees, AJ; Pirtosek, Z; Stern, GM; Webster, R | 1 |
| Meltzer, HY; Parsa, MA; Ramirez, LF; Rohr, T | 1 |
| Boyce, S; Clarke, CA; Crossman, AR; Robertson, RG; Sambrook, MA | 1 |
| Bakay, RA; Byrd, LD; Colbassani, HJ; Herring, CJ; Iuvone, PM; Mandir, A; Sweeney, KM; Watts, RL | 1 |
| Campbell, NR; Goodridge, AE; Hasinoff, BB; Kara, M; Rankine, D | 1 |
| Berchou, RC; Galloway, MP; Kareti, D; LeWitt, PA; Nelson, MV | 1 |
| Boyson, SJ | 1 |
| Berger, HJ; Horstink, MW; Pasman, JW; van't Hof, MA; Zijlmans, JC | 1 |
| Allen, G; Burns, RS; Calne, DB; Peppard, RF; Petruk, KC; Tsui, JK | 1 |
| Baumann, G; Chin, L; Gopinathan, G; Lieberman, A; Miller, E; Neophytides, A | 1 |
| Frankel, JP; Hughes, A; Lees, AJ; Stern, GM | 1 |
| Dousa, MK; Muenter, MD; Tyce, GM | 1 |
| Brown, LK; Miller, A; Moros, DA; Zupnick, HM | 1 |
| Sollazzo, D | 1 |
| Calne, DB; Calne, S; Douglas, J; Postnikoff, D; Poulin, K; Ross, S; Tsui, JK; Woodward, W | 1 |
| Bovingdon, M; Frankel, JP; Kempster, PA; Lees, AJ; Stern, GM; Webster, R | 1 |
| Elizan, TS; Moros, D; Yahr, MD | 1 |
| Chase, TN; Cox, C; Fabbrini, G; Fedio, P; Mohr, E; Schlegel, J; Williams, J | 1 |
| Deleu, D; Ebinger, G; Jacques, M; Michotte, Y | 2 |
| Gauger, LL; Olanow, CW; Werner, EG | 1 |
| Cedarbaum, JM; Kutt, H; McDowell, FH | 2 |
| Gilley, DW; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Aymard, N; Rondot, P; Teinturier, A; Ziegler, M | 1 |
| Rinne, JO; Rinne, UK | 1 |
| Aarli, JA; Gilhus, NE | 1 |
| Gerdes, U; Haagen, K; Ulm, G | 1 |
| Dickins, QS; Dobson, J; Rodnitzky, RL | 1 |
| Crossley, J; Ferguson, I; Peachey, RD; Reynolds, NJ | 1 |
| Davoudi, H; Durso, R; Feldman, RG; Szabo, G | 1 |
| Broe, GA; Genge, S; Hely, MA; Morris, JG; O'Sullivan, DJ; Rail, D; Reid, WG; Williamson, PM | 2 |
| Carter, JH; Hatcher, LF; Nutt, JG; Trotman, TL; Woodward, WR | 1 |
| Cedarbaum, JM; Hoey, M; McDowell, FH | 1 |
| Ahlskog, JE; Bell, GN; Carmichael, SW; Kelly, PJ; Stoddard, SL; van Heerden, JA | 1 |
| Cedarbaum, JM | 1 |
| Jankovic, J; Schwartz, K; Vander Linden, C | 1 |
| Bush, DF; Liss, CL; Morton, A | 1 |
| August, TF; Bush, DF; Lasseter, KC; Musson, DG; Schwartz, S; Smith, ME; Titus, DC; Yeh, KC | 1 |
| Berchou, RC; Galloway, MP; Kareti, D; Kesaree, N; LeWitt, PA; Nelson, MV; Schlick, P | 2 |
| Bush, DF; Hutton, JT; Liss, CL; Morris, JL; Reines, S; Smith, ME | 1 |
| Baronti, F; Chase, TN; Fabbrini, G; Heuser, IJ; Juncos, JL; Mouradian, MM | 1 |
| Feldman, RG; Kelly, MR; Mosbach, PA; Saint Hilaire, MH; Thomas, CA | 1 |
| Reynolds, CM; Riklan, M; Stellar, S | 1 |
| Gibb, WR; Kempster, PA; Lees, AJ; Stern, GM | 1 |
| Factor, SA; Ingenito, AM; Sanchez-Ramos, JR; Weiner, WJ | 1 |
| Luquin, MR; Obeso, JA; Vaamonde, J | 2 |
| Baruzzi, A; Contin, M; Martinelli, P; Procaccianti, G; Riva, R | 1 |
| Ingvarsson, PE; Johnels, B; Steg, G; Thorselius, M; Valls, M | 1 |
| Emskötter, T; Heidenreich, C; Lachenmayer, L | 1 |
| Friedman, JH; Lannon, MC | 1 |
| Factor, SA; Sanchez-Ramos, JR; Weiner, WJ | 1 |
| Golden, WE; Lavender, RC; Metzer, WS | 1 |
| Ahlskog, JE; Carmichael, SW; Kelly, PJ; Stoddard, SL; Tyce, GM; van Heerden, JA | 1 |
| Factor, SA; Hefti, F; Weiner, WJ | 1 |
| Barter, R; Koller, WC; Vetere-Overfield, B | 1 |
| Douyon, R; Klutchko, B; Rotrosen, J; Serby, M | 1 |
| Case, TC; Hruby, VJ; Rockway, T; Snider, SR | 1 |
| Critchley, P; Grandas Perez, FJ; Jenner, PG; Marsden, CD; Nomoto, M; Parkes, JD; Quinn, NP; Stahl, S | 1 |
| Koller, WC; Lang, AE; Marsden, CD; Quinn, NP | 1 |
| Baumann, G; Chin, L; Lieberman, A | 1 |
| Cummings, JL; Friedenberg, DL | 1 |
| Huber, SJ; Paulson, GW; Shulman, HG; Shuttleworth, EC | 2 |
| Bratton, M; Jost, MG; Lannon, MC; Lockhart-Pretti, P; Thomas, CA | 1 |
| Bazan, E; de Yebenes, JG; Mena, MA; Muradas, V; Reiriz, J | 1 |
| Basciani, M; Gambi, D; Ghilardi, MF; Onofrj, M | 1 |
| Jankovic, J | 1 |
| Ahlskog, JE; Bailey, PA; Bell, GN; McManis, PG; Muenter, MD | 1 |
| Ahlskog, JE; Muenter, MD | 2 |
| Herskovits, E; Leston, J; Yorio, A | 1 |
| Ogawa, N; Ujike, H; Yamamoto, M | 1 |
| Cedarbaum, JM; Dhar, AK; Kutt, H; McDowell, FH; Watkins, S | 1 |
| Boyes, BE; Cumming, P; Martin, WR; McGeer, EG | 1 |
| Birkmayer, W | 1 |
| Bodis-Wollner, I; Onofrj, M | 1 |
| Birkmayer, JD; Birkmayer, W | 1 |
| Duvoisin, RC; Golbe, LI | 1 |
| Ahlskog, JE; Duvoisin, RC; Foo, SH; Golbe, LI; Gopinathan, G; Lieberman, AN; Muenter, MD; Neophytides, AN | 1 |
| Gillman, MA; Sandyk, R | 1 |
| Etemadzadeh, E; Kaakkola, S; Lindén, IB; Männistö, P; Nissinen, E; Pohto, P | 1 |
| Lieberman, AN | 2 |
| Betto, P; Giambenedetti, M; Lucarelli, C; Ricciarello, G; Ruggeri, S; Stocchi, F | 1 |
| Albrecht, JW; Hutton, JT; Kopetzky, MT; Román, GC | 1 |
| Carroll, VS; Carvey, PM; Gilley, D; Goetz, CG; Klawans, HL; Shannon, KM; Tanner, CM | 1 |
| Bouchard, S; Gawel, MJ; Libman, I; Riopelle, RJ | 1 |
| Denham, MJ; Deshmukh, AA; Dobbs, RJ; Dobbs, SM; Leeman, AL; Nicholson, PW; O'Neill, CJ; Royston, JP | 1 |
| Berger, J; Factor, SA; Sanchez-Ramos, J; Weiner, WJ | 1 |
| Ferraro, TN; Hare, TA; Manyam, BV | 1 |
| Como, P; Kurlan, R | 1 |
| Allain, H; Bentué-Ferrer, D; Reymann, JM; Sabouraud, O; Van den Driessche, J | 1 |
| Cedarbaum, JM; Hoey, M; Kutt, H; McDowell, FH | 1 |
| Elias, JW; Hutton, JT; Imke, SC; Morris, JL; Román, GC | 1 |
| Bergamasco, B; Chiadò, I; De Gennaro, T; Delsedime, M; Gilli, M; Rainero, I; Riccio, A | 1 |
| Carruthers, M; Quinn, N | 1 |
| Duvoisin, RC; Heikkila, R; Sage, JI; Sonsalla, PK; Trooskin, S | 1 |
| Bukhanov, VP | 1 |
| Comella, CL; Goetz, CG; Klawans, HL; Penn, RD; Shannon, KM; Tanner, CM; Witt, TR | 1 |
| Brown, RG; Gotham, AM; Marsden, CD; Nissenbaum, H; Quinn, NP; Toone, B | 1 |
| Agnoli, A; Brughitta, G; Ruggieri, S; Stocchi, F | 1 |
| Gopinathan, G; Lieberman, AN; Neophytides, A; Pasternack, P | 1 |
| Carvey, PM; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Friedman, JH; Max, J; Swift, R | 1 |
| Janota, I; Marsden, CD; Parkes, D; Quinn, N | 1 |
| Agniel, A; Celsis, P; Demonet, JF; Doyon, B; Marc-Vergnes, JP; Montastruc, JL; Puel, M; Rascol, A | 1 |
| Bouchard, S; Gawel, M; Libman, I; Riopelle, R | 1 |
| Jankovic, J; Orman, J | 1 |
| Alberts, MJ; Olanow, CW | 1 |
| Chase, TN; Fabbrini, G; Juncos, JL; Kask, AM; Mouradian, MM; Serrati, C | 1 |
| Clough, CG | 1 |
| Carroll, VS; Goetz, CG; Klawans, HL; Shannon, KM; Tanner, CM | 2 |
| Corbin, DO; Williams, AC | 1 |
| Herbster, G; Koller, WC | 1 |
| Chase, TN; Fabbrini, G; Juncos, JL; Mouradian, MM; Serrati, C | 1 |
| Chase, TN; Fabbrini, G; Juncos, JL; Mouradian, MM | 1 |
| Breck, L; Cedarbaum, JM; Kutt, H; McDowell, FH | 2 |
| Bozek, CB; Calne, DB; Calne, S; Purves, S; Suchowersky, O | 1 |
| Patterson, JF | 1 |
| Klawans, HL; Paleologos, N | 1 |
| Wilson, JA | 1 |
| Carter, JH; Nutt, JG; Woodward, WR | 1 |
| Clarke, A; Kurlan, R; Miller, C; Rivera-Calimlim, L; Rubin, AJ; Shoulson, I | 1 |
| Langdon, N; Malcolm, PN; Parkes, JD | 1 |
| Calne, DB; Glover, R; Lau, E; Schulzer, M; Waterman, K | 1 |
| Doe, J | 1 |
| Gershanik, OS; Leist, A | 1 |
| van der Drift, JH | 1 |
| Glantz, RH; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Friedman, J | 1 |
| Ballard, PA; Langston, JW; Tetrud, JW | 1 |
| Caranasos, GJ; Cluff, LE; Stewart, RB | 1 |
| Bakker, K; Bruno, G; Chase, TN; Ruggieri, S; Tamminga, CA | 1 |
| Feldman, RG; Lannon, MC | 1 |
| Kapfhammer, HP; Kuss, HJ; Rüther, E | 1 |
| Caraceni, T; Giovannini, P; Grassi, MP; Piccolo, I; Scigliano, G; Soliveri, P | 1 |
| Reches, A | 1 |
| Wirz, D | 1 |
| Bitton, V; Melamed, E; Zelig, O | 1 |
| Di Battista, G; Di Meo, L; Figà-Talamanca, L; Gualandi, C; Lo Russo, F; Neri, G | 1 |
| Berglund, B; Kaijser, L; Sachs, C | 1 |
| Askenasy, JJ; Yahr, MD | 1 |
| Calne, DB; Jaffe, M; Larsen, TA; LeWitt, PA; Newman, RP | 1 |
| Azevedo, M; Coelho, H; Manso, C | 1 |
| Friedman, A | 1 |
| Murray, TS; Wilson, JA | 1 |
| Admani, AK; Cordingley, GJ; Harris, RI; Verma, S | 1 |
| Benvenuti, F; Bindi, A; Costantini, S; De Scisciolo, G; Pantaleo, T; Rossi, L; Zappoli, R | 1 |
| Anderson, JL; Nutt, JG; Woodward, WR | 1 |
| Zhou, XD | 1 |
| Yu, HZ | 1 |
| Bermejo Pareja, F; de Yébenes, JG; Martinez-Martin, P; Muradas, V | 1 |
| Auffranc, JC; Berbis, P; Fabre, JF; Garnier, JP; Privat, Y | 1 |
| Chase, TN; Fermaglich, J | 1 |
| Chase, TN; Woods, AC | 1 |
| Glasgow, GL; Henley, JW; Willoughby, EW | 1 |
| Chase, TN | 1 |
| Rondot, P | 1 |
| Braham, J; Sarova-Pinhas, I | 1 |
| Cotzias, GC; Mena, I; Papavasiliou, PS | 1 |
| Markham, CH | 1 |
| Carreray, N; Del Amo, F; Delgado, G; Marti-Massó, JF; Martínez-Lage, JM | 1 |
| Fermaglich, J | 1 |
| Mones, RJ | 2 |
| Olanow, CW; Schwartz, AM; Spencer, A | 1 |
| Andrews, CJ; Somerville, B | 1 |
| Bianchine, JR; Sunyapridakul, L | 1 |
| Barry, PE; Marsden, CD; Parkes, JD; Zilkha, KJ | 1 |
| Chase, TN; Donnelly, EF | 1 |
| Klawans, HL; Ringel, SP | 1 |
| Dinsmore, SR; Mrochek, JE; Ohrt, DW | 1 |
| Cotzias, GC; Lawrence, WH; Papavasiliou, PS | 1 |
| Brody, JA; Chase, TN; Holden, EM | 2 |
| Mars, H | 2 |
| Duvoisin, RC; Marsden, CD | 1 |
| Diamond, SG; Markham, C; Treciokas, LJ | 1 |
| Miller, EM; Wiener, L | 1 |
| Cotzias, GC; Dahl, LK; Düby, SE | 1 |
138 review(s) available for carbidopa and Parkinson Disease
| Article | Year |
|---|---|
A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease | 2022 |
SARS-CoV-2 vaccination, Parkinson's disease, and other movement disorders: case series and short literature review.
Topics: Carbidopa; COVID-19; COVID-19 Vaccines; Deep Brain Stimulation; Drug Combinations; Humans; Immunization, Secondary; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Treatment Outcome; Vaccination | 2022 |
Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Humans; Levodopa; Parkinson Disease | 2022 |
Determination of levodopa by chromatography-based methods in biological samples: a review.
Topics: Carbidopa; Catecholamines; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease | 2022 |
The Prephase Nursing in Levodopa Carbidopa Intestinal Gel Therapy.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Neurodegenerative Diseases; Parkinson Disease; Quality of Life | 2022 |
Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Follow-Up Studies; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life; Sleep | 2022 |
Molecular understanding of the translational models and the therapeutic potential natural products of Parkinson's disease.
Topics: Aged; Biological Products; Carbidopa; Cholinergic Antagonists; Dopamine; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase; Neurodegenerative Diseases; Parkinson Disease | 2022 |
Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine; Humans; Levodopa; Parkinson Disease | 2022 |
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson's Disease: A Systematic Review and Bayesian Network Meta-analysis.
Topics: Aged; Apomorphine; Carbidopa; Humans; Levodopa; Middle Aged; Network Meta-Analysis; Parkinson Disease; Quality of Life | 2022 |
[Triple combination of levodopa, carbidopa and entacapone by intrajejunal pump in advanced Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Observational Studies as Topic; Parkinson Disease | 2022 |
Acute/subacutae demyelinating polyneuropathy in Parkinson's Disease patients on levodopa-carbidopa intestinal gel therapy: systematic review with new case report.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Polyneuropathies; Prospective Studies | 2023 |
The Use of Liquid Sinemet in Routine Clinical Practice of Advanced Parkinson's Disease: A Comparison of Available Options.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Postural Balance; Time and Motion Studies | 2023 |
A systematic review of the potential consequences of abnormal serum levels of vitamin B6 in people living with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Epilepsy; Humans; Levodopa; Parkinson Disease; Polyneuropathies; Vitamin B 12; Vitamin B 6; Vitamins | 2023 |
Infusion Therapies in the Treatment of Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2023 |
Tools and criteria to select patients with advanced Parkinson's disease for device-aided therapies: a narrative review.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2023 |
Current and novel infusion therapies for patients with Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechols; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2023 |
Levodopa-Carbidopa Intestinal Gel Injection for Patient with Severe Parkinson's Disease Followed by Total Hip Arthroplasty: A Case Report and Literature Review.
Topics: Antiparkinson Agents; Arthroplasty, Replacement, Hip; Carbidopa; Drug Combinations; Dyskinesias; Female; Gels; Humans; Levodopa; Middle Aged; Parkinson Disease | 2023 |
Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson's disease?
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Parkinson Disease; Quality of Life; Standard of Care | 2023 |
Percutaneous Endoscopic Gastrostomy with Jejunal Extension Tube for the Delivery of Levodopa Carbidopa Intestinal Gel: Clinical Practice Guidelines of the Romanian Society of Digestive Endoscopy.
Topics: Antiparkinson Agents; Carbidopa; Consensus; Drug Administration Routes; Drug Combinations; Drug Compounding; Endoscopy, Gastrointestinal; Equipment Design; Gastrostomy; Gels; Humans; Infusion Pumps; Jejunum; Levodopa; Parkinson Disease; Treatment Outcome | 2019 |
Levodopa/Carbidopa Enteral Suspension: A Review in Advanced Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2019 |
A systematic review on the clinical experience with melevodopa/carbidopa fixed combination in patients with Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2019 |
Diagnosis and Treatment of Parkinson Disease: A Review.
Topics: Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Diagnosis, Differential; Disease Progression; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease; Prognosis | 2020 |
The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson's Disease: A Systematic Review.
Topics: Administration, Oral; Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2020 |
Levodopa/carbidopa/entacapone for the treatment of early Parkinson's disease: a meta-analysis.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Humans; Levodopa; Nitriles; Parkinson Disease | 2020 |
Levodopa Inhalation Powder: A Review in Parkinson's Disease.
Topics: Administration, Inhalation; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Powders | 2020 |
The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Clinical Decision-Making; Deep Brain Stimulation; Dopamine Agents; Drug Combinations; Humans; Infusions, Subcutaneous; Levodopa; Parkinson Disease | 2020 |
LCIG in treatment of non-motor symptoms in advanced Parkinson's disease: Review of literature.
Topics: Antiparkinson Agents; Carbidopa; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life | 2020 |
Medical Management and Prevention of Motor Complications in Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Disease Management; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2020 |
Drugs for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Dopaminergic Neurons; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 2021 |
Comparison chart: Drugs for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Dopamine Agonists; Humans; Kidney Diseases; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2020 |
Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta-Analysis.
Topics: Activities of Daily Living; Antiparkinson Agents; Apomorphine; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life | 2021 |
Phytobezoar Associated with Levodopa-carbidopa Intestinal Gel Infusion in Patients with Parkinson's Disease: A Case Report and Literature Review.
Topics: Antiparkinson Agents; Bezoars; Carbidopa; Humans; Levodopa; Parkinson Disease | 2021 |
Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life | 2021 |
The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Observational Studies as Topic; Parkinson Disease; Quality of Life; Retrospective Studies | 2021 |
On demand therapy for Parkinson's disease patients: Opportunities and choices.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine Agonists; Drug Administration Routes; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2021 |
Effects of rehabilitation on reducing dyskinesias in a Parkinson's disease patient abusing therapy with levodopa-carbidopa intestinal gel: a paradigmatic case report and literature review.
Topics: Carbidopa; Drug Combinations; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2021 |
Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine; Dopamine Agents; Dopamine Agonists; Drug Combinations; Humans; Infusion Pumps, Implantable; Infusions, Intravenous; Infusions, Subcutaneous; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2017 |
Using tube feeding and levodopa-carbidopa intestinal gel application in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Enteral Nutrition; Female; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease; Quality of Life | 2018 |
Levodopa-carbidopa intestinal gel: 'dismantling the road blocks of a journey'.
Topics: Administration, Intranasal; Antiparkinson Agents; Carbidopa; Drug Combinations; Gastrostomy; Humans; Jejunostomy; Jejunum; Levodopa; Parkinson Disease; Patient Compliance | 2018 |
Adjunctive Therapies in Parkinson's Disease: How to Choose the Best Treatment Strategy Approach.
Topics: Algorithms; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2018 |
Apomorphine in the treatment of Parkinson's disease: a review.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2018 |
[Selection of the optimal device-aided therapy in Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Gels; Humans; Hungary; Levodopa; Parkinson Disease; Quality of Life | 2019 |
Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review.
Topics: Antiparkinson Agents; Basal Ganglia; Carbidopa; Dopamine Agonists; Drug Carriers; Drug Combinations; Drug Compounding; Drug Liberation; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Signal Transduction | 2019 |
The Accordion Pill
Topics: Administration, Oral; Carbidopa; Delayed-Action Preparations; Gastrointestinal Tract; Half-Life; Humans; Levodopa; Parkinson Disease; Solubility | 2019 |
Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Observational Studies as Topic; Parkinson Disease; Precision Medicine; Prospective Studies; United States | 2019 |
Parkinson Disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Exercise; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Therapies, Investigational | 2019 |
Treatment of Parkinson's disease in the advanced stage.
Topics: Antiparkinson Agents; Carbidopa; Dopamine Agonists; Drug Combinations; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2013 |
When the going gets tough: how to select patients with Parkinson's disease for advanced therapies.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease; Patient Selection | 2013 |
[Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study].
Topics: Antiparkinson Agents; Carbidopa; Catechols; Corpus Striatum; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2013 |
[Pharmacotherapy of Parkinson's disease: progress or regress?].
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dopamine; Dopamine Antagonists; Drug Combinations; Humans; Levodopa; Parkinson Disease; Substantia Nigra | 2013 |
[The treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Combined Modality Therapy; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Physical Therapy Modalities | 2013 |
[Treatment possibilities in advanced Parkinson's disease].
Topics: Administration, Oral; Age Factors; Antiparkinson Agents; Apomorphine; Carbidopa; Cognition Disorders; Deep Brain Stimulation; Dopamine Agents; Drug Tolerance; Duodenum; Dyskinesia, Drug-Induced; Gels; Humans; Infusion Pumps, Implantable; Levodopa; Parkinson Disease; Quality of Life; Severity of Illness Index | 2013 |
Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration.
Topics: Antiparkinson Agents; Carbidopa; Drug Administration Routes; Humans; Jejunum; Levodopa; Parkinson Disease | 2014 |
[Clinical studies with levodopa/carbidopa intestinal gel].
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Cognition; Confounding Factors, Epidemiologic; Dopamine Agents; Drug Delivery Systems; Gels; Humans; Intestines; Levodopa; Parkinson Disease; Peripheral Nervous System Diseases; Quality of Life; Research Design; Sample Size; Sleep | 2014 |
[Management of complications related to intraduodenal infusion of levodopa/carbidopa in patients with Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Therapy, Combination; Duodenum; Gastrointestinal Diseases; Gastrostomy; Granuloma; Humans; Infusion Pumps; Infusions, Parenteral; Levodopa; Multicenter Studies as Topic; Observational Studies as Topic; Pain; Parkinson Disease; Peritonitis; Postoperative Complications; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Surgical Stomas | 2014 |
Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls.
Topics: Amantadine; Antiparkinson Agents; Carbidopa; Catechols; Dopamine Agonists; Drug Administration Schedule; Drug Combinations; Hospitalization; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitriles; Nursing Care; Parkinson Disease | 2014 |
IPX066 , a mixed immediate/sustained-release levodopa preparation for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease; Time Factors | 2014 |
Polyneuropathy associated with duodenal infusion of levodopa in Parkinson's disease: features, pathogenesis and management.
Topics: Administration, Oral; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Parkinson Disease; Polyneuropathies; Vitamin B 12 | 2015 |
[Levodopa: the story continues].
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Male; Parkinson Disease | 2014 |
Novel formulations and modes of delivery of levodopa.
Topics: Animals; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease | 2015 |
[Pharmacoeconomic aspects of using levodopa/carbidopa intestinal gel in Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Europe; Humans; Levodopa; Parkinson Disease | 2014 |
[Treatment for advanced Parkinson's disease with intestinal levodopa/carbidopa gel: review of efficacy and safety].
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2014 |
Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Dyskinesia, Drug-Induced; Half-Life; Humans; Levodopa; Parkinson Disease | 2015 |
Carbidopa/levodopa extended-release capsules (Rytary).
Topics: Animals; Antiparkinson Agents; Capsules; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2015 |
Approach to the patient with Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Diagnosis, Differential; Drug Combinations; Humans; Levodopa; Parkinson Disease; Primary Health Care; Risk Factors | 2015 |
Best practice in placement of percutaneous endoscopic gastrostomy with jejunal extension tube for continuous infusion of levodopa carbidopa intestinal gel in the treatment of selected patients with Parkinson's disease in the Nordic region.
Topics: Antiparkinson Agents; Carbidopa; Gastrostomy; Gels; Humans; Levodopa; Parkinson Disease; Patient Selection; Postoperative Complications; Quality of Life; Scandinavian and Nordic Countries | 2015 |
Current treatment and future prospects of dopa-induced dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Practice Guidelines as Topic; Treatment Outcome | 2015 |
[Current possibilities of quality of life improvement in the late stages of Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Dopamine Agents; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome | 2015 |
Duopa--a carbidopa/levodopa enteral suspension for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Chemistry, Pharmaceutical; Drug Administration Routes; Drug Combinations; Drug Costs; Humans; Levodopa; Motor Activity; Parkinson Disease; Treatment Outcome | 2015 |
Carbidopa levodopa enteral suspension.
Topics: Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease; Suspensions | 2015 |
Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Interactions; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Movement disorders: advances in 2015.
Topics: Animals; Antiparkinson Agents; Carbidopa; DNA-Binding Proteins; Drug Combinations; Humans; Levodopa; Mitochondrial Proteins; Movement Disorders; Parkinson Disease; Transcription Factors | 2016 |
[Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Dopamine Agents; Dyskinesias; Gastrostomy; Gels; Humans; Intestines; Jejunostomy; Levodopa; Parkinson Disease; Quality of Life | 2015 |
New and emerging medical therapies in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Routes; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Quality of Life | 2016 |
Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2016 |
Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Quality of Life | 2016 |
An update on the diagnosis and treatment of Parkinson disease.
Topics: Age of Onset; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Dyskinesias; Humans; Levodopa; Life Expectancy; Parkinson Disease; Practice Guidelines as Topic; Risk Assessment | 2016 |
Continuous dopaminergic stimulation therapy for Parkinson's disease - recent advances.
Topics: Administration, Cutaneous; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2016 |
[Practical Use of the Levodopa Pump].
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Duodenum; Equipment Design; Gastrostomy; Humans; Infusion Pumps, Implantable; Jejunum; Levodopa; Neurologic Examination; Parkinson Disease | 2016 |
Comment on: "Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review".
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Intestines; Levodopa; Parkinson Disease | 2016 |
Novel Levodopa Formulations for Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Chemistry, Pharmaceutical; Drug Combinations; Humans; Levodopa; Nitriles; Parkinson Disease | 2016 |
The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine.
Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Drug Administration Routes; Drug Combinations; Gels; Humans; Intestines; Levodopa; Parkinson Disease | 2016 |
Algorithms for the treatment of motor problems in Parkinson's disease.
Topics: Algorithms; Antiparkinson Agents; Carbidopa; Consensus; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease | 2017 |
Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia.
Topics: Antiparkinson Agents; Apomorphine; Australia; Carbidopa; Deep Brain Stimulation; Drug Combinations; Humans; Infusions, Parenteral; Infusions, Subcutaneous; Levodopa; Parkinson Disease | 2017 |
Pharmacokinetics of Rytary
Topics: Animals; Antiparkinson Agents; Capsules; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Drug Compounding; Humans; Levodopa; Parkinson Disease | 2017 |
Development of new levodopa treatment strategies in Parkinson's disease-from bedside to bench to bedside.
Topics: Animals; Carbidopa; Central Nervous System; Drug Approval; Drug Combinations; Drug Delivery Systems; Drug Design; European Union; Gels; History, 20th Century; History, 21st Century; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Tablets | 2017 |
The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease.
Topics: Aged; Animals; Antiparkinson Agents; Carbidopa; Drug Interactions; Humans; Levodopa; Parkinson Disease; Tissue Distribution | 2007 |
Pharmacologic management of Parkinson's disease in long-term care residents: maintaining functionality to improve quality of life.
Topics: Accidental Falls; Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Disease Progression; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Monoamine Oxidase Inhibitors; Nursing Homes; Parkinson Disease; Patient Care Planning; Practice Guidelines as Topic; Quality of Life; Safety Management | 2007 |
Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Topics: Antiparkinson Agents; Biological Availability; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Hyperkinesis; Levodopa; Male; Parkinson Disease; Solubility; Time Factors | 2010 |
[Intraduodenal infusion of levodopa].
Topics: Carbidopa; Deep Brain Stimulation; Dopamine Agents; Drug Administration Routes; Duodenum; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2010 |
Entacapone.
Topics: Animals; Antiparkinson Agents; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Half-Life; Humans; Levodopa; Nitriles; Parkinson Disease | 2010 |
Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; MEDLINE; Parkinson Disease; Randomized Controlled Trials as Topic | 2011 |
Treatment of advanced Parkinson's disease with levodopa/carbidopa intestinal gel is associated with improvements in Hoehn and Yahr stage.
Topics: Antiparkinson Agents; Carbidopa; Cross-Over Studies; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Outcome Assessment, Health Care; Parkinson Disease; Randomized Controlled Trials as Topic; Severity of Illness Index | 2012 |
Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease | 2012 |
IPX066: a novel carbidopa-levodopa extended-release formulation.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2012 |
Clinical inquiry. Which drugs work best for early Parkinson's disease?
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Family Practice; Humans; Indoles; Levodopa; Motor Skills; Neurologic Examination; Parkinson Disease | 2012 |
Duodopa® treatment for advanced Parkinson's disease: a review of efficacy and safety.
Topics: Animals; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Drug Combinations; Humans; Levodopa; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome | 2012 |
[Proposed alternative to standard apomorphine challenge test].
Topics: Antidotes; Antiparkinson Agents; Apomorphine; Carbidopa; Domperidone; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Injections, Subcutaneous; Levodopa; Motor Activity; Parkinson Disease; Severity of Illness Index; Time Factors | 2012 |
[Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
Topics: Aftercare; Ambulatory Care; Antiparkinson Agents; Apomorphine; Benserazide; Carbidopa; Caregivers; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Infusions, Subcutaneous; Levodopa; Parkinson Disease; Patient Education as Topic; Patient Selection; Retrospective Studies | 2012 |
Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Administration Routes; Evidence-Based Practice; Humans; Levodopa; Parkinson Disease | 2013 |
Two advances in the management of Parkinson disease.
Topics: Age Factors; Antiparkinson Agents; Benzothiazoles; Carbidopa; Dyskinesias; Electric Stimulation Therapy; Forecasting; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Risk Factors; Stereotaxic Techniques; Thiazoles | 2002 |
Entacapone/levodopa/carbidopa combination tablet: Stalevo.
Topics: Administration, Oral; Antiparkinson Agents; Carbidopa; Catechols; Clinical Trials as Topic; Drug Combinations; Humans; Levodopa; Movement Disorders; Nitriles; Parkinson Disease; Tablets | 2003 |
Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
Topics: Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease | 2004 |
[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
Topics: Akathisia, Drug-Induced; Animals; Antiparkinson Agents; Carbidopa; Catechols; Clinical Trials as Topic; Dopamine; Drug Therapy, Combination; Humans; Hyperhomocysteinemia; Levodopa; MPTP Poisoning; Neuroprotective Agents; Nitriles; Parkinson Disease; Parkinsonian Disorders; Rats; Treatment Outcome | 2005 |
Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Topics: Antiparkinson Agents; Brain; Carbidopa; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Delayed-Action Preparations; Dopa Decarboxylase; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease | 2006 |
Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Care; Nitriles; Parkinson Disease | 2006 |
Motor fluctuations in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Motor Activity; Neurosurgical Procedures; Parkinson Disease; Tremor | 2006 |
Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease.
Topics: Carbidopa; Dyskinesias; Gels; Humans; Infusion Pumps; Infusions, Parenteral; Levodopa; Parkinson Disease | 2006 |
[Prevention and treatment of fluctuations in patients with Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dopamine Agonists; Drug Administration Routes; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Infusion Pumps, Implantable; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Treatment Outcome | 2006 |
Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitriles; Parkinson Disease; Patient Education as Topic; Pharmacists; Professional Role; Severity of Illness Index | 2007 |
The pharmacology of Parkinson's disease: basic aspects and recent advances.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Bromocriptine; Carbidopa; Corpus Striatum; Dopamine; Ergolines; Humans; Kidney; Kinetics; Levodopa; Lisuride; Liver; Methyldopa; Norepinephrine; Parkinson Disease; Pergolide; Receptors, Dopamine; Selegiline; Serotonin; Stereotyped Behavior; Substantia Nigra; Tyramine | 1984 |
Sinemet and the treatment of Parkinsonism.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Chemical Phenomena; Chemistry; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Prognosis | 1981 |
Treatment of Parkinson's disease. From theory to practice.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Dopamine; Drug Combinations; Free Radicals; Humans; Levodopa; Oxygen; Parkinson Disease; Selegiline | 1994 |
The syndrome of gait ignition failure: a report of six cases.
Topics: Aged; Benserazide; Brain; Carbidopa; Diagnosis, Differential; Drug Therapy, Combination; Female; Gait; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement Disorders; Neurologic Examination; Parkinson Disease; Syndrome; Tomography, X-Ray Computed | 1993 |
Treatment of Parkinson's disease.
Topics: Alzheimer Disease; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Neurons; Parkinson Disease; Receptors, Dopamine; Selegiline | 1993 |
Treatment of early Parkinson's disease: are complicated strategies justified?
Topics: Animals; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pergolide; Selegiline | 1996 |
Initiating therapy for Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Amantadine; Antiparkinson Agents; Carbidopa; Cholinergic Antagonists; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline | 1998 |
Too many treatments for Parkinson's disease: how should they be used?
Topics: Antiparkinson Agents; Carbidopa; Decision Making; Drug Combinations; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Stereotaxic Techniques | 2000 |
[Pharmacological treatments of Parkinson's disease].
Topics: Amantadine; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Genetic Therapy; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitrophenols; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Tolcapone | 2001 |
Parkinson's disease. Therapeutic strategies to improve patient function and quality of life.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life | 2002 |
[Serotonin syndrome: report of a fatal case and review of the literature].
Topics: Aged; Antiparkinson Agents; Carbidopa; Depressive Disorder, Major; Drug Combinations; Drug Synergism; Fatal Outcome; Fluoxetine; Humans; Levodopa; Male; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin Syndrome | 2002 |
Recent advances in research on Parkinsonism.
Topics: Acetylcholinesterase; Adult; Apomorphine; Benserazide; Brain; Bromocriptine; Carbidopa; Dopa Decarboxylase; Dopamine; Drug Therapy, Combination; gamma-Aminobutyric Acid; Humans; Levodopa; Norepinephrine; Parkinson Disease; Selegiline; Serotonin; Substance P; Tyrosine 3-Monooxygenase | 1978 |
Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
Topics: Benserazide; Binding Sites; Carbidopa; Carboxy-Lyases; Drug Interactions; Humans; Hydrazines; Kinetics; Levodopa; Liver Function Tests; Parkinson Disease | 1976 |
Recent advances in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Depression, Chemical; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Postoperative Complications; Pyridoxine; Stereotaxic Techniques | 1975 |
An integrated approach to patient management in Parkinson's disease.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Dopamine Agents; Drug Combinations; Humans; Levodopa; Parkinson Disease; Selegiline | 1992 |
Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease.
Topics: Carbidopa; Delayed-Action Preparations; Disability Evaluation; Drug Administration Schedule; Humans; Levodopa; Parkinson Disease; Time Factors | 1992 |
Newly-diagnosed Parkinson's disease: a therapeutic update.
Topics: Antiparkinson Agents; Brain; Carbidopa; Humans; Levodopa; Parkinson Disease | 1992 |
Neuroleptic malignant syndrome. When levodopa withdrawal is the cause.
Topics: Aged; Carbidopa; Humans; Levodopa; Male; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1991 |
Medical treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 1989 |
The promise and limitations of controlled-release oral levodopa administration.
Topics: Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1989 |
Rationale for continuous dopaminomimetic therapy of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1989 |
Parkinson's disease: recent advances in therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Antiparkinson Agents; Carbidopa; Dopamine; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Pyridines | 1988 |
Clinically desirable drug interactions.
Topics: Aminoglycosides; Amoxicillin; Ampicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Carbidopa; Diuretics; Drug Combinations; Drug Interactions; Drug Synergism; Humans; Hydroxamic Acids; Hypokalemia; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Penicillins; Probenecid; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1985 |
Noradrenergic influences on dopaminergic function and the pharmacology of dihydroxyphenylserine (DOPS): implication for Parkinson's disease.
Topics: Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Brain; Carbidopa; Dopamine; Droxidopa; Levodopa; Locus Coeruleus; Myocardium; Norepinephrine; Pargyline; Parkinson Disease; Serine; Stereoisomerism; Tyrosine | 1985 |
Update on the treatment of Parkinson's disease.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Synergism; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline; Time Factors | 1985 |
Serotonergic mechanisms and extrapyramidal function in man.
Topics: 5-Hydroxytryptophan; Carbidopa; Cerebellar Diseases; Creutzfeldt-Jakob Syndrome; Down Syndrome; Extrapyramidal Tracts; Fenclonine; Homovanillic Acid; Humans; Huntington Disease; Hydroxyindoleacetic Acid; Imipramine; Levodopa; Muscular Diseases; Paralysis; Parkinson Disease; Parkinson Disease, Secondary; Probenecid; Reserpine; Serotonin; Spinal Cord Diseases; Tetrabenazine; Time Factors | 1974 |
Individualization of levodopa therapy.
Topics: Amantadine; Amphetamine; Anesthetics; Animals; Antihypertensive Agents; Apomorphine; Arrhythmias, Cardiac; Carbidopa; Depression, Chemical; Diet; Disulfiram; Drug Interactions; Drug Therapy, Combination; Endocrine Glands; Glaucoma; Humans; Hydrogen-Ion Concentration; Levodopa; Mice; Parasympatholytics; Parkinson Disease; Stomach | 1974 |
292 trial(s) available for carbidopa and Parkinson Disease
| Article | Year |
|---|---|
Fasting state is one of the factors associated with plasma levodopa fluctuations during levodopa‒carbidopa intestinal gel treatment.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Eating; Fasting; Female; Gels; Humans; Intestines; Levodopa; Lunch; Male; Motor Activity; Parkinson Disease | 2021 |
ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Catechols; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Infusions, Subcutaneous; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Proof of Concept Study; Treatment Outcome | 2021 |
Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum.
Topics: Antiparkinson Agents; Carbidopa; Cross-Over Studies; Dopamine Agonists; Drug Combinations; Female; Gels; Humans; Infusions, Subcutaneous; Jejunum; Levodopa; Male; Parkinson Disease | 2022 |
Cost-Effectiveness and Cost-Utility of Early Levodopa in Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Humans; Levodopa; Parkinson Disease | 2022 |
Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Humans; Levodopa; Parkinson Disease | 2022 |
Do we start too late? Insights from the real-world non-interventional BALANCE study on the present use of levodopa/carbidopa intestinal gel in advanced Parkinson's disease in Germany and Switzerland.
Topics: Antiparkinson Agents; Carbidopa; Dopamine; Drug Combinations; Gels; Germany; Humans; Levodopa; Parkinson Disease; Quality of Life; Switzerland | 2022 |
Levodopa Response in Patients With Early Parkinson Disease: Further Observations of the LEAP Study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Tremor | 2023 |
Effect of Carbidopa Dose on Levodopa Pharmacokinetics With and Without Catechol-O-Methyltransferase Inhibition in Healthy Subjects.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Healthy Volunteers; Humans; Levodopa; Parkinson Disease | 2023 |
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
Topics: Antiparkinson Agents; Carbidopa; Cellulitis; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2022 |
The effect of functional status impairment on nursing home admission risk among patients with advanced Parkinson's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Female; Gels; Homes for the Aged; Humans; Levodopa; Male; Medicare; Monte Carlo Method; Nursing Homes; Parkinson Disease; Physical Functional Performance; Severity of Illness Index; United States | 2020 |
Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa.
Topics: Antiparkinson Agents; Carbidopa; Cognition; Cross-Over Studies; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2020 |
The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study.
Topics: Aged; Carbidopa; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Drug Combinations; Feasibility Studies; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D5; Severity of Illness Index | 2020 |
Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism.
Topics: Carbidopa; Catechol O-Methyltransferase; Catechols; Cross-Over Studies; Dopa Decarboxylase; Double-Blind Method; Drug Combinations; Drug Delivery Systems; Female; Gels; Genotype; Humans; Levodopa; Male; Models, Biological; Nitriles; Parkinson Disease; Polymorphism, Genetic | 2020 |
Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Feasibility Studies; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index; Single-Blind Method | 2021 |
Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®).
Topics: Aged; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Time Factors | 2021 |
Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life | 2021 |
Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion.
Topics: Adult; Antiparkinson Agents; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Humans; Infusions, Subcutaneous; Levodopa; Male; Parkinson Disease; Single-Blind Method | 2021 |
Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Mucuna; Outcome Assessment, Health Care; Parkinson Disease; Phytotherapy; Pilot Projects; Plant Preparations; Seeds | 2018 |
Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Compulsive Behavior; Double-Blind Method; Drug Combinations; Female; Gels; Humans; International Cooperation; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Polyneuropathies; Weight Loss | 2018 |
A Transitional Probability Model for Parkinson's Disease Motor States With Applications to Missing Data.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Double-Blind Method; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Markov Chains; Middle Aged; Models, Statistical; Movement; Parkinson Disease | 2019 |
Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Drug Combinations; Drug Substitution; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole | 2019 |
Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time-to-Treatment | 2019 |
Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease.
Topics: Administration, Inhalation; Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2019 |
Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill
Topics: Aged; Antiparkinson Agents; Carbidopa; Cohort Studies; Cross-Over Studies; Drug Combinations; Drug Compounding; Drug Delivery Systems; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Proof of Concept Study; Treatment Outcome | 2019 |
Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Models, Biological; Parkinson Disease | 2013 |
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.
Topics: Aged; Carbidopa; Chemistry, Pharmaceutical; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease; Treatment Outcome | 2013 |
A rapid non invasive L-DOPA-¹³C breath test for optimally suppressing extracerebral AADC enzyme activity - toward individualizing carbidopa therapy in Parkinson’s disease.
Topics: Brain; Carbidopa; Dopa Decarboxylase; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2012 |
Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2014 |
Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechols; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires | 2014 |
Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prodrugs; Treatment Outcome | 2014 |
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.
Topics: Aged; Carbidopa; Double-Blind Method; Female; Gels; Humans; Infusions, Parenteral; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Treatment Outcome | 2014 |
Compassionate trial of levodopa carbidopa intestinal gel infusion in two patients with progressive supranuclear palsy.
Topics: Aged; Antiparkinson Agents; Carbidopa; Compassionate Use Trials; Female; Gels; Humans; Levodopa; Male; Parkinson Disease; Supranuclear Palsy, Progressive; Treatment Outcome | 2014 |
[Nocturnal symptoms of Parkinson's disease and approaches to their correction].
Topics: Carbidopa; Catechols; Drug Combinations; Dyskinesias; Humans; Levodopa; Muscle Cramp; Nocturia; Parkinson Disease; Restless Legs Syndrome | 2013 |
Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Biological Availability; Carbidopa; Double-Blind Method; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease; Tablets | 2014 |
Neuromuscular complexity during gait is not responsive to medication in persons with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dopamine Agents; Electromyography; Female; Gait; Humans; Leg; Levodopa; Male; Middle Aged; Muscle, Skeletal; Parkinson Disease; Walking | 2014 |
Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Treatment Outcome; Walking | 2014 |
[The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease].
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Female; Gels; Health Status; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2014 |
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Severity of Illness Index; Treatment Outcome | 2015 |
Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.
Topics: Aged; Antiparkinson Agents; Carbidopa; Europe; Female; Gels; Humans; International Cooperation; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2015 |
Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.
Topics: Age Factors; Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Delivery Systems; Female; Gels; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2015 |
[The use of stalevo in the treatment of patients with Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2014 |
Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Treatment Outcome | 2015 |
Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Drug Combinations; Drug Delivery Systems; Female; Follow-Up Studies; Gastrointestinal Tract; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2015 |
Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Precision Medicine; Tablets | 2015 |
Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2015 |
Obstructive sleep apnea in Parkinson's disease patients: effect of Sinemet CR taken at bedtime.
Topics: Aged; Arousal; Carbidopa; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Sleep Apnea, Obstructive; Wakefulness | 2016 |
Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Topics: Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Data Interpretation, Statistical; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2015 |
Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Parkinson Disease; Treatment Outcome | 2015 |
Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson's disease: the LEAP-study.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Netherlands; Parkinson Disease; Quality of Life; Time-to-Treatment | 2015 |
Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease.
Topics: Aged; Antiparkinson Agents; Capsules; Carbidopa; Cohort Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2016 |
Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Australia; Carbidopa; Dopamine Agents; Duodenum; Dyskinesias; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases; Prospective Studies; Psychomotor Performance; Quality of Life | 2016 |
Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
Topics: Administration, Mucosal; Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Dyskinesia, Drug-Induced; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2016 |
Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Chromatography, High Pressure Liquid; Cysteine; Dipeptides; Drug Combinations; Female; GPI-Linked Proteins; Humans; Levodopa; Male; Middle Aged; Nerve Tissue Proteins; Oxidative Stress; Parkinson Disease; Pilot Projects | 2016 |
Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease | 2016 |
Effect of Levodopa + Carbidopa on the Laryngeal Electromyographic Pattern in Parkinson Disease.
Topics: Aged; Antiparkinson Agents; Brazil; Carbidopa; Drug Administration Schedule; Drug Combinations; Electromyography; Female; Humans; Laryngeal Muscles; Levodopa; Male; Middle Aged; Parkinson Disease; Phonation; Predictive Value of Tests; Prospective Studies; Time Factors; Treatment Outcome; Voice Quality | 2017 |
Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Drug Combinations; Female; Humans; Infusions, Parenteral; Levodopa; Male; Nitriles; Parkinson Disease; Treatment Outcome | 2017 |
Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Drug Substitution; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2017 |
Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.
Topics: Administration, Oral; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Drug Delivery Systems; Gels; Humans; Levodopa; Parkinson Disease | 2017 |
Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Breath Tests; Caprylates; Carbidopa; Carbon Isotopes; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastric Emptying; Humans; Intestinal Absorption; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Solubility | 2008 |
Bilateral impairments of skilled reach-to-eat in early Parkinson's disease patients presenting with unilateral or asymmetrical symptoms.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Disability Evaluation; Double-Blind Method; Drug Combinations; Feeding Behavior; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease; Prospective Studies; Severity of Illness Index | 2008 |
Fatigue in levodopa-naive subjects with Parkinson disease.
Topics: Aged; Antiparkinson Agents; Brain; Carbidopa; Double-Blind Method; Fatigue; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tomography, Emission-Computed, Single-Photon | 2008 |
[The clinical-pharmacoeconomic study of efficacy of stalevo in the treatment of Parkinson's disease with motor fluctuations].
Topics: Antiparkinson Agents; Carbidopa; Catechols; Cost-Benefit Analysis; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Disorders; Severity of Illness Index | 2008 |
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome | 2009 |
Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial).
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Outpatients; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2008 |
Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechols; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index | 2009 |
[Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Treatment Outcome | 2009 |
Long-term experience with continuous duodenal levodopa-carbidopa infusion (Duodopa): report of six patients.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Administration Schedule; Duodenum; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease; Time; Time Factors; Treatment Outcome | 2009 |
Soft tissue-anchored transcutaneous port attached to an intestinal tube for long-term gastroduodenal infusion of levodopa/carbidopa in Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Catheters, Indwelling; Connective Tissue; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2009 |
Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Disability Evaluation; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors | 2009 |
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Hypertension; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Piperidines; Pyrimidines; Receptors, N-Methyl-D-Aspartate | 2009 |
Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy.
Topics: Activities of Daily Living; Behavioral Symptoms; Carbidopa; Disability Evaluation; Dopamine Agents; Female; Humans; Levodopa; Male; Motor Activity; Outcome Assessment, Health Care; Parkinson Disease; Sensitivity and Specificity; Severity of Illness Index; Surveys and Questionnaires | 2010 |
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechols; Drug-Related Side Effects and Adverse Reactions; Dyskinesias; Feasibility Studies; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2010 |
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nitrophenols; Parkinson Disease; Severity of Illness Index; Tolcapone; Tyrosine | 2010 |
Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS.
Topics: Aged; Antiparkinson Agents; Blood Pressure; Carbidopa; Catechols; Double-Blind Method; Droxidopa; Drug Interactions; Female; Humans; Male; Middle Aged; Multiple System Atrophy; Nitriles; Norepinephrine; Parkinson Disease; Prodrugs; Pure Autonomic Failure; Vasoconstriction | 2011 |
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Topics: Aged; Ambulatory Care Facilities; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Feasibility Studies; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Severity of Illness Index; Time Factors; Tolcapone; Treatment Outcome | 2010 |
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Progression; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Risk; Time Factors; Treatment Outcome | 2010 |
A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.
Topics: Acetophenones; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Endpoint Determination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Treatment Outcome | 2010 |
Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Intention to Treat Analysis; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2010 |
Effect of controlled-release levodopa on the microstructure of sleep in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Sleep; Sleep Wake Disorders | 2011 |
Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Gait; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Treatment Outcome | 2010 |
[Pharmacotherapy of motor manifestations in late stages of Parkinson's disease].
Topics: Aged; Carbidopa; Catechols; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2010 |
Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenum; Female; Gels; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 2011 |
Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Combinations; Drug Therapy, Combination; Female; Half-Life; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tyrosine | 2011 |
Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease; Tablets; Time Factors | 2012 |
Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Drug Administration Schedule; Emotions; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Time | 2012 |
[Levodopa medications in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drugs, Generic; Female; Humans; Levodopa; Male; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2011 |
Levodopa ameliorated anorectal constipation in de novo Parkinson's disease: The QL-GAT study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Constipation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2011 |
Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Time Factors | 2011 |
Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechols; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Prospective Studies; Quality of Life; Single-Blind Method | 2011 |
Dopaminergic drug-induced modulation of the expression of the dopamine transporter in peripheral blood lymphocytes in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Drug Combinations; Female; Flow Cytometry; Gene Expression Regulation; Humans; Indoles; Levodopa; Lymphocytes; Male; Middle Aged; Parkinson Disease; Pramipexole | 2011 |
[Nocturnal motor symptoms of Parkinson's disease and their treatment with the three-component drug levodopa/carbidopa/entacapone].
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sleep Disorders, Intrinsic | 2011 |
Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an in vivo [(11)C]-harmine positron emission tomography study.
Topics: Carbidopa; Carbon Radioisotopes; Corpus Striatum; Dopamine; Dopamine Agonists; Drug Combinations; Harmine; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease; Positron-Emission Tomography; Prefrontal Cortex; Protein Binding; Serotonin; Substrate Specificity; Time Factors; Tryptophan | 2012 |
Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Area Under Curve; Carbidopa; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2012 |
Dopamine and performance in a reinforcement learning task: evidence from Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Association Learning; Carbidopa; Choice Behavior; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Female; Generalization, Psychological; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Nucleus Accumbens; Oxygen; Parkinson Disease; Photic Stimulation; Prefrontal Cortex; Psychomotor Performance; Reinforcement, Psychology | 2012 |
Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Administration Routes; Drug Combinations; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Treatment Outcome | 2012 |
[The optimization of using levodopa in patients with Parkinson's disease: results of the OPTIMA study].
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2012 |
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusion Pumps; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease | 2013 |
Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Disorders of Excessive Somnolence; Drug Administration Routes; Drug Combinations; Duodenum; Female; Gastrostomy; Gels; Humans; Infusion Pumps, Implantable; Jejunum; Levodopa; Male; Middle Aged; Nocturnal Myoclonus Syndrome; Parkinson Disease; Prospective Studies; Severity of Illness Index; Sleep Disorders, Intrinsic; Treatment Outcome | 2013 |
Ropinirole does not affect plasma arginine vasopressin levels in patients with advanced Parkinson's disease.
Topics: Aged; Arginine Vasopressin; Carbidopa; Catechols; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Humans; Inappropriate ADH Syndrome; Indoles; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2012 |
Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
Topics: Activities of Daily Living; Aged; Bromocriptine; Carbidopa; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinson Disease; Prospective Studies; Withholding Treatment | 2002 |
Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Autonomic Nervous System; Blood Pressure; Carbidopa; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Supine Position | 2003 |
Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.
Topics: Antiparkinson Agents; Atrophy; Brain; Carbidopa; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Globus Pallidus; Humans; Hypokinesia; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Muscle Rigidity; Neurosurgical Procedures; Parkinson Disease; Severity of Illness Index; Treatment Outcome; Tremor | 2003 |
Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Purines; Safety; Treatment Outcome | 2003 |
[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
Topics: Antiparkinson Agents; Biological Availability; Carbidopa; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2003 |
Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Double-Blind Method; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Pain Measurement; Parkinson Disease; Pramipexole; Quality of Life; Thiazoles | 2004 |
Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients.
Topics: Aged; Area Under Curve; Carbidopa; Catechols; Cross-Over Studies; Delayed-Action Preparations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Single-Blind Method | 2004 |
Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Delayed-Action Preparations; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Single-Blind Method; Treatment Outcome | 2004 |
Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Biological Availability; Carbidopa; Catechols; Chromatography, High Pressure Liquid; Double-Blind Method; Drug Interactions; Drug Resistance; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2004 |
Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Indoles; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Pilot Projects; Pramipexole; Thiazoles | 2004 |
Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cholinesterase Inhibitors; Cross-Over Studies; Donepezil; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Humans; Indans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines | 2004 |
An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
Topics: Adult; Aged; Carbidopa; Catechols; Drug Combinations; Drug Tolerance; Female; Humans; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease | 2005 |
Levodopa and the progression of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Corpus Striatum; Disease Progression; Dopamine Plasma Membrane Transport Proteins; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Tomography, Emission-Computed, Single-Photon | 2004 |
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Drug Therapy, Combination; Duodenum; Dyskinesia, Drug-Induced; Female; Gels; Humans; Intubation; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Quality of Life; Severity of Illness Index; Single-Blind Method; Surveys and Questionnaires; Suspensions; Videotape Recording | 2005 |
A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Parkinson Disease; Patient Satisfaction; Surveys and Questionnaires; Tablets | 2005 |
Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Disability Evaluation; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Pain Measurement; Parkinson Disease; Quality of Life; Severity of Illness Index; Single-Blind Method; Surveys and Questionnaires; Treatment Outcome | 2005 |
Motor deficits in Parkinsonian reaching: dopa-sensitivity influenced by real-world task constraint.
Topics: Activities of Daily Living; Aged; Amantadine; Antiparkinson Agents; Arm; Benzothiazoles; Biomechanical Phenomena; Carbidopa; Catechols; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Movement; Nitriles; Parkinson Disease; Pramipexole; Thiazoles | 2006 |
Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Area Under Curve; Carbidopa; Catechols; Chromatography, High Pressure Liquid; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Tyrosine | 2006 |
Dopamine agonist therapy for Parkinson disease and pathological gambling.
Topics: Carbidopa; Dopamine Agonists; Female; Gambling; Humans; Levodopa; Male; MEDLINE; Middle Aged; Parkinson Disease; Retrospective Studies | 2006 |
Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study).
Topics: Adult; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Catechols; Cross-Over Studies; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Patient Satisfaction; Treatment Outcome | 2006 |
[Stalevo (levodopa/carbidopa/entacapon)--a new generation drug in the treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2006 |
Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease.
Topics: Acute Disease; Carbidopa; Chronic Disease; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypogastric Plexus; Levodopa; Male; Middle Aged; Parasympathetic Fibers, Postganglionic; Parkinson Disease; Synaptic Transmission; Treatment Outcome; Urinary Bladder; Urinary Bladder, Neurogenic; Urination Disorders | 2007 |
Comment on Shpirer et al. ("Excessive daytime sleepiness in patients with Parkinson's disease: a polysomnographic study").
Topics: Aged; Antiparkinson Agents; Carbidopa; Disorders of Excessive Somnolence; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Polysomnography; Reaction Time; Statistics, Nonparametric | 2007 |
Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Catechols; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tyrosine | 2007 |
Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Administration Schedule; Drug Therapy, Combination; Duodenum; Dyskinesias; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2007 |
Should levodopa dose be reduced when switched to stalevo?
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2008 |
Greater motor improvement in right hemibody Parkinson's patients after dopaminergic medications.
Topics: Aged; Analysis of Variance; Carbidopa; Dopamine Agents; Female; Functional Laterality; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Movement Disorders; Neuropsychological Tests; Parkinson Disease | 2009 |
[The study on the assessment of the new levodopa drug--stalevo (levodopa/carbidopa/entacapone), in treatment of Parkinson's disease in out-patient clinical practice (the results of the open START-M)].
Topics: Activities of Daily Living; Aged; Ambulatory Care Facilities; Carbidopa; Catechols; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Outpatients; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2007 |
Deprenyl in Parkinson disease.
Topics: Adult; Aged; Carbidopa; Dopamine; Double-Blind Method; Drug Combinations; Epinephrine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methoxyhydroxyphenylglycol; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1981 |
Controlled-release carbidopa/levodopa in the treatment of Parkinsonism.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1984 |
Dyskinesias associated with lithium therapy in parkinsonism.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Lithium; Male; Middle Aged; Parkinson Disease; Random Allocation | 1984 |
Prolactin secretion in Parkinson disease.
Topics: Adult; Aged; Blood-Brain Barrier; Bromocriptine; Carbidopa; Dopamine; Drug Combinations; Female; Humans; Hypothalamus, Anterior; Levodopa; Male; Middle Aged; Parkinson Disease; Pituitary Gland; Placebos; Prolactin; Receptors, Dopamine; Thyrotropin-Releasing Hormone | 1981 |
Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
Topics: 5-Hydroxytryptophan; Adolescent; Adult; Aged; Carbidopa; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Kynurenine; Levodopa; Male; Middle Aged; Myoclonus; Parkinson Disease; Scleroderma, Systemic; Serotonin | 1980 |
Recent advances in the treatment of Parkinson's disease: the role of bromocriptine.
Topics: Bromocriptine; Carbidopa; Clinical Trials as Topic; Follow-Up Studies; Humans; Levodopa; Parkinson Disease | 1981 |
Weekly drug holiday in Parkinson disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1981 |
Parkinson's disease: Cogentin with Sinemet, a better response.
Topics: Aged; Antiparkinson Agents; Benztropine; Carbidopa; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Tropanes | 1982 |
Latency and successive reaction time in Parkinson's disease--the effects of carbidopa and amantadine.
Topics: Amantadine; Carbidopa; Humans; Parkinson Disease; Reaction Time | 1981 |
Increased ratio of carbidopa to levodopa in treatment of Parkinson's disease.
Topics: Aged; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1980 |
The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Bromocriptine; Carbidopa; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Least-Squares Analysis; Levodopa; Male; Parkinson Disease; Prospective Studies; Selegiline; Statistics, Nonparametric; Treatment Outcome | 1995 |
Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a multicenter pilot study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Aspartic Acid; Carbidopa; Choline; Corpus Striatum; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Magnetic Resonance Spectroscopy; Male; Middle Aged; Parkinson Disease; Pilot Projects; Protons | 1995 |
Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone | 1995 |
Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Selegiline; Treatment Outcome | 1995 |
Carbidopa/levodopa and selegiline do not affect platelet mitochondrial function in early parkinsonism.
Topics: Adult; Aged; Analysis of Variance; Blood Platelets; Carbidopa; Citrate (si)-Synthase; Electron Transport; Electron Transport Complex II; Electron Transport Complex III; Female; Humans; Levodopa; Male; Middle Aged; Mitochondria; Multienzyme Complexes; NAD(P)H Dehydrogenase (Quinone); Oxidoreductases; Parkinson Disease; Plateletpheresis; Selegiline; Succinate Dehydrogenase | 1995 |
Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Solutions; Tablets; Therapeutic Equivalency | 1994 |
The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.
Topics: Aged; Brain; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Dihydroxyphenylalanine; Drug Synergism; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Middle Aged; Nitriles; Occipital Lobe; Parkinson Disease; Tomography, Emission-Computed | 1994 |
The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Prevalence; Prospective Studies; Severity of Illness Index; Survival Analysis; Treatment Failure | 1994 |
Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.
Topics: Adult; Aged; Cabergoline; Carbidopa; Dopamine Agents; Drug Combinations; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Receptors, Dopamine | 1993 |
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.
Topics: Aged; Blood Pressure; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Hemodynamics; Homovanillic Acid; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Pulse; Respiration | 1993 |
A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Electrocardiography; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Motor Skills; Neurologic Examination; Parkinson Disease; Pergolide | 1994 |
Milacemide therapy for Parkinson's disease.
Topics: Acetamides; Aged; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Muscle Rigidity; Neurologic Examination; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Single-Blind Method; Synaptic Transmission | 1993 |
Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Double-Blind Method; Drug Combinations; Duodenum; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Tablets | 1993 |
Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
Topics: Antiparkinson Agents; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Movement Disorders; Muscle Rigidity; Neurologic Examination; Parkinson Disease | 1993 |
Broad bean (Vicia faba) consumption and Parkinson's disease.
Topics: Carbidopa; Fabaceae; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Plants, Medicinal | 1993 |
Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Benserazide; Carbidopa; Carboxy-Lyases; Delayed-Action Preparations; Drug Combinations; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1993 |
Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study.
Topics: Activity Cycles; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Solutions; Tablets | 1993 |
Human transplacental transfer of carbidopa/levodopa.
Topics: Antiparkinson Agents; Carbidopa; Dopamine; Female; Fetus; Homovanillic Acid; Humans; Levodopa; Maternal-Fetal Exchange; Parkinson Disease; Pregnancy; Tyrosine | 1995 |
[The use of the Sinemet-CR preparation in treating Parkinson's disease].
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Higher Nervous Activity; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1995 |
Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1996 |
Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Movement Disorders; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone | 1995 |
Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Double-Blind Method; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2; Treatment Outcome | 1996 |
Intranasal apomorphine rescue therapy for parkinsonian "off" periods.
Topics: Administration, Intranasal; Antiemetics; Antiparkinson Agents; Apomorphine; Benzamides; Carbidopa; Dopamine Agonists; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Vomiting | 1996 |
Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa.
Topics: Aged; Carbidopa; Circadian Rhythm; Cross-Over Studies; Delayed-Action Preparations; Dihydroxyphenylalanine; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1996 |
Objective measurement of activation of rigidity: diagnostic, pathogenetic and therapeutic implications in parkinsonism.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Hand Strength; Humans; Isometric Contraction; Levodopa; Male; Muscle Rigidity; Parkinson Disease; Physical Exertion; Reproducibility of Results; Sensitivity and Specificity; Torque; Trihexyphenidyl | 1996 |
Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Metabolic Clearance Rate; Motor Skills; Neurologic Examination; Parkinson Disease; Therapeutic Equivalency | 1996 |
International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; International Cooperation; Levodopa; Middle Aged; Parkinson Disease | 1996 |
Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1997 |
Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled, crossover study.
Topics: Adult; Anticonvulsants; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Lamotrigine; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Treatment Outcome; Triazines | 1997 |
[The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
Topics: Age of Onset; Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Diet Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Plasma | 1997 |
Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients.
Topics: Absorption; Antiparkinson Agents; Biological Availability; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1994 |
Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
Topics: Activities of Daily Living; Aged; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Carbidopa; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Levodopa; Longitudinal Studies; Male; Matched-Pair Analysis; Motor Skills; Parkinson Disease; Quality of Life; Sickness Impact Profile | 1997 |
Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Domperidone; Dopamine Antagonists; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Emptying; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Severity of Illness Index | 1997 |
Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease.
Topics: Activities of Daily Living; Administration, Oral; Aged; Analysis of Variance; Antiparkinson Agents; Carbidopa; Disease Progression; Duodenum; Female; Humans; Infusion Pumps; Infusions, Parenteral; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Time and Motion Studies; Time Factors; Treatment Outcome; Videotape Recording | 1998 |
The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation.
Topics: Administration, Oral; Adult; Antiparkinson Agents; Benzophenones; Biological Availability; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Interactions; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone | 1998 |
A trial of dextromethorphan in parkinsonian patients with motor response complications.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Dextromethorphan; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Motor Skills; N-Methylaspartate; Neurologic Examination; Parkinson Disease | 1998 |
Quality of life in patients with Parkinson's disease who transfer from standard levodopa to Sinemet CR: the STAR Study. The STAR Multicenter Study Group.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease; Quality of Life; Treatment Outcome | 1998 |
Implications of the 5-year CR FIRST trial. Sinemet CR Five-Year International Response Fluctuation Study.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1998 |
Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients.
Topics: Aged; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Eating; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1998 |
Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Treatment Outcome | 1998 |
Is stereotactic surgical treatment still necessary for Parkinson's disease in the contemporary trend of medical therapy with dopamine receptor agonist?
Topics: Aged; Aged, 80 and over; Bromocriptine; Carbidopa; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Stereotaxic Techniques; Treatment Outcome | 1997 |
Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Prospective Studies | 1998 |
Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Carbidopa; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease | 1999 |
Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.
Topics: Aged; Antiparkinson Agents; Biological Transport; Carbidopa; Cocaine; Corpus Striatum; Dopamine; Drug Therapy, Combination; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Monoamine Oxidase; Occipital Lobe; Parkinson Disease; Selegiline; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 1999 |
Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group.
Topics: Activities of Daily Living; Aged; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1999 |
COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone | 1999 |
The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease.
Topics: Aged; Brain; Brain Mapping; Carbidopa; Carrier Proteins; Cocaine; Corpus Striatum; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Motor Skills; Nerve Tissue Proteins; Parkinson Disease; Pergolide; Putamen; Tomography, Emission-Computed, Single-Photon | 1999 |
Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Models, Statistical; Nitrophenols; Parkinson Disease; Population; Risk Factors; Single-Blind Method; Tolcapone | 2000 |
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2000 |
The long-duration response to L-dopa in the treatment of early PD.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Treatment Outcome | 2000 |
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Selegiline; Substance Withdrawal Syndrome | 2000 |
Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone.
Topics: Adaptation, Psychological; Adult; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Quality of Life; Sick Role; Sickness Impact Profile; Tolcapone; Treatment Outcome | 2000 |
Suppressed sympathetic skin response in Parkinson disease.
Topics: Acoustic Stimulation; Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Electric Stimulation; Evoked Potentials; Evoked Potentials, Auditory; Female; Foot; Hand; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time; Reference Values; Selegiline; Skin; Sympathetic Nervous System | 2000 |
Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Therapy, Combination; Heterocyclic Compounds, 2-Ring; Humans; Levodopa; Male; Middle Aged; Oximes; Parkinson Disease; Treatment Outcome | 2002 |
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Benzothiazoles; Biological Availability; Carbidopa; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Parkinson Disease; Postmenopause; Pramipexole; Sex Factors; Thiazoles | 2002 |
Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone on the cardiovascular system of patients with parkinson's disease.
Topics: Adult; Aged; Arrhythmias, Cardiac; Carbidopa; Cardiac Complexes, Premature; Cardiovascular System; Clinical Trials as Topic; Drug Combinations; Female; Humans; Hydrazines; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Parkinson Disease; Tachycardia | 1975 |
Bromocriptine and levodopa (with or without carbidopa) in parkinsonism.
Topics: Aged; Bromocriptine; Carbidopa; Clinical Trials as Topic; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation; Ergolines; Female; Follow-Up Studies; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Time Factors | 1976 |
Deprenyl in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Phenethylamines | 1977 |
Comparison of levodopa with carbidopa or benserazide in parkinsonism.
Topics: Aged; Benserazide; Carbidopa; Consumer Behavior; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
[Effect of MK-486 alone on Parkinsonism; studies on the clinical symptoms and catecholamine concentrations in the blood, urine and cerebrospinal fluid].
Topics: Aged; Carbidopa; Catecholamines; Clinical Trials as Topic; Dihydroxyphenylalanine; Dopamine; Female; Homovanillic Acid; Humans; Hydrazines; Male; Middle Aged; Parkinson Disease | 1977 |
Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease.
Topics: Adult; Aged; Amantadine; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
Nomifensine in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Isoquinolines; Levodopa; Male; Middle Aged; Nomifensine; Parkinson Disease; Placebos; Trihexyphenidyl | 1977 |
Treatment of Parkinson's disease with lergotrile mesylate.
Topics: Acetonitriles; Antiparkinson Agents; Bromocriptine; Carbidopa; Carboxy-Lyases; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Parkinson Disease | 1977 |
Long-term treatment of Parkinson's disease with L-Dopa and Dopa-decarboxylase inhibitor: therapeutic results and side effects.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1978 |
A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease.
Topics: Adult; Benserazide; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Vomiting | 1978 |
Treatment of parkinsonism with N-n-propyl norapomorphine and levodopa (with or without carbidopa).
Topics: Aged; Apomorphine; Carbidopa; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Growth Hormone; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1978 |
A comparative clinical investigation of the therapeutic effect of levodopa alone and in combination with a decarboxylase inhibitor (carbidopa) in cases of Parkinson's disease.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Drug Combinations; Electrocardiography; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1978 |
Effect of a slow release preparation of levodopa on Parkinson's disease in combination with a peripheral decarboxylase inhibitor.
Topics: Adult; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1978 |
Treatment of Parkinson's disease with sodium valproate: clinical, pharmacological, and biochemical observations.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; gamma-Aminobutyric Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Valproic Acid | 1979 |
Comparison of enteric-coated levodopa with levodopa-carbidopa combination. A double-blind crossover trial.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Tablets, Enteric-Coated | 1979 |
[The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
Topics: Aged; Benserazide; Carbidopa; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
Levodopa with benserazide or carbidopa in Parkinson disease.
Topics: Benserazide; Biological Availability; Carbidopa; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
Cyproheptadine in levodopa-induced dyskinesia in parkinsonism.
Topics: Aged; Carbidopa; Cyproheptadine; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1978 |
Clonidine and the anti-parkinsonian response to L-DOPA or piribedil.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Clonidine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Piribedil; Placebos | 1976 |
[The clinical experience with the decarboxylase-blocked levodopa (Nacom) in the Parkinsonism patients].
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
Psychiatric symptoms during l-dopa therapy for Parkinson's disease and their relationship to physical disability.
Topics: Aged; Amantadine; Carbidopa; Clinical Trials as Topic; Depression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Interview, Psychological; Levodopa; Male; Mental Status Schedule; Methyldopa; Middle Aged; Parkinson Disease; Placebos; Recurrence; Trihexyphenidyl | 1976 |
[Sinomet and Madopar, a comparative study on the treatment of Parkinson's disease].
Topics: Benserazide; Carbidopa; Clinical Trials as Topic; Drug Combinations; Drug Evaluation; Humans; Levodopa; Parkinson Disease | 1976 |
Amantadine and a fixed combination of carbidopa and levodopa in parkinsonism: a preliminary report.
Topics: Aged; Amantadine; Carbidopa; Clinical Trials as Topic; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
[Treatment of Parkinson's syndrome with L-dopa and L-carbidopa (author's transl)].
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hydrazines; Hyperkinesis; Levodopa; Male; Middle Aged; Parkinson Disease; Pyridoxine | 1976 |
Madopar versus sinemet. A clinical study on their effectiveness.
Topics: Adult; Aged; Benserazide; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Serine | 1975 |
Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Metoclopramide; Middle Aged; Movement Disorders; Nausea; Parkinson Disease; Parkinson Disease, Secondary; Pimozide; Placebos; Promethazine | 1975 |
Alpha methyldopahydrazine as an adjunct to levodopa therapy in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Time Factors | 1975 |
Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Mental Disorders; Middle Aged; Movement Disorders; Parkinson Disease | 1975 |
The effects of combining carbidopa with levodopa for Parkinson's disease.
Topics: Carbidopa; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hydrazines; Hypotension, Orthostatic; Levodopa; Male; Nausea; Parkinson Disease; Vomiting | 1975 |
L-dopa and carbidopa (sinemet) in the management of parkinsonism.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis | 1975 |
Treatment of Parkinson's disease with aporphines. Possible role of growth hormone.
Topics: Administration, Oral; Aged; Apomorphine; Carbidopa; Clinical Trials as Topic; Drug Therapy, Combination; Female; Growth Hormone; Humans; Kidney; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Secretory Rate | 1976 |
Treatment of "on-off effect" with a dopa decarboxylase inhibitor.
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1975 |
Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial.
Topics: Aged; Benserazide; Carbidopa; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
The evolution of dementia in idiopathic Parkinson's disease: neuropsychological and clinical evidence in support of subtypes.
Topics: Age Factors; Aged; Bromocriptine; Carbidopa; Dementia; Drug Therapy, Combination; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinson Disease | 1992 |
Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. The Dutch Sinemet CR Study Group.
Topics: Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Patient Satisfaction; Sleep Stages | 1992 |
Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Gait; Humans; Levodopa; Middle Aged; Parkinson Disease; Tablets | 1992 |
Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.
Topics: Adult; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Metabolic Clearance Rate; Methyldopa; Neurologic Examination; Parkinson Disease | 1992 |
Trial of Sinemet CR4 in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease | 1992 |
Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients.
Topics: Benserazide; Carbidopa; Delayed-Action Preparations; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Parkinson Disease | 1992 |
Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.
Topics: Adult; Aged; Carbidopa; Delayed-Action Preparations; Dopamine Agents; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Oxazines; Parkinson Disease | 1991 |
A single-dose study of the pharmacodynamic effects of chlormethiazole, temazepam and placebo in elderly parkinsonian patients.
Topics: Aged; Benserazide; Carbidopa; Chlormethiazole; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Sleep Initiation and Maintenance Disorders; Sleep Stages; Temazepam | 1991 |
Long-term evaluation of Sinemet CR in parkinsonian patients with motor fluctuations.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Movement; Parkinson Disease; Time Factors | 1991 |
L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinson's disease patients with motor response fluctuations.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Selegiline; Time Factors | 1991 |
Controlled release levodopa/carbidopa (Sinemet CR4) in Parkinson's disease--an open evaluation of efficacy and safety.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
Sinemet CR in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos | 1991 |
Standard and controlled-release levodopa/carbidopa in patients with fluctuating Parkinson's disease on a protein redistribution diet. A preliminary report.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dietary Proteins; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation; Female; Humans; Levodopa; Male; Parkinson Disease | 1991 |
Objective outcome criteria in trials of anti-parkinsonian therapy in the elderly: sensitivity, specificity and reliability of measures of brady- and hypo-kinesia.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Blood Pressure; Carbidopa; Gait; Humans; Levodopa; Middle Aged; Parkinson Disease; Psychomotor Performance; Random Allocation | 1991 |
Depression treatment in Parkinson's disease.
Topics: Antidepressive Agents, Tricyclic; Carbidopa; Depression; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Humans; Levodopa; Nortriptyline; Parkinson Disease | 1991 |
An open multicenter trial of Sinemet CR in levodopa-naive Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Tolerance; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease | 1991 |
L-deprenyl, a MAO-B inhibitor, as an adjunct to conventional L-dopa therapy in Parkinson's disease: experience in 200 patients.
Topics: Aged; Carbidopa; Follow-Up Studies; Humans; Levodopa; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Selegiline | 1990 |
The beneficial effect of chronic lisuride administration compared with levodopa in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Female; Follow-Up Studies; Humans; Levodopa; Lisuride; Long-Term Care; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Determinants of gait in the elderly parkinsonian on maintenance levodopa/carbidopa therapy.
Topics: Aged; Aged, 80 and over; Blood Pressure; Carbidopa; Double-Blind Method; Female; Gait; Humans; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease; Randomized Controlled Trials as Topic | 1990 |
A long-term study of Parkinson's patients subjected to autoimplants of perfused adrenal medulla into the caudate nucleus. CPH Neural Transplantation Group.
Topics: Adrenal Medulla; Carbidopa; Caudate Nucleus; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Perfusion; Tissue Transplantation; Transplantation, Autologous; Transplantation, Heterotopic | 1990 |
Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR).
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Prognosis; Statistics as Topic; Time Factors | 1990 |
Diurnal differences in response to oral levodopa.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Circadian Rhythm; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Decreased efficacy of levodopa with carbidopa in parkinsonian patients after adrenal-to-caudate implants.
Topics: Adrenal Medulla; Adult; Carbidopa; Corpus Striatum; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Random Allocation | 1990 |
Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
The effect of dietary protein on the efficacy of L-dopa: a double-blind study.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Clinical Trials as Topic; Dietary Proteins; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Selegiline | 1989 |
CV 205-502: safety, tolerance to, and efficacy of increasing doses in patients with Parkinson's disease in a double-blind, placebo crossover study.
Topics: Adult; Aged; Aminoquinolines; Antiparkinson Agents; Carbidopa; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1989 |
Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease.
Topics: Aged; Amino Acids; Carbidopa; Clinical Trials as Topic; Dietary Proteins; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1989 |
A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance.
Topics: Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Motor Skills; Parkinson Disease; Random Allocation | 1989 |
Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Randomized Controlled Trials as Topic | 1989 |
An open multicenter long-term treatment evaluation of Sinemet CR. Sinemet CR Multicenter Study Group.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Multicenter Studies as Topic; Parkinson Disease; Random Allocation; Time Factors | 1989 |
Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Fasting; Half-Life; Humans; Intestinal Absorption; Levodopa; Middle Aged; Parkinson Disease; Random Allocation; Reference Values; Tablets; Tyrosine | 1989 |
Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Random Allocation; Tyrosine | 1989 |
Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Movement Disorders; Multicenter Studies as Topic; Parkinson Disease; Randomized Controlled Trials as Topic | 1989 |
Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1989 |
Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1989 |
Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Consumer Behavior; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Time Factors | 1988 |
Treatment of Parkinson's disease with pergolide: a double-blind study.
Topics: Activities of Daily Living; Adult; Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Random Allocation | 1988 |
Pergolide: long-term use in Parkinson's disease.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Placebos; Retrospective Studies | 1988 |
Long term bromocriptine treatment in de novo parkinsonian patients.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1988 |
Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Self Concept | 1987 |
Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Random Allocation; Selegiline | 1988 |
Prolonged serum levodopa levels with controlled-release carbidopa-levodopa in the treatment of Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Motor Activity; Parkinson Disease | 1988 |
A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Neurologic Examination; Parkinson Disease | 1987 |
Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa.
Topics: Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Humans; Levodopa; Parkinson Disease; Random Allocation; Sleep | 1987 |
A double-blind evaluation of ciladopa in Parkinson's disease.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Piperazines; Random Allocation | 1987 |
Clinical significance of the relationship between O-methyldopa levels and levodopa intake.
Topics: Animals; Carbidopa; Corpus Striatum; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Rats; Rats, Inbred Strains; Tyrosine | 1988 |
Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa.
Topics: Aged; Carbidopa; Chronic Disease; Delayed-Action Preparations; Disability Evaluation; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
Topics: Aged; Bromocriptine; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1987 |
Parallel double-blind study of pergolide in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Parkinson Disease; Pergolide; Random Allocation | 1987 |
Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Random Allocation | 1987 |
The Sydney multicentre study of Parkinson's disease. The first 18 months.
Topics: Australia; Bromocriptine; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1987 |
Adjuvant therapy of parkinsonian tremor.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clonazepam; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Primidone; Propranolol; Random Allocation; Tremor; Trihexyphenidyl | 1987 |
Controlled release levodopa-carbidopa (CR-5) in the management of parkinsonian motor fluctuations.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Time Factors | 1987 |
Double-blind trial of pergolide for Parkinson's disease.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Ergolines; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1985 |
Caerulein treatment of Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Ceruletide; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1985 |
Motor function in the normal aging population: treatment with levodopa.
Topics: Aged; Aging; Carbidopa; Dopamine; Drug Combinations; Humans; Levodopa; Middle Aged; Movement; Movement Disorders; Parkinson Disease | 1985 |
Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
Topics: Activities of Daily Living; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1985 |
Methyldopa or methyldopahydrazine as levodopa synergists.
Topics: Carbidopa; Dihydroxyphenylalanine; Drug Synergism; Humans; Hydrazines; Methyldopa; Parkinson Disease | 1973 |
L-alpha-methyldopa hydrazine (Carbidopa) combined with L-dopa in the treatment of Parkinson's disease.
Topics: Aged; Blood Pressure; Carbidopa; Clinical Trials as Topic; Depression, Chemical; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Nausea; Parkinson Disease; Placebos; Posture; Vomiting | 1974 |
Evaluation of alpha methyl dopa and alpha methyl dopa hydrazine with L-dopa therapy.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Evaluation; Drug Therapy, Combination; Humans; Hydrazines; Methyldopa; Middle Aged; Parkinson Disease | 1974 |
A double-blind controlled study of MK-486 in Parkinson's disease.
Topics: Aged; Anorexia Nervosa; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Dihydroxyphenylalanine; Evaluation Studies as Topic; Female; Humans; Hydrazines; Male; Middle Aged; Nausea; Parkinson Disease; Placebos | 1973 |
Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Carboxy-Lyases; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Therapy, Combination; Female; Humans; Hydrazines; Male; Middle Aged; Movement Disorders; Nausea; Parkinson Disease; Placebos | 1974 |
Sinemet.
Topics: Carbidopa; Clinical Trials as Topic; Drug Combinations; Humans; Hydrazines; Levodopa; Parkinson Disease | 1974 |
Intellectual and memory function in parkinsonian and non-parkinsonian patients treated with L-dopa.
Topics: Adult; Aged; Carbidopa; Dihydroxyphenylalanine; Educational Status; Female; Humans; Intelligence; Intelligence Tests; Male; Memory; Middle Aged; Parkinson Disease; Placebos; Psychological Tests | 1973 |
832 other study(ies) available for carbidopa and Parkinson Disease
| Article | Year |
|---|---|
Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2021 |
Polyneuropathy monitoring in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel.
Topics: Antiparkinson Agents; Carbidopa; Gels; Humans; Levodopa; Parkinson Disease; Polyneuropathies | 2021 |
Melanochrome-based colorimetric assay for quantitative detection of levodopa in co-presence of carbidopa and its application to relevant anti-Parkinson drugs.
Topics: Antiparkinson Agents; Carbidopa; Colorimetry; Drug Combinations; Humans; Levodopa; Parkinson Disease; Tablets | 2022 |
Modulation of dopamine tone induces frequency shifts in cortico-basal ganglia beta oscillations.
Topics: Action Potentials; Animals; Basal Ganglia; Beta Rhythm; Carbidopa; Cerebral Cortex; Chlorocebus aethiops; Dopamine; Electrodes, Implanted; Eye-Tracking Technology; Female; Humans; Levodopa; Magnetic Resonance Imaging; Nerve Net; Organic Chemicals; Parkinson Disease; Parkinsonian Disorders; Pupil; Stereotaxic Techniques | 2021 |
Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gels; Humans; Levodopa; Parkinson Disease; Prospective Studies; Quality of Life | 2022 |
Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats.
Topics: Animals; Bacteria; Carbidopa; Cross-Sectional Studies; Gastrointestinal Microbiome; Gastrointestinal Motility; Humans; Levodopa; Parkinson Disease; Rats; Tyrosine Decarboxylase | 2022 |
Spinocerebellar ataxia type 3: response to levodopa infusion in two cases.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Infusions, Parenteral; Levodopa; Machado-Joseph Disease; Neurodegenerative Diseases; Parkinson Disease; Parkinsonian Disorders | 2022 |
[Adverse effects and complications of continuous intestinal infusion of levodopa-carbidopa in a cohort of patients with Parkinson's disease in a tertiary hospital].
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies; Tertiary Care Centers | 2022 |
Clinical Pharmacology of Entacapone (Comtan) From the FDA Reviewer.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechols; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease; United States; United States Food and Drug Administration | 2022 |
The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Drug Combinations; Gels; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Quality of Life | 2022 |
Letter to the editor, "Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications".
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2022 |
Levodopa/carbidopa intestinal gel for pain related to levodopa-induced motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Pain; Parkinson Disease | 2022 |
Continuous Dopaminergic Stimulation Improves Cortical Maladaptive Changes in Advanced Parkinson's Disease.
Topics: Carbidopa; Dopamine; Dyskinesias; Humans; Levodopa; Motor Cortex; Parkinson Disease | 2022 |
The relationship between the distinct ratios of benserazide and carbidopa to levodopa and motor complications in Parkinson's disease: A retrospective cohort study.
Topics: Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2022 |
A rare complication of jejunal extension of a percutaneous endoscopic gastrostomy tube for levodopa-carbidopa intestinal gel administration.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gastrostomy; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2022 |
Refractory status epilepticus due to vitamin B
Topics: Carbidopa; Humans; Levodopa; Parkinson Disease; Status Epilepticus; Vitamin B 6; Vitamins | 2022 |
Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Homocysteine; Humans; Levodopa; Nitriles; Oxadiazoles; Parkinson Disease | 2022 |
Vitamin B6 Deficiency Anemia Attributed to Levodopa/Carbidopa Intestinal Gel Therapy for Parkinson's Disease: A Diagnostic Pitfall for Myelodysplastic Syndrome with Ring Sideroblasts.
Topics: Aged; Anemia; Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Male; Myelodysplastic Syndromes; Parkinson Disease; Pyridoxine; Vitamin B 6; Vitamin B 6 Deficiency | 2022 |
Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the OBSERVE-PD observational study.
Topics: Antiparkinson Agents; Carbidopa; Cross-Sectional Studies; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Severity of Illness Index | 2022 |
Ascorbic acid can alleviate the degradation of levodopa and carbidopa induced by magnesium oxide.
Topics: Antiparkinson Agents; Ascorbic Acid; Carbidopa; Humans; Levodopa; Magnesium Oxide; Parkinson Disease | 2022 |
Use of levodopa-carbidopa intestinal gel to treat patients with multiple system atrophy.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Multiple System Atrophy; Parkinson Disease; Retrospective Studies | 2022 |
Up-regulated expression of miRNA-29b in patients with Parkinson's disease on levodopa gel infusion.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Infusions, Parenteral; Levodopa; MicroRNAs; Parkinson Disease | 2023 |
Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson's disease on levodopa/carbidopa intestinal gel infusion.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies; Weight Loss | 2022 |
Ten-year trends of the characteristics in patients with advanced Parkinson's disease at the time of intestinal gel therapy introduction
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gels; Humans; Levodopa; Male; Neurodegenerative Diseases; Parkinson Disease; Retrospective Studies | 2022 |
Adverse effects of levodopa/carbidopa intrajejunal gel treatment: A single-center long-term follow-up study.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Follow-Up Studies; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life | 2022 |
Tolcapone improves outcomes in patients with Parkinson disease treated by levodopa/carbidopa intestinal gel: A pilot study.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Drug Combinations; Homocysteine; Humans; Levodopa; Parkinson Disease; Pilot Projects; Quality of Life; Tolcapone | 2022 |
Motor and nonmotor symptoms in patients treated with 24-hour daily levodopa-carbidopa intestinal gel infusion: Analysis of the COmedication Study assessing Mono- and cOmbination therapy with levodopa-carbidopa inteStinal gel (COSMOS).
Topics: Antiparkinson Agents; Carbidopa; Cross-Sectional Studies; Drug Combinations; Gait Disorders, Neurologic; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life; Retrospective Studies | 2022 |
Carbidopa suppresses estrogen receptor-positive breast cancer via AhR-mediated proteasomal degradation of ERα.
Topics: Animals; Breast Neoplasms; Carbidopa; Cell Line, Tumor; Estrogen Receptor alpha; Estrogens; Female; Humans; Mice; Parkinson Disease; Receptors, Aryl Hydrocarbon; Receptors, Estrogen | 2022 |
How resistant are levodopa-resistant axial symptoms? Response of freezing, posture, and voice to increasing levodopa intestinal infusion rates in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gait Disorders, Neurologic; Gels; Humans; Levodopa; Middle Aged; Parkinson Disease; Posture | 2023 |
Phytoconstituents of Datura metel extract improved motor coordination in haloperidol-induced cataleptic mice: Dual-target molecular docking and behavioural studies.
Topics: alpha-Synuclein; Animals; Antioxidants; Antiparkinson Agents; Atropine Derivatives; Carbidopa; Cholinergic Antagonists; Datura metel; Dopa Decarboxylase; Haloperidol; Levodopa; Methanol; Mice; Molecular Docking Simulation; Parkinson Disease; Phytochemicals; Plant Extracts; Scopolamine | 2023 |
Neurologists' preferences for device-aided therapy for advanced Parkinson's disease in Japan.
Topics: Antiparkinson Agents; Bayes Theorem; Carbidopa; Humans; Japan; Levodopa; Neurologists; Parkinson Disease | 2023 |
Sex Is the Main Determinant of Levodopa Clinical Pharmacokinetics: Evidence from a Large Series of Levodopa Therapeutic Monitoring.
Topics: Aged; Antiparkinson Agents; Carbidopa; Female; Humans; Levodopa; Male; Parkinson Disease; Retrospective Studies | 2022 |
Revisiting levodopa for advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Parkinson Disease | 2022 |
Determination of the motor status of patients with advanced Parkinson's disease under levodopa-carbidopa intestinal gel using a machine learning model.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Prospective Studies; Quality of Life | 2023 |
Inhibition of PDE10A in a New Rat Model of Severe Dopamine Depletion Suggests New Approach to Non-Dopamine Parkinson's Disease Therapy.
Topics: Animals; Carbidopa; Catalepsy; Dopamine; Levodopa; Parkinson Disease; Rats | 2022 |
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: long-term results from COSMOS.
Topics: Antiparkinson Agents; Carbidopa; Cross-Sectional Studies; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2023 |
Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome.
Topics: Carbidopa; Enteral Nutrition; Gastrostomy; Humans; Levodopa; Parkinson Disease | 2023 |
Long-Duration Response to Levodopa, Motor Learning, and Neuroplasticity in Early Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Humans; Learning; Levodopa; Parkinson Disease; Time Factors | 2023 |
The impact of dysphagia in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel.
Topics: Antiparkinson Agents; Carbidopa; Deglutition Disorders; Dementia; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2023 |
New-onset impulse control disorders after treatment with levodopa-carbidopa intestinal gel in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Disruptive, Impulse Control, and Conduct Disorders; Humans; Levodopa; Parkinson Disease | 2023 |
Levodopa/carbidopa intestinal gel via percutaneous endoscopic transgastric jejunostomy in advanced Parkinson's disease: hitting two birds with one stone?
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Jejunostomy; Levodopa; Parkinson Disease | 2023 |
Fecal microbiota transplantation for Parkinson's disease using levodopa - carbidopa intestinal gel percutaneous endoscopic gastro-jejeunal tube.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Fecal Microbiota Transplantation; Gels; Humans; Levodopa; Parkinson Disease | 2023 |
Levodopa Carbidopa Intestinal Gel in Advanced Parkinson's Disease: DUOGLOBE Final 3-Year Results.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Prospective Studies; Quality of Life | 2023 |
Before blaming levodopa/carbidopa intestinal gel for demyelinating polyneuropathy, all differential aetiologies must be ruled out.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Polyneuropathies | 2023 |
Response to 'Before blaming levodopa/carbidopa intestinal gel for demyelinating polyneuropathy, all differential aetiologies must be ruled out'.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Polyneuropathies | 2023 |
Are Parkinson's disease patients referred too late for device-aided therapies and how can better informed and earlier referrals be encouraged?
Topics: Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Humans; Levodopa; Parkinson Disease; Quality of Life | 2023 |
Classification of l-DOPA pharmacokinetics shapes and creating a predictive model.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2023 |
Transgastric Jejunostomy (PEG-J) for Continuous Infusion of Levodopa-Carbidopa Intestinal Gel: An Approach for Parkinson's Disease Treatment.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Jejunostomy; Levodopa; Parkinson Disease; Quality of Life | 2023 |
Antinociceptive effects of carbidopa levodopa on normal rats and Parkinson's disease mice.
Topics: Analgesics; Animals; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Mice; Pain; Parkinson Disease; Rats | 2023 |
Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Infusions, Subcutaneous; Levodopa; Parkinson Disease; Prospective Studies; Retrospective Studies | 2023 |
Rescue levodopa-carbidopa intestinal gel (LCIG) therapy in Parkinson's disease patients with suboptimal response to deep brain stimulation.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Retrospective Studies | 2019 |
[Chronic inflammatory demyelinating polyradiculoneuropathy associated with treatment using intraduodenal infusion of levodopa-carbidopa].
Topics: Antiparkinson Agents; Carbidopa; Diagnosis, Differential; Dopamine; Drug Combinations; Duodenum; Female; Folic Acid; Humans; Infusions, Parenteral; Levodopa; Metabolic Networks and Pathways; Methionine; Middle Aged; Parkinson Disease; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 2019 |
Endoscopic management of duodenal levodopa-carbidopa therapy of advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenoscopy; Female; Gastrostomy; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2019 |
Investigating Stochastic Differential Equations Modelling for Levodopa Infusion in Patients with Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease; Precision Medicine; Stochastic Processes | 2020 |
Long-term safety and efficacy of 24-hour levodopa-carbidopa intestinal gel in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2019 |
Beyond 10 years of levodopa intestinal infusion experience: Analysis of mortality and its predictors.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cause of Death; Drug Combinations; Female; Humans; Infusions, Parenteral; Levodopa; Longitudinal Studies; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Prognosis; Retrospective Studies | 2020 |
Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson's disease: A large single-center study.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catheters, Indwelling; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Endoscopy, Gastrointestinal; Female; France; Gastrostomy; Gels; Humans; Infusion Pumps; Intestinal Absorption; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2020 |
Multicenter study of levodopa carbidopa intestinal gel in Parkinson’s disease: the Turkish experience
Topics: Activities of Daily Living; Aged; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reproducibility of Results | 2020 |
Complex dyskinesias in Parkinson patients on levodopa/carbidopa intestinal gel.
Topics: Aged; Antiparkinson Agents; Carbidopa; Case-Control Studies; Cross-Sectional Studies; Drug Combinations; Dyskinesia, Drug-Induced; Female; Gels; Humans; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2019 |
Clinical Trial Highlights - Infusion Therapies.
Topics: Apomorphine; Carbidopa; Clinical Trials as Topic; Dopamine Agonists; Drug Combinations; Gels; Humans; Infusion Pumps, Implantable; Infusions, Subcutaneous; Jejunum; Levodopa; Parkinson Disease | 2020 |
Supplementary management with Pycnogenol® in Parkinson's disease to prevent cognitive impairment.
Topics: Carbidopa; Cognition; Cognitive Dysfunction; Dietary Supplements; Drug Combinations; Female; Free Radicals; Humans; Levodopa; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Registries | 2020 |
Istradefylline (Nourianz) for Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Drug Administration Schedule; Humans; Levodopa; Parkinson Disease; Purines | 2020 |
"On-State" Freezing of Gait: Insights and Treatment With Levodopa Intestinal Gel Infusion.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gait; Gait Disorders, Neurologic; Gels; Humans; Levodopa; Parkinson Disease | 2020 |
Video analysis of long-term effects of levodopa-carbidopa intestinal gel on gait and posture in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gait; Gels; Humans; Levodopa; Parkinson Disease; Pilot Projects; Posture | 2020 |
The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infant, Newborn; Levodopa; Male; Parkinson Disease; Quality of Life | 2020 |
Compliance with levodopa-carbidopa intestinal gel in a selected population in central south Italy: Beyond sex, a possible gender effect.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Infusions, Parenteral; Italy; Levodopa; Male; Medication Adherence; Middle Aged; Parkinson Disease; Patient Dropouts; Sex Factors | 2020 |
Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson's disease: results of the Italian GLORIA patient population.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Italy; Levodopa; Parkinson Disease; Quality of Life | 2020 |
[Movement Disorders: What Are You Doing? What Can We Do?]
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Dopamine Agonists; Essential Tremor; Humans; Levodopa; Parkinson Disease | 2020 |
Outcome of Parkinson's Disease Patients Affected by COVID-19.
Topics: Aged; Aged, 80 and over; Betacoronavirus; Carbidopa; Coronavirus Infections; COVID-19; Female; Humans; Levodopa; Male; Pandemics; Parkinson Disease; Pneumonia, Viral; SARS-CoV-2; Treatment Outcome | 2020 |
Levodopa infusion in Parkinson's disease: Individual quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Caregivers; Cost of Illness; Drug Combinations; Female; Humans; Infusions, Parenteral; Jejunum; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Prospective Studies; Psychomotor Performance; Quality of Life; Treatment Outcome | 2020 |
Biphasic Levodopa-Induced Freezing of Gait in Parkinson's Disease.
Topics: Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Gait Disorders, Neurologic; Humans; Levodopa; Male; Parkinson Disease | 2020 |
[New Therapeutic Options for the Individualised Titration of Levodopa].
Topics: Antiparkinson Agents; Carbidopa; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2021 |
Pearls and Oy-sters: Vitamin B
Topics: Aged, 80 and over; Antiparkinson Agents; Carbidopa; Electroencephalography; Epilepsy; Fatal Outcome; Female; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Status Epilepticus; Vitamin B 6 Deficiency | 2020 |
Levodopa-carbidopa intestinal gel is an option in Parkinson's disease with hyponatremia induced by dopamine agonists.
Topics: Antiparkinson Agents; Carbidopa; Dopamine Agonists; Drug Combinations; Gels; Humans; Hyponatremia; Levodopa; Parkinson Disease | 2020 |
Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Capsules; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2020 |
Opicapone and Levodopa-Carbidopa Intestinal Gel Infusion: The Way Forward Towards Cost Savings for Healthcare Systems?
Topics: Aged; Carbidopa; Catechol O-Methyltransferase Inhibitors; Cost Savings; Delivery of Health Care; Dopamine Agonists; Drug Combinations; Female; Gels; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Retrospective Studies | 2020 |
Quality Improvement in Parkinson's Disease: A Successful Program to Enhance Timely Administration of Levodopa in the Hospital.
Topics: Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Hospital Departments; Hospitalization; Hospitals, Urban; Humans; Length of Stay; Levodopa; Male; Middle Aged; Parkinson Disease; Process Assessment, Health Care; Quality Improvement; Time Factors | 2020 |
Real-Life Use of Levodopa/Carbidopa Intestinal Gel in Parkinson's Disease According to Analysis of Pump Data.
Topics: Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Gels; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; Levodopa; Male; Medication Adherence; Middle Aged; Parkinson Disease | 2020 |
EQUIDopa: A responsive web application for the levodopa equivalent dose calculator.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease | 2020 |
Predictors of Time to Discontinuation of Levodopa-Carbidopa Intestinal Gel Infusion: A Retrospective Cohort Study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2020 |
Neurochemical, neurobehavioral and histochemical effects of therapeutic dose of l-dopa on striatal neurons in rats: Protective effect of virgin coconut oil.
Topics: Animals; Behavior, Animal; Carbidopa; Coconut Oil; Corpus Striatum; Levodopa; Male; Neurons; Neuroprotective Agents; Parkinson Disease; Rats, Sprague-Dawley | 2020 |
Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients
Topics: Abdomen, Acute; Aged; Carbidopa; Catheterization; Deglutition Disorders; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Dysarthria; Dyskinesias; Endoscopy; Female; Gait; Gels; Humans; Intestines; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome; Turkey | 2021 |
Intrajejunal vs oral levodopa-carbidopa therapy in Parkinson disease: A retrospective cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Carbidopa; Cohort Studies; Drug Combinations; Female; Humans; Injections; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Romania | 2020 |
Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gastrointestinal Microbiome; Gels; Humans; Levodopa; Metabolome; Parkinson Disease; RNA, Ribosomal, 16S | 2021 |
Intestinal burying of the jejunal-tube of a PEG-J levodopa-carbidopa release system for Parkinson's disease. Successful endoscopic management.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Jejunum; Levodopa; Parkinson Disease | 2021 |
Parkinson Disease.
Topics: Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Disease Progression; Drug Combinations; Family Practice; Humans; Levodopa; Parkinson Disease; Physical Therapy Modalities | 2020 |
Levodopa-carbidopa intrajejunal infusion in Parkinson's disease: untangling the role of age.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cross-Sectional Studies; Drug Combinations; Gait Disorders, Neurologic; Gels; Humans; Italy; Levodopa; Parkinson Disease; Quality of Life | 2021 |
Real-world assessment of the impact of "OFF" episodes on health-related quality of life among patients with Parkinson's disease in the United States.
Topics: Aged; Carbidopa; Cross-Sectional Studies; Drug Combinations; Female; Health Status; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Regression Analysis; Surveys and Questionnaires; Symptom Flare Up; United States | 2021 |
Device-aided therapies for advanced Parkinson disease: insights from an international survey.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Gels; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease | 2021 |
Melanocytic Hyperactivation Simulating an Acral Lentiginous Melanoma in a Patient With Parkinson Disease Treated by Levodopa.
Topics: Aged; Antiparkinson Agents; Carbidopa; Diagnosis, Differential; Drug Combinations; Female; Humans; Hyperpigmentation; Levodopa; Melanins; Melanocytes; Melanoma; Parkinson Disease; Predictive Value of Tests; Skin; Skin Neoplasms; Skin Pigmentation; Treatment Outcome | 2021 |
Buried Bumper Syndrome: A common complication of levodopa intestinal infusion for Parkinson disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Endoscopy, Gastrointestinal; Enteral Nutrition; Equipment Failure; Female; Gastrostomy; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Prospective Studies; Retrospective Studies | 2021 |
Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2021 |
Levodopa/dopa decarboxylase inhibitor associated microscopic colitis: An under-recognized drug reaction.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Cohort Studies; Colitis, Microscopic; Drug Combinations; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2021 |
Pharmacological evaluation of vanillic acid in rotenone-induced Parkinson's disease rat model.
Topics: Animals; Antioxidants; Antiparkinson Agents; Behavior, Animal; Body Weight; Carbidopa; Catalase; Catalepsy; Disease Models, Animal; Dopamine; Drug Combinations; Female; Glutathione; Levodopa; Locomotion; Male; Mesencephalon; Muscular Diseases; Oxidative Stress; Parkinson Disease; Postural Balance; Rats, Sprague-Dawley; Rotenone; Superoxides; Thiobarbituric Acid Reactive Substances; Vanillic Acid | 2021 |
Concomitant Medication Usage with Levodopa-Carbidopa Intestinal Gel: Results from the COSMOS Study.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2021 |
The Social Value of Improvement in Activities of Daily Living among the Advanced Parkinson's Disease Population.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Parkinson Disease; Social Values | 2020 |
Role of Vitamins in Advanced Therapy for Parkinson's Disease: Decoding the Paradox.
Topics: Antiparkinson Agents; Carbidopa; Humans; Parkinson Disease; Vitamins | 2022 |
[Optimal dose of levodopa-carbidopa intestinal gel in the treatment of diphasic dyskinesia and freezing of gait].
Topics: Activities of Daily Living; Carbidopa; Dyskinesias; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Middle Aged; Parkinson Disease | 2021 |
The impact of device-assisted therapies on the gut microbiome in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gastrointestinal Microbiome; Gels; Humans; Levodopa; Parkinson Disease | 2022 |
Body mass index variations in patients with Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion: A case control study versus standard of care and subthalamic nucleus deep brain stimulation.
Topics: Antiparkinson Agents; Body Mass Index; Carbidopa; Case-Control Studies; Deep Brain Stimulation; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies; Standard of Care; Subthalamic Nucleus | 2021 |
The impact of tube replacement timing during LCIG therapy on PEG-J associated adverse events: a retrospective multicenter observational study.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gastric Bypass; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2021 |
Per-oral image guided gastrojejunostomy insertion for levodopa-carbidopa intestinal gel in Parkinson's disease is safe and may be advantageous.
Topics: Aged; Antiparkinson Agents; Carbidopa; Digestive System Surgical Procedures; Drug Combinations; Female; Gastrostomy; Gels; Humans; Jejunum; Levodopa; Male; Middle Aged; Outcome and Process Assessment, Health Care; Parkinson Disease; Surgery, Computer-Assisted | 2021 |
Scalable Asymmetric Syntheses of Foslevodopa and Foscarbidopa Drug Substances for the Treatment of Parkinson's Disease.
Topics: Carbidopa; Humans; Hydrogenation; Levodopa; Parkinson Disease; Pharmaceutical Preparations | 2022 |
Surgical treatment of buried bumper syndrome in patients with Parkinson´s disease and duodenal levodopa/carbidopa infusion therapy.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Enteral Nutrition; Gastrostomy; Humans; Levodopa; Parkinson Disease | 2021 |
Measuring General Expectations of Advanced Stage Treatment Outcomes in Parkinson's Disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Motivation; Parkinson Disease; Prognosis; Treatment Outcome | 2021 |
SCL20A2 mutation mimicking fluctuating Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Mutation; Parkinson Disease; Sodium-Phosphate Cotransporter Proteins, Type III | 2017 |
Use of advanced therapies for Parkinson's disease in Norway.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Drug Utilization; Gels; Healthcare Disparities; Humans; Infusions, Parenteral; Levodopa; Norway; Parkinson Disease; Patient Education as Topic | 2017 |
Liquid levodopa-carbidopa in advanced Parkinson's disease with motor complications.
Topics: Aged; Antiparkinson Agents; Ascorbic Acid; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2017 |
Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Parkinson Disease; Peripheral Nervous System Diseases; Vitamin B Complex | 2017 |
Peripheral neuropathy in 30 duodopa patients with vitamins B supplementation.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases; Pilot Projects; Prospective Studies; Vitamin B Complex; Vitamin D Deficiency | 2017 |
An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life | 2017 |
Central conduction abnormalities in patients receiving levodopa-carbidopa intestinal gel infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Central Nervous System; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Neural Conduction; Parkinson Disease; Peripheral Nervous System; Polyneuropathies; Prospective Studies | 2017 |
Sulfasalazine-Induced Crystalluria Causing Severe Acute Kidney Injury.
Topics: Acute Kidney Injury; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Carbidopa; Cholinesterase Inhibitors; Crohn Disease; Donepezil; Drug Combinations; Fluid Therapy; Humans; Indans; Kidney Calculi; Levodopa; Male; Parkinson Disease; Piperidines; Severity of Illness Index; Sulfasalazine; Ultrasonography | 2017 |
Enteral feeding in Parkinson's patients receiving levodopa/carbidopa intestinal gel.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Enteral Nutrition; Gels; Humans; Levodopa; Male; Parkinson Disease | 2017 |
Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Treatment Outcome; Weight Loss | 2017 |
Cascade stomach associated with delayed-on or no-on phenomenon in a patient with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Barium; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Radiography; Stomach Diseases | 2017 |
Long-term safety and effectiveness of levodopa-carbidopa intestinal gel infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Administration Routes; Drug Combinations; Drug Monitoring; Female; Gels; Humans; Intestinal Absorption; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Quality of Life; Spain; Time; Treatment Outcome | 2017 |
Continuous dopaminergic stimulation in a patient treated with daytime Levodopa-carbidopa intestinal gel and overnight Rotigotine: a case report.
Topics: Aged; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Male; Parkinson Disease; Receptors, Dopamine; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2017 |
The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Drug Combinations; Female; Gels; Health Expenditures; Health Resources; Humans; Ireland; Levodopa; Male; Markov Chains; Parkinson Disease; Quality-Adjusted Life Years | 2017 |
Initiation of Levodopa-Carbidopa Intestinal Gel Infusion Using Telemedicine (Video Communication System) Facilitates Efficient and Well-Accepted Home Titration in Patients with Advanced Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Sweden; Telemedicine; Time Factors; Treatment Outcome; Video Recording | 2017 |
Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Parkinson Disease; Registries | 2017 |
Levodopa-carbidopa intestinal gel therapy after deep brain stimulation.
Topics: Aged; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2018 |
The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biological Availability; Carbidopa; Corpus Striatum; Dopamine; Drug Combinations; HeLa Cells; Humans; Levodopa; Male; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Permeability; Picolinic Acids; Prodrugs; Solubility; Structure-Activity Relationship | 2017 |
l-Dopa/carbidopa intestinal gel and subthalamic nucleus stimulation: Effects on cognition and behavior.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cognition; Deep Brain Stimulation; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Subthalamic Nucleus; Treatment Outcome | 2017 |
Patient Preferences for Device-Aided Treatments Indicated for Advanced Parkinson Disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Choice Behavior; Deep Brain Stimulation; Drug Combinations; Drug Delivery Systems; Duodenum; Equipment Design; Female; Humans; Infusion Pumps; Internet; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Preference; Surveys and Questionnaires; United States | 2017 |
Improvement in Severe Orthostatic Hypotension Following Carbidopa Dose Reduction.
Topics: Aged; Carbidopa; Dopamine Agents; Dose-Response Relationship, Drug; Female; Humans; Hypotension, Orthostatic; Parkinson Disease | 2018 |
Continuous intestinal infusion of levodopa-carbidopa in patients with advanced Parkinson's disease in Spain: Subanalysis by autonomous community.
Topics: Antiparkinson Agents; Carbidopa; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies; Spain | 2021 |
Effects of intestinal Levodopa infusion on freezing of gait in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gait Disorders, Neurologic; Gels; Humans; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2018 |
Prelemniscal Lesion for Selective Improvement of Parkinson Disease Tremor.
Topics: Aged; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Parkinson Disease; Treatment Outcome; Tremor; Ventral Thalamic Nuclei | 2018 |
A wrinkle in ON-time - A GI structural abnormality confounding levodopa therapy with Duodopa rescue; a case study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Hernia, Hiatal; Humans; Levodopa; Male; Parkinson Disease | 2018 |
Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Carbidopa; Caregivers; Cost of Illness; Cross-Sectional Studies; Drug Combinations; Family; Female; Humans; Italy; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Quality of Life; Socioeconomic Factors; Surveys and Questionnaires; Treatment Outcome | 2018 |
Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Caregivers; Comorbidity; Cost of Illness; Disruptive, Impulse Control, and Conduct Disorders; Drug Combinations; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gastrostomy; Gels; Humans; Levodopa; Male; Parkinson Disease; Prospective Studies; Psychotropic Drugs; Quality of Life; Severity of Illness Index; Sleep; Treatment Outcome | 2018 |
Workforce participation and activities in Parkinson's disease patients receiving device-aided therapy.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Denmark; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Retrospective Studies; Sweden | 2018 |
Jejunal pulling syndrome: A peculiar LCIG complication.
Topics: Aged; Antiparkinson Agents; Bezoars; Carbidopa; Drug Combinations; Gastric Bypass; Gels; Humans; Infusions, Parenteral; Intestinal Volvulus; Jejunum; Levodopa; Male; Parkinson Disease | 2018 |
Levodopa-carbidopa intestinal gel: is the naso-jejunal phase a redundant convention?
Topics: Administration, Intranasal; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastrostomy; Gels; Humans; Infusion Pumps, Implantable; Jejunostomy; Jejunum; Length of Stay; Levodopa; Male; Middle Aged; Parkinson Disease | 2018 |
Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's disease.
Topics: Activities of Daily Living; Age Factors; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Europe; Female; Gels; Humans; International Cooperation; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2018 |
Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry.
Topics: Accelerometry; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Parkinson Disease; Precision Medicine; Quality of Life; Single-Blind Method; Tablets; Treatment Outcome | 2018 |
Acute cholecystitis induced by surgery for levodopa-carbidopa intestinal gel therapy: Possible relationship to pre-existing gallstones.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cholecystitis, Acute; Drug Combinations; Gallstones; Humans; Infusions, Parenteral; Jejunostomy; Levodopa; Male; Parkinson Disease | 2018 |
Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson's Disease.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Biological Availability; Brain Chemistry; Capsules; Carbidopa; Catechols; Dopamine; Drug Compounding; Female; Hydrophobic and Hydrophilic Interactions; Levodopa; Mice; Mice, Inbred C57BL; Microscopy, Electron, Scanning; Nitriles; Parkinson Disease | 2018 |
Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson's disease patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Case-Control Studies; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Parkinson Disease; Tablets; Young Adult | 2018 |
[Outpatient establishment and initial management of treatment with intraduodenal levodopa-carbidopa infusion in advanced Parkinson's disease].
Topics: Aged; Algorithms; Ambulatory Care; Antiparkinson Agents; Carbidopa; Clinical Protocols; Disease Management; Drug Combinations; Duodenum; Female; Gastrostomy; Humans; Infusions, Parenteral; Intestinal Absorption; Intubation, Gastrointestinal; Levodopa; Male; Parkinson Disease | 2018 |
Assessment of Duodopa
Topics: Aged; Antiparkinson Agents; Carbidopa; Caregivers; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Treatment Outcome | 2018 |
Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antiparkinson Agents; Carbidopa; Consensus; Drug Combinations; Europe; Female; Gels; Humans; Levodopa; Male; Parkinson Disease; Specialization; Young Adult | 2018 |
Levodopa-Carbidopa-Related Rash in Parkinson's Disease: A Case Series.
Topics: Adult; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Exanthema; Female; Humans; Levodopa; Middle Aged; Parkinson Disease | 2018 |
[Levodopa-carbidopa intestinal gel treatment introduced by surgical gastrostomy in a patient of Parkinson's disease after Billroth II gastrojejunostomy].
Topics: Aged; Antiparkinson Agents; Carbidopa; Dosage Forms; Drug Combinations; Drug Compounding; Duodenal Ulcer; Gastric Bypass; Gastrostomy; Gels; Humans; Levodopa; Male; Parkinson Disease; Treatment Outcome | 2018 |
The effect of continuous levodopa treatment during the afternoon hours.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusion Pumps, Implantable; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Time Factors | 2019 |
Possible modulation of concurrent Parkinson's disease in the management of metastatic GIST: a review of two cases.
Topics: Aged; Antineoplastic Agents; Antiparkinson Agents; Carbidopa; Drug Combinations; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Levodopa; Liver Neoplasms; Male; Parkinson Disease; Severity of Illness Index; Stomach Neoplasms | 2018 |
Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Weight Loss | 2019 |
Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cost of Illness; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2019 |
Proposition of zinc supplementation during levodopa-carbidopa intestinal gel treatment.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Administration Routes; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Parkinson Disease; Prospective Studies; Zinc | 2018 |
Conversion of L-dopa to Extended Release L-dopa (Rytary®) in Patients with Fluctuating Parkinson's Disease: Predictors of Dose.
Topics: Aged; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Substitution; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Patient Preference; Retrospective Studies | 2019 |
Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2018 |
Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Drug Combinations; Gels; Health Expenditures; Health Services; Health Status; Humans; Infusion Pumps, Implantable; Levodopa; Markov Chains; Models, Econometric; Parkinson Disease; Quality-Adjusted Life Years; Scotland; Severity of Illness Index; Wales | 2019 |
Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry.
Topics: Aged; Carbidopa; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Gels; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Registries | 2019 |
Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors | 2019 |
Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2019 |
Sensor-based algorithmic dosing suggestions for oral administration of levodopa/carbidopa microtablets for Parkinson's disease: a first experience.
Topics: Actigraphy; Administration, Oral; Aged; Aged, 80 and over; Algorithms; Antiparkinson Agents; Carbidopa; Drug Combinations; Feasibility Studies; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Wearable Electronic Devices | 2019 |
[Analysis of PEG-J associated complications in 14 adult patients treated with levodopa-carbidopa intestinal gel].
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenal Diseases; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Gastrostomy; Gels; Humans; Intestinal Perforation; Jejunostomy; Levodopa; Male; Middle Aged; Parkinson Disease; Peritonitis; Retrospective Studies; Skin Diseases; Surgical Stomas | 2019 |
Managing treatment fluctuations in Parkinson disease: "On" again-, "off" again.
Topics: Carbidopa; Catechols; Humans; Levodopa; Nitriles; Parkinson Disease | 2019 |
Mucuna Pruriens Combined with Carbidopa in Parkinson's Disease: A Case Report.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Drug Therapy, Combination; Female; Humans; Middle Aged; Mucuna; Parkinson Disease; Patient Preference; Phytotherapy; Plant Preparations | 2019 |
[Complications and troubleshooting at the initial introduction of Levodopa-carbidopa continuous infusion gel therapy: A single-center study].
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastric Bypass; Gastrostomy; Gels; Glycosides; Humans; Infusion Pumps; Intubation; Levodopa; Male; Middle Aged; Parkinson Disease; Pregnanes; Retrospective Studies; Skin Diseases, Infectious | 2019 |
Does levodopa have a disease-modifying effect in Parkinson's disease? Evidence from a delayed-start trial.
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Parkinson Disease | 2019 |
Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson's disease.
Topics: Administration, Mucosal; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gait; Gels; Humans; Intestinal Mucosa; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance | 2019 |
Dyskinesia-Hyperpyrexia Syndrome in Parkinson's disease with Deep Brain Stimulation and high-dose levodopa/carbidopa and entacapone.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Combined Modality Therapy; Deep Brain Stimulation; Drug Combinations; Drug Therapy, Combination; Fever; Humans; Hyperkinesis; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2019 |
Dopamine dysregulation syndrome induced by proxy.
Topics: Aged; Carbidopa; Disruptive, Impulse Control, and Conduct Disorders; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Substance-Related Disorders; Syndrome | 2019 |
Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Carbidopa; Cognitive Dysfunction; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Drug Substitution; Electronic Health Records; Female; Humans; Infusions, Subcutaneous; Levodopa; Male; Medication Adherence; Middle Aged; Parkinson Disease; Retrospective Studies | 2019 |
Technique and outcome of percutaneous endoscopic transgastric jejunostomy for continuous infusion of levodopa-carbidopa intestinal gel for treatment of Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Drug Combinations; Endoscopy, Gastrointestinal; Female; Gels; Humans; Jejunostomy; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Retrospective Studies; Treatment Outcome | 2019 |
Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cohort Studies; Drug Combinations; Female; Follow-Up Studies; Gastrostomy; Gels; Humans; Infusion Pumps; Italy; Jejunum; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Prospective Studies; Retrospective Studies; Treatment Outcome | 2019 |
Inhaled levodopa (Inbrija) for Parkinson's disease.
Topics: Administration, Inhalation; Antiparkinson Agents; Carbidopa; Drug Combinations; Dry Powder Inhalers; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2019 |
Levodopa/carbidopa intestinal gel infusion can improve camptocormia in Parkinson's disease.
Topics: Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Muscular Atrophy, Spinal; Parkinson Disease; Spinal Curvatures; Treatment Outcome | 2019 |
Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Gels; Germany; Humans; Infusions, Parenteral; Infusions, Subcutaneous; Levodopa; Neurology; Parkinson Disease; Practice Patterns, Physicians' | 2019 |
Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastrostomy; Gels; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; Jejunum; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Registries; Retrospective Studies | 2019 |
Motor matters: tackling heterogeneity of Parkinson's disease in functional MRI studies.
Topics: Antiparkinson Agents; Basal Ganglia; Carbidopa; Disability Evaluation; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Reproducibility of Results; Sensitivity and Specificity; Severity of Illness Index | 2013 |
Clinical aspects of comorbid schizophrenia and idiopathic Parkinson's disease.
Topics: Antiparkinson Agents; Antipsychotic Agents; Brain; Carbidopa; Catechols; Clozapine; Diagnosis, Differential; Fluphenazine; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Schizophrenia; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2014 |
Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Cross-Sectional Studies; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Retrospective Studies; Socioeconomic Factors; Spain | 2014 |
Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.
Topics: Adult; Amantadine; Antiparkinson Agents; Benzothiazoles; Carbidopa; Catechols; Disruptive, Impulse Control, and Conduct Disorders; Drug Combinations; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pramipexole; Selegiline | 2013 |
Extended-release carbidopa-levodopa in Parkinson's disease.
Topics: Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Motor Skills Disorders; Parkinson Disease | 2013 |
Mydriasis in a Parkinson disease patient on low-dose carbidopa/levodopa.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Mydriasis; Parkinson Disease | 2013 |
Heterotopic ossification following distal radius fractures in a patient with Parkinson disease treated with levodopa-carbidopa.
Topics: Antiparkinson Agents; Carbidopa; Causality; Drug Combinations; Fracture Fixation, Internal; Humans; Levodopa; Male; Middle Aged; Ossification, Heterotopic; Parkinson Disease; Radiography; Radius Fractures | 2013 |
[Continuous dopaminergic stimulation in Parkinson disease: possibilities in 2013].
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Gels; Humans; Intestines; Levodopa; Parkinson Disease | 2013 |
Letter regarding "Heterotopic ossification following distal radius fractures in a patient with Parkinson disease treated with levodopa-carbidopa".
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Male; Ossification, Heterotopic; Parkinson Disease | 2013 |
In reply.
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Male; Ossification, Heterotopic; Parkinson Disease | 2013 |
[Livedo reticularis secondary to amantadine in a patient with Parkinson disease].
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Livedo Reticularis; Parkinson Disease | 2014 |
Guillain-Barre/CIDP-like neuropathy in two parkinsonian patients following intestinal levodopa/carbidopa treatment.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Guillain-Barre Syndrome; Humans; Levodopa; Parkinson Disease; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 2014 |
Drugs for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 2013 |
Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2014 |
Jejunal levodopa infusion in Parkinson's disease.
Topics: Carbidopa; Female; Humans; Levodopa; Male; Parkinson Disease | 2014 |
Intestinal levodopa infusion: the Belgian experience.
Topics: Aged; Antiparkinson Agents; Belgium; Carbidopa; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Treatment Outcome | 2014 |
Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechols; Chromatography, Reverse-Phase; Cysteine; Dipeptides; Drug Delivery Systems; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Nitriles; Parkinson Disease; Time Factors | 2014 |
Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients.
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Carbidopa; Caregivers; Drug Administration Routes; Drug Combinations; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Patient Selection; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Surveys and Questionnaires; Treatment Outcome | 2014 |
Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cognition Disorders; Cognitive Dysfunction; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Gastrostomy; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2014 |
Parkinson disease: Intestinal levodopa infusion in PD--the first randomized trial.
Topics: Carbidopa; Female; Humans; Levodopa; Male; Parkinson Disease | 2014 |
Do adipose tissue-derived mesenchymal stem cells ameliorate Parkinson's disease in rat model?
Topics: Adipose Tissue; Amino Acids; Animals; Antigens, CD; Brain; Brain-Derived Neurotrophic Factor; Carbidopa; Cell Differentiation; Cells, Cultured; Chemokine CCL2; Disease Models, Animal; Drug Combinations; Female; Gene Expression; Genes, sry; Levodopa; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Ovariectomy; Parkinson Disease; Rats, Sprague-Dawley; Rotenone; Transforming Growth Factor beta; Tyrosine 3-Monooxygenase | 2014 |
Effect of levodopa and carbidopa on non-motor symptoms and signs of Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2014 |
Subacute peripheral neuropathy under duodopa therapy without cobalamin deficiency and despite supplementation.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Infusions, Parenteral; Jejunum; Levodopa; Male; Parkinson Disease; Polyneuropathies; Vitamin B 12 | 2014 |
Direct endoscopic jejunosotomy for the administration of levodopa-carbidopa intestinal gel in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gels; Humans; Jejunostomy; Levodopa; Male; Middle Aged; Parkinson Disease | 2014 |
Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Nitrophenols; Parkinson Disease; Psychomotor Performance; Statistics, Nonparametric; Tolcapone; Treatment Outcome | 2014 |
Gastric bezoar complication of Duodopa(®) therapy in Parkinson's disease, treated with Coca-Cola(®).
Topics: Aged; Antiparkinson Agents; Bezoars; Carbidopa; Carbonated Beverages; Drug Combinations; Humans; Levodopa; Male; Parkinson Disease; Stomach | 2014 |
A new HILIC-MS/MS method for the simultaneous analysis of carbidopa, levodopa, and its metabolites in human plasma.
Topics: Aged; Antiparkinson Agents; Carbidopa; Chromatography, Liquid; Drug Monitoring; Drug Stability; Female; Humans; Hydrophobic and Hydrophilic Interactions; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2014 |
Successful treatment of dopamine dysregulation syndrome with valproic acid.
Topics: Antimanic Agents; Carbidopa; Compulsive Behavior; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Valproic Acid | 2014 |
Levodopa-carbidopa intestinal gel (LCIG) infusion during pregnancy and delivery: first documented case.
Topics: Adult; Antiparkinson Agents; Carbidopa; Female; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease; Pregnancy; Treatment Outcome | 2014 |
Continuous infusion of levodopa-carbidopa intestinal gel in Parkinson's disease.
Topics: Carbidopa; Female; Humans; Levodopa; Male; Parkinson Disease | 2014 |
Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Cost-Benefit Analysis; Deep Brain Stimulation; Drug Administration Schedule; Gels; Germany; Humans; Injections, Subcutaneous; Levodopa; Markov Chains; Models, Econometric; Parkinson Disease; Quality of Life; Quality-Adjusted Life Years | 2015 |
Evaluation of levodopa and carbidopa antioxidant activity in normal human lymphocytes in vitro: implication for oxidative stress in Parkinson's disease.
Topics: Antioxidants; Carbidopa; Cells, Cultured; DNA Damage; Humans; Levodopa; Lymphocytes; Male; Middle Aged; Oxidative Stress; Parkinson Disease | 2015 |
Teaching NeuroImages: Pisa syndrome in Parkinson disease.
Topics: Aged; Carbidopa; Drug Combinations; Dystonia; Humans; Indoles; Levodopa; Male; Parkinson Disease; Posture; Scoliosis | 2014 |
Towards an expert system for accurate diagnosis and progress monitoring of Parkinson's disease.
Topics: Algorithms; Antiparkinson Agents; Biomarkers; Carbidopa; Deep Brain Stimulation; Disease Progression; Drug Therapy, Combination; Expert Systems; Humans; Levodopa; Parkinson Disease; Sensitivity and Specificity | 2015 |
Anterior cingulate dopamine turnover and behavior change in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Dopamine; Female; Gyrus Cinguli; Humans; Male; Middle Aged; Neuropsychological Tests; Nitrophenols; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Tolcapone | 2015 |
24 h Levodopa-carbidopa intestinal gel may reduce falls and "unresponsive" freezing of gait in Parkinson's disease.
Topics: Accidental Falls; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gait Disorders, Neurologic; Gels; Humans; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Time Factors | 2015 |
Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: Management inclinical practice.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Gels; Humans; Jejunum; Levodopa; Parkinson Disease | 2015 |
[Experience with levodopa/carbidopa intestinal gel in the treatment of advanced Parkinson's disease in Hungary].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Gels; Humans; Hungary; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Selection; Quality of Life; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
Continuous levodopa infusion is better—for now.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Female; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease | 2015 |
Initiating intrajejunal infusion of levodopa/carbidopa intestinal gel: an outpatient model.
Topics: Carbidopa; Drug Combinations; Gels; Humans; Jejunum; Levodopa; Outpatients; Parkinson Disease | 2015 |
New and emerging treatments for Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned rats.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Carbidopa; Chromatography, High Pressure Liquid; Corpus Striatum; Dependovirus; Dopamine; Electrochemical Techniques; Genetic Therapy; Genetic Vectors; Humans; Immunohistochemistry; Levodopa; Male; Neostriatum; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2015 |
Capgras delusion for animals and inanimate objects in Parkinson's Disease: a case report.
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Capgras Syndrome; Carbidopa; Clozapine; Cognitive Dysfunction; Delusions; Dibenzothiazepines; Dogs; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Parkinson Disease; Pets; Plants; Quetiapine Fumarate | 2015 |
Levodopa-carbidopa intrajejunal gel in advanced Parkinson disease with "on" freezing of gait.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Italy; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2015 |
Knotting of Duodopa® duodenal infusion system.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catheterization; Catheters; Drug Combinations; Duodenum; Equipment Failure; Female; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease | 2015 |
Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Duodenum; Dyskinesia, Drug-Induced; Dyskinesias; Female; Follow-Up Studies; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Registries; Spain; Treatment Outcome | 2015 |
Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
Topics: Aged; Anhedonia; Apathy; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Substance Withdrawal Syndrome | 2015 |
Depression, anxiety and non-motor symptoms on initiation of intrajejunal levodopa/carbidopa therapy.
Topics: Adult; Aged; Antiparkinson Agents; Anxiety; Carbidopa; Depression; Drug Combinations; Female; Humans; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales; Time Factors | 2016 |
Electroencephalographic lateralization, clinical correlates and pharmacological response in untreated Parkinson's disease.
Topics: Aged; Alpha Rhythm; Antiparkinson Agents; Beta Rhythm; Carbidopa; Drug Combinations; Electroencephalography; Female; Frontal Lobe; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Occipital Lobe; Parkinson Disease; Severity of Illness Index | 2015 |
Reply to letter: Suicide in Parkinson's disease patients treated with levodopa-carbidopa Intestinal Gel.
Topics: Antiparkinson Agents; Carbidopa; Female; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease | 2015 |
Suicide in Parkinson's Disease Patients Treated With Levodopa-Carbidopa Intestinal Gel.
Topics: Antiparkinson Agents; Carbidopa; Female; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease | 2015 |
Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease.
Topics: Administration, Cutaneous; Adult; Aged; Antiparkinson Agents; Carbidopa; Equipment Failure; Female; Follow-Up Studies; Gastric Bypass; Gastroscopy; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Safety; Postoperative Complications; Prospective Studies; Treatment Outcome; Vascular Access Devices | 2016 |
Dopamine dysregulation syndrome and punding in levodopa-carbidopa intestinal gel (LCIG) infusion: A serious but preventable complication.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Delivery Systems; Humans; Infusions, Parenteral; Levodopa; Male; Parkinson Disease | 2015 |
Improvement of dyskinesias with L-dopa infusion in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dyskinesias; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Quality of Life | 2016 |
Continuous duodenal levodopa infusion in a patient with Crohn's disease and small bowel surgery - Case report.
Topics: Antiparkinson Agents; Carbidopa; Crohn Disease; Drug Combinations; Duodenum; Humans; Intestine, Small; Levodopa; Male; Middle Aged; Parkinson Disease | 2015 |
Suicide and dopamine agonist withdrawal syndrome in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Female; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease | 2015 |
Dopamine dysregulation syndrome in Parkinson's disease patients on levodopa-carbidopa intestinal gel.
Topics: Behavior, Addictive; Carbidopa; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease; Syndrome | 2015 |
Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases; Prospective Studies | 2016 |
Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Combinations; Duodenum; Female; Gels; Humans; Infusions, Parenteral; Intubation, Gastrointestinal; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Quality of Life | 2015 |
Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials, Phase III as Topic; Drug Combinations; Female; Gastric Bypass; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Multicenter Studies as Topic; Outcome Assessment, Health Care; Parkinson Disease; Prospective Studies | 2016 |
Reply to letter: Dopamine dysregulation syndrome in Parkinson's disease patients on levodopa-carbidopa intestinal gel.
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Male; Parkinson Disease | 2016 |
The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastric Bypass; Gels; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Quality of Life; Retrospective Studies; Romania | 2016 |
Compensatory striatal-cerebellar connectivity in mild-moderate Parkinson's disease.
Topics: Aged; Brain Mapping; Carbidopa; Caudate Nucleus; Cerebellum; Drug Combinations; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Motor Activity; Motor Cortex; Neural Pathways; Parkinson Disease; Putamen; Severity of Illness Index | 2016 |
Effects of soybean ingestion on pharmacokinetics of levodopa and motor symptoms of Parkinson's disease--In relation to the effects of Mucuna pruriens.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Diet; Double-Blind Method; Female; Glycine max; Humans; Levodopa; Male; Middle Aged; Mucuna; Parkinson Disease | 2016 |
DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
Topics: Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Central Nervous System Stimulants; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dose-Response Relationship, Drug; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Rotation; Sympatholytics; Time Factors | 2016 |
A case of severe leg oedema in a patient with Parkinson's disease treated with pramipexole.
Topics: Antiparkinson Agents; Benzothiazoles; Carbidopa; Drug Combinations; Drug Therapy, Combination; Edema; Humans; Leg; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Treatment Outcome | 2016 |
24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Muscle Rigidity; Outcome Assessment, Health Care; Parkinson Disease; Sleep Wake Disorders | 2016 |
Physicians' experience with RYTARY (carbidopa and levodopa) extended-release capsules in patients who have Parkinson disease.
Topics: Antiparkinson Agents; Capsules; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Substitution; Humans; Levodopa; Parkinson Disease; Physicians | 2016 |
Clinical management of patients with advanced Parkinson's disease treated with continuous intestinal infusion of levodopa/carbidopa.
Topics: Antiparkinson Agents; Carbidopa; Caregivers; Clinical Trials as Topic; Databases, Bibliographic; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease; Treatment Outcome | 2016 |
Advanced therapies in Parkinson's disease: Long-term retrospective study.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Cohort Studies; Deep Brain Stimulation; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Thalamus; Treatment Outcome | 2016 |
Outpatient titration of carbidopa/levodopa enteral suspension (Duopa).
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Outpatients; Parkinson Disease; Suspensions; Treatment Outcome | 2017 |
Endoscopic alternative to buried bumper syndrome secondary to Duodopa
Topics: Aged; Antiparkinson Agents; Carbidopa; Catheters, Indwelling; Device Removal; Drug Combinations; Emergencies; Equipment Design; Foreign-Body Migration; Gastroscopes; Gastroscopy; Gastrostomy; Humans; Infusion Pumps, Implantable; Levodopa; Male; Parkinson Disease; Tomography, X-Ray Computed | 2017 |
Multi-Drug-Loaded Microcapsules with Controlled Release for Management of Parkinson's Disease.
Topics: Animals; Caproates; Capsules; Carbidopa; Catechols; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Humans; Hydrophobic and Hydrophilic Interactions; Lactones; Levodopa; Microscopy, Confocal; Nitriles; Parkinson Disease; Polyesters | 2016 |
Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cohort Studies; Drug Combinations; Female; Gels; Health Care Costs; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Statistics, Nonparametric; Visual Analog Scale | 2016 |
Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Endoscopy, Gastrointestinal; Gastrostomy; Humans; Levodopa; Parkinson Disease | 2016 |
A potential case of remission of Parkinson's disease.
Topics: Aged; Brain; Carbidopa; Dopamine; Drug Combinations; Humans; Levodopa; Male; Meditation; Parkinson Disease; Psychophysiology; Remission Induction | 2016 |
Wearable Sensors for Advanced Therapy Referral in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Monitoring, Ambulatory; Parkinson Disease; Referral and Consultation; Retrospective Studies; Severity of Illness Index | 2016 |
Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Italy; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life | 2016 |
Dopamine dysregulation syndrome and psychosis in 24-h intestinal levodopa infusion for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Dopamine; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Psychotic Disorders | 2016 |
Plantar cutaneous function in Parkinson's disease patients ON and OFF L-dopa.
Topics: Aged; Carbidopa; Discrimination, Psychological; Drug Combinations; Electromyography; Female; Foot; Humans; Levodopa; Lower Extremity; Male; Middle Aged; Muscle, Skeletal; Parkinson Disease; Physical Stimulation; Reflex, Abnormal; Touch; Touch Perception; Vibration | 2016 |
Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cross-Sectional Studies; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Spain | 2016 |
Choosing an Advanced Therapy in Parkinson's Disease; is it an Evidence-Based Decision in Current Practice?
Topics: Apomorphine; Carbidopa; Caregivers; Clinical Decision-Making; Consumer Health Information; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Evidence-Based Practice; Humans; Levodopa; Neurologists; Parkinson Disease; Patient Preference; Qualitative Research | 2016 |
Levodopa/carbidopa intestinal gel therapy for advanced Parkinson Disease: AN early toxic effect for small nerve fibers?
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2016 |
Authors' Reply to Lambarth: "Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review".
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Intestines; Levodopa; Parkinson Disease; Review Literature as Topic | 2016 |
Weight loss and decubitus duodenal ulcer in Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenal Ulcer; Duodenum; Dyskinesias; Endoscopes, Gastrointestinal; Humans; Levodopa; Male; Parkinson Disease; Tomography, X-Ray Computed; Weight Loss | 2016 |
Jejunal catheter placement for levodopa-carbidopa infusion in a patient with Billroth I gastrectomy.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Endoscopy, Gastrointestinal; Gastrectomy; Gastroenterostomy; Humans; Infusion Pumps; Intubation, Gastrointestinal; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease | 2016 |
Necessity of long-term alertness in levodopa-carbidopa intestinal gel infusion for PD patients.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenal Ulcer; Female; Gastrostomy; Humans; Infusions, Parenteral; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease | 2017 |
Jejunitis secondary to Duodopa® probe, a different complication.
Topics: Aged; Antiparkinson Agents; Bezoars; Carbidopa; Drug Combinations; Endoscopy, Gastrointestinal; Female; Humans; Infusion Pumps, Implantable; Jejunal Diseases; Levodopa; Parkinson Disease | 2016 |
Cathecol-O-methyltransferase inhibitors: another possibly useful pharmacological tool for treating Parkinson's disease in pregnancy?
Topics: Adult; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cesarean Section; Female; Gestational Age; Humans; Infant, Newborn; Levodopa; Nitriles; Parkinson Disease; Pregnancy; Pregnancy Complications; Pregnancy Outcome | 2017 |
Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2017 |
Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Area Under Curve; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Tablets | 2017 |
Dyskinesias in levodopa-carbidopa intestinal gel infusion era: New challenges, new features.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2017 |
Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2017 |
Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.
Topics: Age Factors; Antiparkinson Agents; Bifidobacterium; Carbidopa; Case-Control Studies; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Confounding Factors, Epidemiologic; Diet; Drug Combinations; Dysbiosis; Female; Fruit; Gastrointestinal Microbiome; Humans; Lactobacillaceae; Levodopa; Male; Parkinson Disease; Pasteurellaceae; Risk Factors; RNA, Ribosomal, 16S; Sex Factors; United States; Vegetables; Verrucomicrobia | 2017 |
Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy.
Topics: Algorithms; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Decision Support Systems, Clinical; Drug Combinations; Drug Therapy, Combination; Humans; Infusion Pumps; Levodopa; Parkinson Disease | 2017 |
Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up.
Topics: Antiparkinson Agents; Carbidopa; Disease Progression; Drug Combinations; Female; Gels; Health Surveys; Humans; Intestines; Italy; Levodopa; Longitudinal Studies; Male; Parkinson Disease; Retrospective Studies; Substance Withdrawal Syndrome | 2017 |
Prevalence and burden of dysautonomia in advanced Parkinson's disease.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Cross-Sectional Studies; Deep Brain Stimulation; Drug Combinations; Female; Humans; Levodopa; Logistic Models; Male; Parkinson Disease; Prevalence; Primary Dysautonomias; Severity of Illness Index; Subthalamic Nucleus; Surveys and Questionnaires | 2017 |
First clinical experience with levodopa/carbidopa microtablets in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tablets | 2017 |
Levodopa/carbidopa/entacapone-induced acute Pisa syndrome in a Parkinson's disease patient.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Dystonic Disorders; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tomography, Emission-Computed, Single-Photon; Tropanes | 2008 |
Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report.
Topics: Aged; Antiparkinson Agents; Azepines; Benzothiazoles; Cabergoline; Carbidopa; Catatonia; Catechols; Drug Therapy, Combination; Electroconvulsive Therapy; Ergolines; Female; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole | 2009 |
Case studies in the advancement of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary | 2008 |
Reversible Pisa syndrome in patients with Parkinson's disease on dopaminergic therapy.
Topics: Aged; Aged, 80 and over; Benserazide; Benzothiazoles; Brain; Carbidopa; Dopamine Agents; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Time Factors; Tomography, Emission-Computed, Single-Photon; Tropanes | 2009 |
Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Compulsive Behavior; Dopamine Agonists; Female; Gambling; Humans; Indoles; Levodopa; Libido; Male; Middle Aged; Parkinson Disease; Pramipexole; Retrospective Studies | 2009 |
Managing pathological gambling in Parkinson's disease with enteral levodopa/carbidopa infusions.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Drug Therapy, Combination; Follow-Up Studies; Gambling; Humans; Levodopa; Male; Parkinson Disease; Pramipexole | 2009 |
[Long term experience with Stalevo in Szeged, Hungary].
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Drug Resistance; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Pain Measurement; Parkinson Disease; Quality of Life; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Levodopa/carbidopa/entacapone in Parkinson's disease.
Topics: Antiparkinson Agents; Biological Availability; Carbidopa; Catechols; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease | 2009 |
Peripheral COMT inhibition prevents levodopa associated homocysteine increase.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Delayed-Action Preparations; Dihydroxyphenylalanine; Enzyme Inhibitors; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Time Factors; Tyrosine | 2009 |
Drug-induced compulsive behaviors: exceptions to the rule.
Topics: Antiparkinson Agents; Carbidopa; Cocaine; Cocaine-Related Disorders; Compulsive Behavior; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Humans; Parkinson Disease | 2009 |
Sildenafil induced choreoathetosis in men with Parkinson's disease.
Topics: Antiparkinson Agents; Athetosis; Carbidopa; Chorea; Drug Combinations; Drug Interactions; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones | 2010 |
Neuroprotective effects of zonisamide target astrocyte.
Topics: Animals; Antiparkinson Agents; Astrocytes; Basal Ganglia; Carbidopa; Cells, Cultured; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Glial Fibrillary Acidic Protein; Glutathione; Isoxazoles; Male; Mice; Mice, Inbred ICR; Nerve Growth Factors; Neuroprotective Agents; Oxidopamine; Parkinson Disease; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Tyrosine 3-Monooxygenase; Zonisamide | 2010 |
Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Algorithms; Antiparkinson Agents; Carbidopa; Catechols; Cohort Studies; Dosage Forms; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Patient Compliance; Retrospective Studies; Tablets | 2010 |
Levodopa-responsive parkinsonism after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Subarachnoid Hemorrhage; Substantia Nigra | 2010 |
An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.
Topics: Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Enteral Nutrition; Food-Drug Interactions; Humans; Intensive Care Units; Length of Stay; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease | 2010 |
Oxidative stress and aminopeptidases in Parkinson's disease patients with and without treatment.
Topics: Aged; Aminopeptidases; Antiparkinson Agents; Carbidopa; Case-Control Studies; Female; Humans; Lactates; Levodopa; Lipid Peroxides; Lipids; Male; Middle Aged; Oxidative Stress; Parkinson Disease | 2011 |
[The effect of Stalevo-dosing on quality of life of Parkinsonian patients with wearing-off].
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Drug Administration Schedule; Drug Combinations; Female; Humans; Hungary; Levodopa; Male; Middle Aged; Observation; Parkinson Disease; Quality of Life; Treatment Outcome | 2010 |
Carbidopa/levodopa pharmacy errors in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Medication Errors; Parkinson Disease; Pharmacies; Prospective Studies | 2010 |
Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Cost Savings; Cost-Benefit Analysis; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Humans; Indans; Levodopa; Markov Chains; Models, Economic; Nitriles; Parkinson Disease; Quality of Life; Quality-Adjusted Life Years; Stochastic Processes; Time Factors; Treatment Outcome; United States | 2010 |
Delayed-onset parkinsonian tremor following a mesencephalic lesion.
Topics: Antiparkinson Agents; Carbidopa; Dopamine; Drug Combinations; Electromyography; Female; Humans; Levodopa; Magnetic Resonance Imaging; Mesencephalon; Middle Aged; Neurologic Examination; Parkinson Disease; Tegmentum Mesencephali; Tremor | 2011 |
Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease.
Topics: Administration, Cutaneous; Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenum; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Quality of Life; Severity of Illness Index; Treatment Outcome | 2011 |
Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa®) in Sweden.
Topics: Antiparkinson Agents; Carbidopa; Drug Administration Routes; Drug Combinations; Drug Costs; Duodenum; Government Agencies; Humans; Levodopa; Models, Economic; Parkinson Disease; Reimbursement Mechanisms; Sweden; Treatment Outcome | 2010 |
Parkinson disease: adjunctive entacapone therapy increases risk of dyskinesia.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Nitriles; Parkinson Disease; Randomized Controlled Trials as Topic; Receptors, Dopamine | 2010 |
The association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with Parkinson's disease: a retrospective claims-based analysis.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Cohort Studies; Delivery of Health Care; Health Care Costs; Humans; Levodopa; Nitriles; Parkinson Disease; Patient Compliance; Retrospective Studies | 2011 |
Transient executive dysfunction following STNDBS in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cognition Disorders; Deep Brain Stimulation; Executive Function; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Subthalamic Nucleus; Time Factors | 2011 |
[Treatment of non-motor fluctuations with combined drug stalevo in patients with Parkinson's disease].
Topics: Adult; Aged; Carbidopa; Catechols; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2011 |
Increased plasma arginine vasopressin levels in dopamine agonist-treated Parkinson's disease patients.
Topics: Aged; Arginine Vasopressin; Benzothiazoles; Carbidopa; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole | 2011 |
Three year follow up of levodopa plus carbidopa treatment in a prevalent cohort of patients with Parkinson's disease in Hai, Tanzania.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cohort Studies; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Retrospective Studies; Tanzania | 2011 |
Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients.
Topics: Analysis of Variance; Antiparkinson Agents; Carbidopa; Dipeptides; Female; Humans; Levodopa; Male; Oxidative Stress; Parkinson Disease; Tyrosine | 2011 |
Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Disability Evaluation; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Subthalamic Nucleus; Treatment Outcome | 2011 |
A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease.
Topics: Aged; Aging; Antiparkinson Agents; Carbidopa; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; Female; Hand Strength; Humans; Isometric Contraction; Levodopa; Longitudinal Studies; Male; Middle Aged; Muscle Strength; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography; Psychomotor Performance; Radiopharmaceuticals; Reaction Time; Retrospective Studies; Sex Characteristics; Tongue | 2011 |
Synphilin suppresses α-synuclein neurotoxicity in a Parkinson's disease Drosophila model.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Antiparkinson Agents; Blotting, Western; Carbidopa; Carrier Proteins; Disease Models, Animal; Drosophila; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Motor Activity; Nerve Degeneration; Nerve Tissue Proteins; Neurotoxicity Syndromes; Parkinson Disease; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Severe weight loss in a young Parkinson's disease patient: a multidisciplinary approach to diagnosis and treatment.
Topics: Antiparkinson Agents; Carbidopa; Caregivers; Disease Progression; Domestic Violence; Drug Combinations; Eating; Female; Humans; Hypertrichosis; Levodopa; Middle Aged; Nutritional Status; Parkinson Disease; Weight Loss | 2011 |
Levodopa-induced breathing, cognitive and behavioral changes in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cognition Disorders; Drug Combinations; Humans; Levodopa; Male; Mental Disorders; Parkinson Disease; Respiration Disorders | 2011 |
Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Compulsive Behavior; Delusions; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales | 2011 |
Executive control in Parkinson's disease: effects of dopaminergic medication and deep brain stimulation on anti-cue keypress performance.
Topics: Aged; Benserazide; Benzothiazoles; Carbidopa; Cues; Deep Brain Stimulation; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Psychomotor Performance; Reaction Time; Subthalamic Nucleus | 2011 |
A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Gels; Humans; Levodopa; Parkinson Disease; Quality-Adjusted Life Years; United Kingdom | 2011 |
Malnutritional neuropathy under intestinal levodopa infusion.
Topics: Aged; Carbidopa; Humans; Infusions, Parenteral; Levodopa; Male; Malnutrition; Middle Aged; Neurotoxicity Syndromes; Parkinson Disease; Polyneuropathies | 2012 |
Ocular motor and sensory function in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Carbidopa; Combined Modality Therapy; Convergence, Ocular; Deep Brain Stimulation; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Ocular Motility Disorders; Oculomotor Muscles; Parkinson Disease; Prospective Studies; Quality of Life; Sensation; Surveys and Questionnaires; Visual Acuity | 2012 |
Duodopa infusion treatment: a point of view from the gastroenterologist.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastroenterology; Gels; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease | 2011 |
Lees' syndrome: a case series.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Dopamine; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Syndrome | 2011 |
Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Biomarkers; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Progression; Dopa Decarboxylase; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Japan; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Prospective Studies; Treatment Outcome; Tyrosine | 2011 |
Parkinson's disease patients cannot get their dopamine replacement: the 8-Sinemet limit.
Topics: Carbidopa; Dopamine; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2012 |
Nasogastric medication for perioperative Parkinson's rigidity during anaesthesia emergence.
Topics: Amantadine; Anesthesia; Anesthesia Recovery Period; Anesthesia, General; Antiparkinson Agents; Carbidopa; Drug Combinations; Fracture Fixation, Internal; Fractures, Bone; Humans; Humerus; Intraoperative Awareness; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Perioperative Care | 2011 |
Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson's disease leads to improvement in caregivers' stress and burden.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Carbidopa; Caregivers; Drug Combinations; Duodenostomy; Female; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Spouses; Stress, Psychological; Surveys and Questionnaires | 2012 |
Trichophagia affects response to duodenal levodopa/carbidopa gel administration.
Topics: Aged; Antiparkinson Agents; Carbidopa; Compulsive Behavior; Drug Administration Routes; Drug Therapy, Combination; Duodenum; Feeding Behavior; Hair; Humans; Levodopa; Male; Parkinson Disease | 2012 |
Burning mouth syndrome in Parkinson's disease: dopamine as cure or cause?
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Burning Mouth Syndrome; Carbidopa; Dopamine; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Pramipexole | 2012 |
Oral formulations of L-dopa and continuous dopaminergic stimulation.
Topics: Animals; Antiparkinson Agents; Carbidopa; Dopamine Agents; Drug Delivery Systems; Female; Humans; Levodopa; Male; Parkinson Disease | 2012 |
Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2012 |
Levodopa in combination with carbidopa does not affect plasma arginine vasopressin levels in treatment-naïve older patients with Parkinson's disease: A before-after study.
Topics: Arginine Vasopressin; Carbidopa; Controlled Before-After Studies; Humans; Levodopa; Parkinson Disease | 2012 |
Finasteride attenuates pathological gambling in patients with Parkinson disease.
Topics: 5-alpha Reductase Inhibitors; Aged; Antiparkinson Agents; Benzothiazoles; Cabergoline; Carbidopa; Catechols; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Ergolines; Finasteride; Gambling; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Pramipexole; Treatment Outcome; Video Games | 2012 |
Long-term 24-h levodopa/carbidopa gel infusion in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Time Factors | 2012 |
Dopamine dysregulation syndrome including mania related to coadministration of droxidopa.
Topics: Aggression; Antiparkinson Agents; Behavior, Addictive; Benzothiazoles; Bipolar Disorder; Carbidopa; Droxidopa; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Neurotoxicity Syndromes; Parkinson Disease; Pramipexole; Treatment Outcome | 2012 |
Cysteine decrease following acute Levodopa intake in patients with Parkinson's disease.
Topics: Administration, Oral; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Cysteine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2012 |
Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.
Topics: Amantadine; Antiparasitic Agents; Carbidopa; Catechols; Decision Making; Deep Brain Stimulation; Disease Progression; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Quality of Life; Subthalamus | 2012 |
Drugs for treating Parkinson disease.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechols; Drug Combinations; Drugs, Generic; Humans; Indans; Levodopa; Nitriles; Parkinson Disease | 2012 |
Foot dystonia heralding levodopa-induced dyskinesias in Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Dyskinesia, Drug-Induced; Dystonia; Female; Foot Diseases; Humans; Levodopa; Middle Aged; Neurologic Examination; Nitriles; Parkinson Disease | 2013 |
Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Cognition Disorders; Disability Evaluation; Drug Combinations; Duodenum; Female; Humans; Infusions, Parenteral; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Quality of Life; Statistics, Nonparametric | 2013 |
Refractory epileptic seizures due to vitamin B6 deficiency in a patient with Parkinson's disease under duodopa® therapy.
Topics: Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Seizures; Treatment Outcome; Vitamin B 6; Vitamin B 6 Deficiency | 2013 |
[A combined preparation stalevo in Parkinson's disease: a 5-year experience of continuous dopaminergic stimulation].
Topics: Adult; Aged; Aged, 80 and over; Carbidopa; Catechols; Dopamine Agonists; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2012 |
Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Anticonvulsants; Carbidopa; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Valproic Acid | 2013 |
Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study.
Topics: Antiparkinson Agents; Carbidopa; Costs and Cost Analysis; Deep Brain Stimulation; Health Resources; Humans; Levodopa; Parkinson Disease; Severity of Illness Index; Spain; Surveys and Questionnaires | 2013 |
Drug-induced burning mouth syndrome: a new clinico-pathological entity?
Topics: Antiparkinson Agents; Burning Mouth Syndrome; Carbidopa; Female; Humans; Levodopa; Parkinson Disease | 2012 |
Severe gastrointestinal complications in patients with levodopa/carbidopa intestinal gel infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastrointestinal Diseases; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease | 2012 |
Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Biotransformation; Carbidopa; Chemistry, Pharmaceutical; Drug Combinations; Female; Gels; Germany; Humans; Infusion Pumps; Intestinal Absorption; Intubation, Gastrointestinal; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Sweden; Tyrosine | 2013 |
Perioperative medication withholding in patients with Parkinson's disease: a retrospective electronic health records review.
Topics: Aged; Antiparkinson Agents; Carbidopa; Comorbidity; Drug Combinations; Electronic Health Records; Female; Half-Life; Humans; Levodopa; Male; Parkinson Disease; Retrospective Studies; Surgical Procedures, Operative | 2013 |
Acute dopaminergic challenge tests to assess postural/kinetic tremor of different origin: a case report.
Topics: Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Electromyography; Essential Tremor; Female; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Posture; Receptors, Dopamine | 2002 |
[The use of amantadine sulfate in combined therapy of Parkinson's disease].
Topics: Aged; Amantadine; Carbidopa; Dopamine Agents; Drug Combinations; Drug Therapy, Combination; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2002 |
[Hallucinations caused by paroxetine taken together with a levodopa-carbidopa preparation].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Synergism; Drug Therapy, Combination; Female; Hallucinations; Humans; Levodopa; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2002 |
Clozapine withdrawal symptoms in a Parkinson's disease patient.
Topics: Aged; Antipsychotic Agents; Carbidopa; Clozapine; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Hallucinations; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Substance Withdrawal Syndrome | 2002 |
Leg muscle strength is reduced in Parkinson's disease and relates to the ability to rise from a chair.
Topics: Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Combinations; Female; Hip; Humans; Knee; Levodopa; Lower Extremity; Male; Middle Aged; Muscle Weakness; Muscle, Skeletal; Parkinson Disease; Posture; Random Allocation; Severity of Illness Index | 2003 |
Parkinsonian speech disfluencies: effects of L-dopa-related fluctuations.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Basal Ganglia; Carbidopa; Dopamine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Reading; Speech Production Measurement; Stuttering | 2003 |
Rapid intravenous loading of levodopa for human research: clinical results.
Topics: Adult; Aged; Aged, 80 and over; Carbidopa; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Tourette Syndrome | 2003 |
Adverse effects of subthalamic nucleus DBS in a patient with multiple system atrophy.
Topics: Antiparkinson Agents; Atrophy; Carbidopa; Combined Modality Therapy; Contraindications; Deglutition Disorders; Diagnosis, Differential; Dysarthria; Electric Stimulation Therapy; Electrodes, Implanted; Female; Humans; Levodopa; Magnetic Resonance Imaging; Microelectrodes; Middle Aged; Multiple System Atrophy; Parkinson Disease; Pons; Putamen; Subthalamic Nucleus | 2003 |
L-DOPA biotransformation: correlations of dosage, erythrocyte catechol O-methyltransferase and platelet SULT1A3 activities with metabolic pathways in Parkinsonian patients.
Topics: Adenosine Diphosphate; Aged; Arylsulfotransferase; Biotransformation; Blood Platelets; Carbidopa; Catechol O-Methyltransferase; Dose-Response Relationship, Drug; Drug Combinations; Erythrocytes; Female; Humans; Levodopa; Male; Methylation; Middle Aged; Parkinson Disease; S-Adenosylmethionine; Sulfates | 2003 |
[Respiratory regulation during adaptation to intermittent hypoxia in patients with Parkinson disease].
Topics: Adaptation, Physiological; Carbidopa; Dopamine Agents; Humans; Levodopa; Middle Aged; Oxygen; Parkinson Disease; Respiratory Mechanics | 2003 |
Drug adherence in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Chronic Disease; Drug Administration Schedule; Drug Combinations; Drug Monitoring; Female; Humans; Levodopa; Male; Medication Systems; Parkinson Disease; Patient Compliance; Surveys and Questionnaires | 2004 |
Stalevo for Parkinson's disease.
Topics: Carbidopa; Catechols; Diarrhea; Dose-Response Relationship, Drug; Drug Combinations; Humans; Levodopa; Nausea; Nitriles; Parkinson Disease | 2004 |
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Isoxazoles; Levodopa; Microdialysis; Oxidopamine; Parkinson Disease; Rats; Zonisamide | 2004 |
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
Topics: Adult; Aged; Cabergoline; Carbidopa; Dopamine Agonists; Drug Combinations; Echocardiography, Transesophageal; Ergolines; Ergot Alkaloids; Female; Heart Valve Diseases; Humans; Levodopa; Male; Parkinson Disease; Pergolide | 2004 |
[Effect of cerebrolysin on the electroencephalographic indices of brain activity in Parkinson's disease].
Topics: Aged; Amino Acids; Carbidopa; Drug Therapy, Combination; Electroencephalography; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Treatment Outcome | 2004 |
Superficial siderosis of the central nervous system associated with parkinsonism.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Central Nervous System Diseases; Female; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Siderosis | 2004 |
A young onset Parkinson's patient: a case study.
Topics: Activities of Daily Living; Adult; Age of Onset; Amantadine; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Dibenzothiazepines; Disease Progression; Dyskinesias; Humans; Levodopa; Male; Motor Skills; Nurse's Role; Parkinson Disease; Patient Advocacy; Patient Education as Topic; Quality of Life; Quetiapine Fumarate; Rhabdomyolysis; Severity of Illness Index; Social Support; Treatment Outcome | 2004 |
An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Cell Count; Differential Threshold; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Immunohistochemistry; Levodopa; Male; Methylphenidate; Motor Activity; Movement; Nerve Degeneration; Neurons; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Rotarod Performance Test; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
[18F]FDOPA PET and clinical features in parkinsonism due to manganism.
Topics: Adult; Antiparkinson Agents; Brain; Carbidopa; Drug Combinations; Female; Fluorodeoxyglucose F18; Gait; Humans; Levodopa; Magnetic Resonance Imaging; Manganese Poisoning; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals | 2005 |
Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
Topics: Administration, Oral; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Fees, Pharmaceutical; Humans; Levodopa; Parkinson Disease | 2005 |
Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson Disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Female; Gait; Humans; Levodopa; Male; Middle Aged; Motor Skills; Motor Skills Disorders; Parkinson Disease; Severity of Illness Index; Speech Acoustics; Time Factors | 2005 |
[Use of tremonorm in treatment of Parkinson's disease: outpatient experience of Moscow Municipal Health Care Service].
Topics: Carbidopa; Data Interpretation, Statistical; Drug Combinations; Dyspepsia; Humans; Levodopa; Mental Status Schedule; Moscow; Outpatients; Parkinson Disease; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2004 |
Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Catechols; Clinical Trials as Topic; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Dyskinesias; France; Gastrointestinal Diseases; Humans; Levodopa; Parkinson Disease | 2005 |
Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Carbidopa; Catechols; Child; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Female; Humans; Levodopa; Male; Markov Chains; Middle Aged; Parkinson Disease; United Kingdom | 2005 |
[Advanced course of Parkinson disease. Little improved motion with continuous intestinal levodopa administration].
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Intubation, Gastrointestinal; Levodopa; Parkinson Disease | 2005 |
Effects of deep brain stimulation and medication on strength, bradykinesia, and electromyographic patterns of the ankle joint in Parkinson's disease.
Topics: Ankle Joint; Antiparkinson Agents; Biomechanical Phenomena; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Electrodes, Implanted; Electromyography; Humans; Hypokinesia; Isometric Contraction; Levodopa; Muscle Weakness; Muscle, Skeletal; Parkinson Disease; Reference Values; Signal Processing, Computer-Assisted; Statistics as Topic; Torque; Treatment Outcome; Tremor | 2006 |
Psychiatric sequelae of Parkinson disease: a case report.
Topics: Antiparkinson Agents; Cabergoline; Carbidopa; Compulsive Behavior; Drug Combinations; Ergolines; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sex Offenses | 2006 |
Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2006 |
[Continuous treatment with levodopa of Parkinson disease].
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenum; Humans; Infusion Pumps; Levodopa; Middle Aged; Parkinson Disease | 2005 |
Augmentation of artistic productivity in Parkinson's disease.
Topics: Antiparkinson Agents; Art; Carbidopa; Creativity; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Frontal Lobe; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Poetry as Topic | 2006 |
Absorption of orally disintegrating carbidopa-levodopa requires intact small bowel function.
Topics: Administration, Oral; Aged; Carbidopa; Disease Progression; Dopamine Agents; Drug Combinations; Female; Humans; Intestinal Pseudo-Obstruction; Intestine, Small; Levodopa; Middle Aged; Parkinson Disease; Patient Selection; Substance Withdrawal Syndrome; Treatment Failure | 2005 |
Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Clinical Trials as Topic; Cohort Studies; Computer Simulation; Dopa Decarboxylase; Dopamine Agents; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Levodopa; Longitudinal Studies; Male; Middle Aged; Models, Biological; Parkinson Disease | 2005 |
OFF-off rebound dyskinesia in subthalamic nucleus deep brain stimulation of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Corpus Striatum; Deep Brain Stimulation; Dominance, Cerebral; Drug Therapy, Combination; Dyskinesias; Electrodes, Implanted; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Secondary Prevention; Stereotaxic Techniques; Substance Withdrawal Syndrome; Subthalamic Nucleus | 2006 |
Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Carbidopa; Dopamine Agents; Drug Administration Routes; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Treatment Outcome | 2006 |
[Dopamine receptors agonists (mirapex) in the treatment of Parkinson's disease].
Topics: Anxiety; Benzothiazoles; Carbidopa; Delayed-Action Preparations; Depression; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Receptors, Dopamine D1; Thiazoles; Treatment Outcome | 2006 |
Parkinsonism-hyperpyrexia syndrome: the role of electroconvulsive therapy.
Topics: Acetaminophen; Acyclovir; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Anxiety Agents; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiparkinson Agents; Antiviral Agents; Anxiety; Carbidopa; Ceftriaxone; Cervical Vertebrae; Depression; Dexamethasone; Diazepam; Doxepin; Electroconvulsive Therapy; Humans; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Oxycodone; Pain; Parkinson Disease; Selegiline; Spinal Injuries | 2006 |
Skin rash associated with Sinemet does not equal levodopa allergy.
Topics: Aged; Antiparkinson Agents; Carbidopa; Coloring Agents; Drug Combinations; Drug Eruptions; Drug Hypersensitivity; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Skin; Withholding Treatment | 2007 |
Panic attack like episodes possibly associated with pramipexole therapy in Parkinson's disease.
Topics: Anxiety Disorders; Benzothiazoles; Carbidopa; Central Nervous System; Diazepam; Dopamine Agonists; Dose-Response Relationship, Drug; Female; GABA Agonists; Humans; Levodopa; Middle Aged; Panic Disorder; Parkinson Disease; Pramipexole; Self Administration | 2007 |
Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Interactions; Levodopa; Male; Nerve Fibers; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Substantia Nigra | 2007 |
[Association between amytrophic lateral sclerosis and Parkinson's disease].
Topics: Aged; Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Cabergoline; Carbidopa; Dopamine Agents; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Riluzole; Time Factors; Tomography, X-Ray Computed | 2007 |
Ziprasidone for drug-induced psychotic symptoms in Parkinson's Disease.
Topics: Acute Disease; Antipsychotic Agents; Brief Psychiatric Rating Scale; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Psychoses, Substance-Induced; Thiazoles | 2008 |
[The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life].
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Carbidopa; Catechols; Cholinergic Antagonists; Dopamine Agonists; Drug Combinations; Female; Humans; Hungary; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Selegiline; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2008 |
Low CSF GABA in Parkinsonian patients who respond poorly to therapy or suffer from the "on-off" phenomenon.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Ergolines; Female; gamma-Aminobutyric Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Radioligand Assay | 1982 |
Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa.
Topics: Administration, Oral; Carbidopa; Dopamine; Drug Combinations; Humans; Infusions, Parenteral; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Adrenergic; Time Factors | 1982 |
Dopaminergic deficiency and delayed visual evoked potentials in humans.
Topics: Adult; Antipsychotic Agents; Carbidopa; Dopamine; Drug Therapy, Combination; Evoked Potentials, Visual; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenothiazines; Schizophrenia | 1982 |
Cholinergic and dopaminergic mechanisms in Parkinson's disease after long term levodopa administration.
Topics: Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Receptors, Cholinergic; Receptors, Dopamine; Time Factors | 1982 |
Carbidopa/levodopa therapy of coexistent drug-induced parkinsonism and tardive dyskinesia.
Topics: Aged; Antipsychotic Agents; Carbidopa; Drug Combinations; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome and Process Assessment, Health Care; Parkinson Disease; Parkinson Disease, Secondary | 1983 |
Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa.
Topics: Adult; Aged; Carbidopa; Cysteinyldopa; Dihydroxyphenylalanine; Humans; Melanoma; Middle Aged; Parkinson Disease; Skin Neoplasms | 1983 |
[Circadian rhythm of catecholamine excretion, effect of L-DOPA and Nacom in various diseases of the nervous system].
Topics: Adult; Aged; Carbidopa; Catecholamines; Drug Combinations; Dystonia Musculorum Deformans; Female; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Muscular Dystrophies; Nervous System Diseases; Neurotic Disorders; Parkinson Disease | 1983 |
Urinary homovanillic acid and c-AMP in drug-free Parkinson patients: effect of L-dopa treatment.
Topics: Aged; Carbidopa; Cyclic AMP; Drug Combinations; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenylacetates | 1981 |
Deprenyl (selegiline) in combination treatment of Parkinson's disease.
Topics: Aged; Benserazide; Carbidopa; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
Therapy of neurologic disorders in the elderly.
Topics: Aged; Amantadine; Anticoagulants; Brain Ischemia; Bromocriptine; Carbidopa; Dexamethasone; Drug Interactions; Heparin; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Trihexyphenidyl | 1984 |
Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study.
Topics: Adult; Aged; Carbidopa; Cerebellar Diseases; Droxidopa; Female; Humans; Kinetics; Male; Middle Aged; Olivary Nucleus; Parkinson Disease; Pons; Serine | 1984 |
Simultaneous determination of L-dopa and 3-O-methyldopa in human serum by high-performance liquid chromatography.
Topics: Adult; Carbidopa; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Epinephrine; Humans; Levodopa; Male; Methyltyrosines; Norepinephrine; Parkinson Disease; Tyrosine | 1984 |
Treatment of dyskinetic and dystonic disorders with CF 25-397: clinical and pharmacological aspects.
Topics: Aged; Carbidopa; Dystonia; Ergolines; Female; Hepatolenticular Degeneration; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1980 |
Study on the striatal dopamine availability in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Corpus Striatum; Dopamine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Time Factors | 1984 |
Pharmacologic effects of L-dopa are not closely linked temporally to striatal dopamine concentration.
Topics: Animals; Behavior, Animal; Brain; Carbidopa; Corpus Striatum; Dopamine; Dopamine Antagonists; Levodopa; Male; Parkinson Disease; Rats; Rats, Inbred Strains; Substantia Nigra | 1984 |
Cognition and the basal ganglia. Separating mental and motor components of performance in Parkinson's disease.
Topics: Adult; Aged; Attention; Basal Ganglia; Carbidopa; Cognition Disorders; Female; Humans; Levodopa; Male; Memory; Middle Aged; Motor Activity; Movement; Parkinson Disease; Reaction Time | 1984 |
L-dopa decarboxylation in chronically treated patients.
Topics: Adult; Carbidopa; Chemistry, Organic; Decarboxylation; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Organic Chemistry Phenomena; Parkinson Disease; Time Factors | 1984 |
Combined use of benserazide and carbidopa in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Outcome and Process Assessment, Health Care; Parkinson Disease | 1984 |
Severity of Parkinson's disease and the dosage of bromocriptine.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 1984 |
Pergolide in the treatment of Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1984 |
Platelet phenolsulphotransferase activity in Parkinson's disease.
Topics: Age Factors; Arylsulfotransferase; Blood Platelets; Carbidopa; Drug Combinations; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease; Sulfurtransferases; Time Factors | 1983 |
Parkinsonism treated with levodopa: progression and mortality.
Topics: Aged; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease | 1983 |
Dystonia--L-dopa responsive or juvenile parkinsonism?
Topics: Adolescent; Benserazide; Carbidopa; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dystonia; Follow-Up Studies; Growth Hormone; Humans; Infant; Levodopa; Male; Parkinson Disease; Prolactin | 1983 |
Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Carbidopa; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Parkinson Disease, Secondary; Pyridines | 1984 |
One-year trial of pergolide as an adjunct to Sinemet in treatment of Parkinson's disease.
Topics: Athetosis; Carbidopa; Chorea; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Ergolines; Humans; Hypotension; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1984 |
Response to Sinemet 25/100 in Parkinson's disease.
Topics: Aged; Benserazide; Body Weight; Carbidopa; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Sex Factors | 1984 |
Acute effects of levodopa plus carbidopa on evoked potentials in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Evoked Potentials, Visual; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Time Factors | 1984 |
[Usefulness of increasing the proportion of carbidopa to levodopa in the long-term treatment of Parkinson's disease].
Topics: Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies | 1984 |
What to do when Sinemet fails: Part one.
Topics: Antiparkinson Agents; Carbidopa; Dementia; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Psychoses, Substance-Induced | 1984 |
"On-off" phenomenon in Parkinson's disease.
Topics: Animals; Carbidopa; Humans; Levodopa; Methyldopa; Parkinson Disease | 1984 |
Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
Topics: Aged; Apomorphine; Benserazide; Bromocriptine; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Nomifensine; Parkinson Disease; Prolactin; Receptors, Dopamine; Selegiline; Tremor | 1980 |
Abnormal regulation of prolactin release in idiopathic Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Dopamine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Thyrotropin-Releasing Hormone | 1980 |
Effect of levodopa on thyroid function and prolactin release. A study in patients with Parkinson's disease.
Topics: Aged; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Thyroid Gland; Thyrotropin; Thyrotropin-Releasing Hormone | 1981 |
The effect of carbidopa and benserazide on human plasma 5-hydroxytryptophan levels.
Topics: 5-Hydroxytryptophan; Adult; Benserazide; Carbidopa; Chlorpromazine; Dihydroxyphenylalanine; Humans; Hydrazines; Middle Aged; Parkinson Disease; Schizophrenia; Tryptophan | 1982 |
Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Amphetamines; Biogenic Amines; Carbidopa; Depression; Drug Combinations; Female; Humans; Levodopa; Male; Methamphetamine; Middle Aged; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Selegiline; Tyramine | 1982 |
[Biochemical evaluation of the effectiveness of antiparkinson preparations containing L-DOPA].
Topics: Carbidopa; Dihydroxyphenylalanine; Dopamine; Drug Combinations; Epinephrine; Humans; Levodopa; Norepinephrine; Parkinson Disease | 1981 |
Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Thyrotropin; Thyrotropin-Releasing Hormone; Thyroxine; Triiodothyronine | 1982 |
Bromocriptine and lisuride in Parkinson disease.
Topics: Aged; Bromocriptine; Carbidopa; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Lisuride; Middle Aged; Parkinson Disease | 1983 |
A quantitative study of the electroencephalographic response to levodopa treatment in parkinsonian patients.
Topics: Aged; Carbidopa; Cerebral Cortex; Drug Therapy, Combination; Electroencephalography; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1983 |
Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.
Topics: Adult; Aged; alpha-Methyltyrosine; Carbidopa; Dopamine; Dopamine Antagonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyltyrosines; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Reserpine; Synapses; Tetrabenazine | 1983 |
Sustained low-dose levodopa therapy in Parkinson's disease: a 3-year follow-up.
Topics: Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 1983 |
Dopa dose-dependent sexual deviation.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Ergolines; Humans; Male; Middle Aged; Paraphilic Disorders; Parkinson Disease; Pergolide | 1983 |
Pergolide mesylate and idiopathic Parkinson disease.
Topics: Adolescent; Adult; Carbidopa; Child; Child, Preschool; Drug Combinations; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Parkinson Disease; Pergolide | 1982 |
Further studies with pergolide in Parkinson disease.
Topics: Adult; Aged; Carbidopa; Confusion; Drug Combinations; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1982 |
Levodopa-carbidopa.
Topics: Adult; Carbidopa; Female; Humans; Levodopa; Parkinson Disease; Pregnancy | 1980 |
A comparison of levodopa treatment and task demands on visual evoked potentials in hemi-parkinsonism.
Topics: Adult; Aged; Attention; Carbidopa; Dominance, Cerebral; Evoked Potentials, Visual; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1982 |
Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
Topics: Aged; Animals; Benserazide; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Rats | 1982 |
Low CSF gamma-aminobutyric acid levels in Parkinson's Disease. Effect of levodopa and carbidopa.
Topics: Aged; Carbidopa; gamma-Aminobutyric Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1982 |
Meige's syndrome during long-term dopaminergic therapy in Parkinson's disease.
Topics: Aged; Blepharospasm; Carbidopa; Dystonia; Facial Muscles; Female; Humans; Levodopa; Male; Mandibular Diseases; Middle Aged; Parkinson Disease; Syndrome; Time Factors | 1982 |
Parkinsonism in the elderly.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Humans; Levodopa; Parkinson Disease | 1982 |
Management of patients who fail to respond to levodopa therapy.
Topics: Carbidopa; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1982 |
Initial treatment of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Prognosis | 1982 |
Adverse interaction of levodopa with tricyclic antidepressants.
Topics: Aged; Amitriptyline; Carbidopa; Drug Combinations; Drug Interactions; Female; Humans; Imipramine; Levodopa; Parkinson Disease | 1982 |
Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis.
Topics: Aged; Bromocriptine; Carbidopa; Dreams; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Sleep Initiation and Maintenance Disorders; Sleep Stages | 1982 |
New strategies in the management of Parkinson's disease: a biological approach using a phospholipid precursor (CDP-choline).
Topics: Adult; Aged; Benserazide; Carbidopa; Choline; Cytidine Diphosphate Choline; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1982 |
Drug holiday and management of Parkinson disease.
Topics: Aged; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1980 |
Thyroid function in Parkinson disease.
Topics: Aged; Carbidopa; Humans; Hypothyroidism; Levodopa; Middle Aged; Parkinson Disease; Prospective Studies; Thyroid Diseases; Thyroid Gland; Thyrotropin; Thyroxine; Triiodothyronine | 1981 |
Alternate day levodopa therapy in parkinsonism.
Topics: Aged; Carbidopa; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1982 |
Drug-induced asterixis in Parkinson disease.
Topics: Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Muscle Contraction; Muscular Diseases; Parkinson Disease; Posture | 1982 |
Bilateral vocal cord paralysis in Parkinson's disease.
Topics: Aged; Bromocriptine; Carbidopa; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tracheotomy; Vocal Cord Paralysis | 1981 |
Method of addition of bromocriptine to the drug regime of patients with advanced Parkinson's disease.
Topics: Aged; Bromocriptine; Carbidopa; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1981 |
Parkinson's disease: new treatments.
Topics: Acetylcholine; Amantadine; Apomorphine; Bromocriptine; Carbidopa; Counseling; Dopamine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Manifestations; Parkinson Disease; Physical Therapy Modalities; Receptors, Dopamine; Thalamus | 1981 |
Carbidopa-levodopa ratio in Parkinson's disease.
Topics: Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1981 |
Prolactin response as an index of dopaminergic receptor function in Parkinson's disease. Correlation with clinical findings and therapeutic response.
Topics: Adult; Aged; Carbidopa; Circadian Rhythm; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Receptors, Dopamine; Reference Values | 1981 |
[Treatment of parkinson disease with the combination of L-dopa (plus carbidopa) and trazodone].
Topics: Aged; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Trazodone | 1981 |
A case of sporadic juvenile Parkinson's disease.
Topics: Adult; Aging; Carbidopa; Female; Humans; Levodopa; Parkinson Disease | 1981 |
[The combination of L-dopa and carbidopa in therapy of a case of familial juvenile parkinsonism].
Topics: Adult; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease | 1981 |
Dystonic foot response of Parkinsonism.
Topics: Aged; Carbidopa; Dystonia; Foot Diseases; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 1980 |
Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. A pilot study.
Topics: Carbidopa; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1980 |
Low dose perphenazine and levodopa/carbidopa therapy in a patient with Parkinsonism and a psychotic illness.
Topics: Carbidopa; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Perphenazine; Psychotic Disorders | 1980 |
Sinemet - 25/100.
Topics: Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1980 |
Further experiences with low doses of bromocriptine in Parkinson's disease.
Topics: Bromocriptine; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Parkinson Disease | 1980 |
The role of bromocriptine in the treatment of Parkinson's disease.
Topics: Bromocriptine; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Middle Aged; Parkinson Disease | 1980 |
A comparative study of bromocriptine and levodopa in Parkinson's disease.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1980 |
Benserazide and carbidopa as substrates of catechol-O-methyltransferase: new mechanism of action in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Benzyl Compounds; Carbidopa; Catechol O-Methyltransferase; Hydrazines; Kinetics; Liver; Parkinson Disease; S-Adenosylmethionine; Substrate Specificity; Swine | 1980 |
Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson's disease.
Topics: Aged; Amine Oxidase (Copper-Containing); Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Carbidopa; Cross-Sectional Studies; Dialysis; Drug Synergism; Enzyme Inhibitors; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease | 1995 |
Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine; Homovanillic Acid; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Tyrosine | 1995 |
Upper airway obstruction in Parkinson's disease.
Topics: Airway Obstruction; Carbidopa; Dopamine Antagonists; Fasting; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sleep Apnea Syndromes | 1995 |
Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period.
Topics: Body Temperature; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Menstrual Cycle; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease | 1993 |
Neurotransmitter levels in cerebrospinal fluid in relation to severity of symptoms and response to medical therapy in Parkinson's disease.
Topics: Adult; Aged; Biperiden; Carbidopa; Evaluation Studies as Topic; Humans; Levodopa; Middle Aged; Neurotransmitter Agents; Parkinson Disease; Treatment Outcome | 1994 |
The levodopa test in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Geriatric Assessment; Humans; Levodopa; Male; Motor Skills; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Reaction Time; Walking | 1995 |
A probe for intracerebral aromatic amino-acid decarboxylase activity: distribution and kinetics of [18F]6-fluoro-L-m-tyrosine in the human brain.
Topics: Adolescent; Adult; Aromatic-L-Amino-Acid Decarboxylases; Blood-Brain Barrier; Brain; Carbidopa; Corpus Striatum; Dopamine; Female; Fluorine Radioisotopes; Humans; Image Processing, Computer-Assisted; Male; Parkinson Disease; Radionuclide Imaging; Reference Values; Tyrosine | 1995 |
Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: preliminary findings.
Topics: Affect; Aged; Anxiety; Arousal; Carbidopa; Depression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1995 |
Clozapine therapeutic plunge in patient with Parkinson's disease.
Topics: Carbidopa; Clozapine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Psychotic Disorders | 1995 |
Levodopa-induced local cerebral blood flow changes in Parkinson's disease and related disorders.
Topics: Adult; Aged; Carbidopa; Cerebrovascular Circulation; Drug Therapy, Combination; Female; Humans; Intracranial Arteriosclerosis; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Olivopontocerebellar Atrophies; Parkinson Disease; Parkinson Disease, Secondary; Supranuclear Palsy, Progressive; Tomography, X-Ray Computed; Treatment Outcome; Xenon | 1995 |
Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Apomorphine; Brain Tissue Transplantation; Carbidopa; Dextroamphetamine; Disease Models, Animal; Dopamine; Dopamine Agonists; Ergolines; Female; Fetal Tissue Transplantation; Forelimb; Functional Laterality; Levodopa; Motor Activity; Movement Disorders; Norepinephrine; Oxidopamine; Parkinson Disease; Quinpirole; Rats; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Transplantation, Heterotopic | 1995 |
Contemporaneous bilateral postero-ventral pallidotomy for early onset "juvenile type" Parkinson's disease. Case report.
Topics: Antiparkinson Agents; Brain Mapping; Carbidopa; Combined Modality Therapy; Drug Combinations; Drug Therapy, Combination; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Postoperative Complications | 1994 |
Anticholinergic effects in a depressed parkinsonian patient.
Topics: Aged; Benztropine; Carbidopa; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluoxetine; Humans; Levodopa; Male; Parkinson Disease; Treatment Outcome | 1995 |
Adverse reactions to controlled release levodopa/carbidopa in older persons: case reports.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Frail Elderly; Hallucinations; Humans; Levodopa; Male; Mental Status Schedule; Parkinson Disease; Severity of Illness Index | 1995 |
Hereditary parkinsonism with multiple system degeneration: beneficial effect of anticholinergics, but not of levodopa.
Topics: Adult; Amantadine; Basal Ganglia; Carbidopa; Cerebellar Ataxia; Cholinergic Antagonists; Consanguinity; Drug Resistance; Female; Genes, Recessive; Globus Pallidus; Homovanillic Acid; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease; Pedigree; Trihexyphenidyl | 1994 |
Leg pain and numbness in an elderly man.
Topics: Aged; Aged, 80 and over; Bed Rest; Carbidopa; Humans; Leg; Levodopa; Male; Pain; Paresthesia; Parkinson Disease; Posture; Radiography; Spinal Stenosis | 1995 |
Familial levodopa-responsive parkinsonian-pyramidal syndrome.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Carbidopa; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Pedigree | 1994 |
Anticholinergics and dyskinesia.
Topics: Aged; Biperiden; Carbidopa; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Tremor; Trihexyphenidyl | 1994 |
Parkinson's disease: reorganization of the reach to grasp movement in response to perturbation of the distal motor patterning.
Topics: Aged; Antiparkinson Agents; Attention; Carbidopa; Drug Combinations; Female; Hand Strength; Humans; Kinesthesis; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Orientation; Parkinson Disease; Psychomotor Performance; Reaction Time; Selegiline; Size Perception | 1994 |
Peripheral catecholamine output in Parkinson's disease: effects of drug treatment.
Topics: Adrenal Medulla; Aged; Carbidopa; Catecholamines; Corpus Striatum; Epinephrine; Female; Humans; Levodopa; Male; Metanephrine; Middle Aged; Norepinephrine; Parkinson Disease; Vanilmandelic Acid | 1995 |
Portable device for quantifying parkinsonian wrist rigidity.
Topics: Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Muscle Tonus; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Psychotic Disorders; Risk Factors; Transducers | 1994 |
Parkinson's disease: making the diagnosis, selecting drug therapies.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cholinergic Antagonists; Diagnosis, Differential; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
First emergence of "delayed-on" and "dose failure" phenomena in a patient with Parkinson's disease following vagotomy.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenal Ulcer; Female; Gastric Emptying; Gastrointestinal Transit; Humans; Levodopa; Middle Aged; Parkinson Disease; Postoperative Complications; Vagotomy; Vagus Nerve | 1994 |
Punding on levodopa.
Topics: Aged; Brain; Carbidopa; Dopamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Male; Parkinson Disease; Stereotyped Behavior | 1994 |
Adductor laryngeal breathing dystonia in a patient with lubag (X-linked dystonia-Parkinsonism syndrome).
Topics: Airway Obstruction; Antiparkinson Agents; Botulinum Toxins; Carbidopa; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dystonia; Electromyography; Genes, Recessive; Humans; Injections, Intramuscular; Laryngeal Diseases; Levodopa; Male; Middle Aged; Parkinson Disease; Respiration Disorders; Respiratory Insufficiency; Respiratory Sounds; Sex Chromosome Aberrations; X Chromosome | 1994 |
Therapy of patients with Parkinson's disease.
Topics: Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1994 |
Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: relationship to clinical symptoms and subsequent therapeutic outcomes.
Topics: Aged; Biogenic Monoamines; Carbidopa; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 1993 |
Drugs for Parkinson's disease.
Topics: Carbidopa; Dopamine Agents; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1993 |
Individualizing therapy in patients with disabling Parkinson's disease symptoms.
Topics: Aged; Aged, 80 and over; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Parkinson Disease | 1994 |
Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Chorea; Circadian Rhythm; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1994 |
Symptomatic relief from treatment-induced psychosis in Parkinson's disease: an open-label pilot study with remoxipride.
Topics: Aged; Aged, 80 and over; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Limbic System; Long-Term Care; Male; Mesencephalon; Middle Aged; Parkinson Disease; Pilot Projects; Psychoses, Substance-Induced; Receptors, Dopamine D2; Remoxipride | 1994 |
Dopaminergic hallucinosis with fluoxetine in Parkinson's disease.
Topics: Aged; Bromocriptine; Carbidopa; Fluoxetine; Hallucinations; Humans; Levodopa; Male; Parkinson Disease; Visual Perception | 1993 |
Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease.
Topics: Administration, Oral; Aged; Carbidopa; Colloids; Female; Humans; Infusion Pumps; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease | 1993 |
Evaluation of the ratio method compared with graphical analyses for estimating nigrostriatal function in human 18F-dopa PET studies with or without carbidopa.
Topics: Adult; Carbidopa; Corpus Striatum; Dihydroxyphenylalanine; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Parkinson Disease; Reference Values; Substantia Nigra; Tomography, Emission-Computed | 1993 |
Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations.
Topics: Aged; Bromocriptine; Carbidopa; Hallucinations; Humans; Levodopa; Parkinson Disease; Pergolide; Polysomnography; Sleep; Sleep, REM | 1993 |
The influence of a standard meal on Sinemet CR absorption in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dietary Proteins; Drug Administration Schedule; Drug Combinations; Eating; Female; Humans; Intestinal Absorption; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Neurologic Examination; Parkinson Disease | 1993 |
Combination therapy for PD.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 1993 |
Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biopterins; Brain Diseases; Carbidopa; Corpus Striatum; Cyclic AMP; Disease Models, Animal; Dopamine; Dopamine D2 Receptor Antagonists; Homovanillic Acid; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred F344; Receptors, Dopamine D1; Receptors, Dopamine D2; Sensitivity and Specificity; Substantia Nigra; Time Factors | 1993 |
Continuous duodenal infusions of levodopa.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Duodenum; Female; Humans; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Patient Education as Topic | 1993 |
Levodopa pharmacodynamics.
Topics: Carbidopa; Drug Combinations; Drugs, Generic; Humans; Levodopa; Parkinson Disease; United States; United States Food and Drug Administration | 1994 |
Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans.
Topics: Adult; Arteries; Carbidopa; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Fluorine Radioisotopes; Humans; Parkinson Disease; Reference Values; Tomography, Emission-Computed | 1993 |
Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Tyrosine | 1993 |
Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project.
Topics: Carbidopa; Female; Follow-Up Studies; Humans; Levodopa; Male; Minnesota; Parkinson Disease; Parkinson Disease, Secondary; Survival Analysis; Survival Rate; Time Factors | 1993 |
End-of-dose dystonia in Parkinson's disease.
Topics: Adult; Carbidopa; Dystonia; Humans; Infusions, Intravenous; Levodopa; Middle Aged; Parkinson Disease; Selegiline; Substance Withdrawal Syndrome | 1993 |
Dopa-unresponsive pure akinesia or freezing. A condition within a wide spectrum of PSP?
Topics: Benserazide; Carbidopa; Diagnosis, Differential; Drug Therapy, Combination; Humans; Levodopa; Motor Activity; Movement Disorders; Neurologic Examination; Ocular Motility Disorders; Parkinson Disease; Parkinson Disease, Secondary; Supranuclear Palsy, Progressive | 1993 |
Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Motor Activity; Neurologic Examination; Parkinson Disease; Risk Factors | 1993 |
Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clozapine; Dementia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Psychoses, Substance-Induced | 1993 |
Age influences magnitude but not duration of response to levodopa.
Topics: Adult; Age Factors; Aged; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substantia Nigra | 1993 |
The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients.
Topics: Aged; Carbidopa; Dopamine; Dose-Response Relationship, Drug; Droxidopa; Female; Gait; Humans; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease | 1993 |
Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Blood-Brain Barrier; Carbidopa; Delayed-Action Preparations; Dopamine; Dose-Response Relationship, Drug; Drug Combinations; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Tyrosine | 1993 |
Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Treatment Outcome | 1993 |
Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions.
Topics: Aged; Carbidopa; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Tolerance; Dyskinesia, Drug-Induced; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Tyrosine | 1993 |
Nocturnal akathisia in Parkinson's disease: treatment with clozapine.
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Carbidopa; Circadian Rhythm; Clozapine; Confusion; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Psychomotor Agitation; Sleep Wake Disorders | 1993 |
Acetazolamide therapy of menstrual-related fluctuations in Parkinson's disease.
Topics: Acetazolamide; Adult; Carbidopa; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Menstruation Disturbances; Neurologic Examination; Parkinson Disease | 1993 |
Response to L-DOPA in multiple system atrophy.
Topics: Adult; Aged; Carbidopa; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement; Movement Disorders; Muscle Rigidity; Olivopontocerebellar Atrophies; Parkinson Disease; Tremor | 1993 |
Determination of tetrahydropapaveroline in the urine of parkinsonian patients receiving L-dopa-carbidopa (Sinemet) therapy by high-performance liquid chromatography.
Topics: Adsorption; Aluminum Oxide; Antiparkinson Agents; Carbidopa; Cation Exchange Resins; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Drug Combinations; Electrochemistry; Humans; Levodopa; Parkinson Disease; Resins, Synthetic; Silanes; Tetrahydropapaveroline | 1993 |
No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Brain; Cabergoline; Carbidopa; Diabetes Mellitus; Ergolines; Female; Free Radicals; Humans; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Oxidative Stress; Parkinson Disease; Selegiline; Vitamin E | 1995 |
A 61-year-old man with Parkinson's disease.
Topics: 1-Naphthylamine; Antiparkinson Agents; Carbidopa; Depression; Dopamine Agents; Drug Interactions; Drug Therapy, Combination; Family Practice; Humans; Levodopa; Male; Middle Aged; Neurology; Neuroprotective Agents; Parkinson Disease; Selegiline; Sertraline; Vitamin E | 1996 |
Survival and proliferation of nonneural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts.
Topics: Adult; Amantadine; Antiparkinson Agents; Autopsy; Basal Ganglia; Brain Tissue Transplantation; Carbidopa; Cell Division; Cerebral Ventricles; Corpus Striatum; Embryo, Mammalian; Fetal Tissue Transplantation; Fetus; Gestational Age; Graft Survival; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Parkinson Disease; Transplantation, Homologous | 1996 |
Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
Topics: Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 1996 |
[Clinical experience in switching patients from standard levodopa to a controlled-release levodopa].
Topics: Aged; Antiparkinson Agents; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 1996 |
Neutrophil function, nitric oxide, and blood oxidative stress in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catalase; Drug Therapy, Combination; Erythrocytes; Female; Free Radicals; Humans; Hydrogen Peroxide; Levodopa; Luminescent Measurements; Male; Middle Aged; Neutrophils; Nitric Oxide; Oxidative Stress; Parkinson Disease; Reactive Oxygen Species; Superoxide Dismutase | 1996 |
Computational analysis of open loop handwriting movements in Parkinson's disease: a rapid method to detect dopamimetic effects.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Brain; Carbidopa; Drug Therapy, Combination; Female; Handwriting; Humans; Levodopa; Male; Microcomputers; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Signal Processing, Computer-Assisted; Treatment Outcome | 1996 |
High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pergolide | 1996 |
Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use.
Topics: Antiparkinson Agents; Ascorbic Acid; Carbidopa; Drug Combinations; Drug Stability; Drug Storage; Humans; Levodopa; Light; Parkinson Disease; Temperature; Time Factors | 1996 |
Amantadine-induced "vocal" myoclonus.
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Dysarthria; Female; Humans; Levodopa; Myoclonus; Neurologic Examination; Parkinson Disease; Verbal Behavior | 1996 |
Levodopa in pregnancy.
Topics: Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Infant, Newborn; Levodopa; Parkinson Disease; Pregnancy; Pregnancy Complications; Risk Factors | 1996 |
Pharmacokinetic model of oral levodopa and role of carbidopa in parkinsonian patients.
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Dopamine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease | 1995 |
Supplement: treatment for Parkinson's disease.
Topics: Algorithms; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1995 |
Triphasic waves in serotonin syndrome.
Topics: 1-Naphthylamine; Aged; Amantadine; Antiparkinson Agents; Brain Diseases; Carbidopa; Drug Combinations; Drug Therapy, Combination; Electroencephalography; Hallucinations; Humans; Levodopa; Male; Myoclonus; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Sertraline; Syndrome | 1997 |
Comparison of utilization of Sinemet and Parkinson's disease mortality as surrogate indicators of Parkinson's disease in the United States.
Topics: Antiparkinson Agents; Carbidopa; Demography; Drug Combinations; Drug Utilization; Humans; Levodopa; Linear Models; Parkinson Disease; United States | 1997 |
The nurse's role in clinical trials.
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials, Phase IV as Topic; Drug Combinations; Humans; Job Description; Levodopa; Nursing Care; Parkinson Disease | 1996 |
Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
Topics: Adult; Aged; Amino Acids; Antiparkinson Agents; Brain; Carbidopa; Circadian Rhythm; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Severity of Illness Index; Time Factors | 1997 |
Microdialysis-HPLC for plasma levodopa and metabolites monitoring in parkinsonian patients.
Topics: Aged; Carbidopa; Chromatography, High Pressure Liquid; Homovanillic Acid; Humans; Kinetics; Levodopa; Microdialysis; Middle Aged; Parkinson Disease | 1997 |
The stability of carbidopa in solution.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Stability; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease; Solutions | 1997 |
Clinical implications of sustained dopaminergic stimulation.
Topics: Aged; Benserazide; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Lisuride; Parkinson Disease; Reaction Time | 1994 |
Treatment with AC pulsed electromagnetic fields improves the response to levodopa in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Circadian Rhythm; Combined Modality Therapy; Drug Combinations; Electromagnetic Fields; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1997 |
[Body fat loss in patients with Parkinson's disease].
Topics: Adipose Tissue; Aged; Aged, 80 and over; Antiparkinson Agents; Body Mass Index; Body Weight; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1997 |
Coexistence of tics and parkinsonism: evidence for non-dopaminergic mechanisms in tic pathogenesis.
Topics: Aged; Carbidopa; Dopamine; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tic Disorders; Treatment Outcome | 1997 |
Antiparkinsonian drugs causing inappropriate antidiuretic hormone secretion.
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Humans; Inappropriate ADH Syndrome; Levodopa; Longitudinal Studies; Male; Parkinson Disease; Trihexyphenidyl | 1998 |
Square-wave action dystonia in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Dominance, Cerebral; Drug Combinations; Dystonia; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1998 |
The co-ordination and phasing of a bilateral prehension task. The influence of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Functional Laterality; Hand Strength; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Reaction Time; Reference Values | 1998 |
Highlights of the North American and European experiences.
Topics: Antiparkinson Agents; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Humans; Levodopa; Nitrophenols; North America; Parkinson Disease; Randomized Controlled Trials as Topic; Tolcapone | 1998 |
Clozapine for dopaminergic-induced paraphilias in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Carbidopa; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Male; Paraphilic Disorders; Parkinson Disease; Pergolide | 1998 |
Quality of life and Parkinson's disease: the CR FIRST Study.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Emotions; Humans; Levodopa; Parkinson Disease; Quality of Life; Social Isolation; Treatment Outcome | 1998 |
Levodopa in human breast milk: clinical implications.
Topics: Adult; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Lactation; Levodopa; Milk, Human; Osmolar Concentration; Parkinson Disease | 1998 |
Early dopaminergic drug-induced hallucinations in parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dopamine Agents; Female; Follow-Up Studies; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1998 |
Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias.
Topics: Adult; Aged; Carbidopa; Case-Control Studies; Cerebrovascular Circulation; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Thalamus; Tomography, Emission-Computed | 1998 |
Early-occurrence of manual motor blocks in Parkinson's disease: a quantitative assessment.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gait; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Psychomotor Disorders; Treatment Outcome | 1999 |
L-dopa and cancer anorexia.
Topics: Anorexia; Carbidopa; Dopamine Agents; Humans; Levodopa; Male; Parkinson Disease; Urinary Bladder Neoplasms | 1999 |
[High dosage therapy of Parkinson disease. New dopamine agonist pramipexol allows reduction of L-dopa dose down to zero].
Topics: Antiparkinson Agents; Benzothiazoles; Carbidopa; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pramipexole; Thiazoles | 1999 |
Parkinson's disease: therapeutic choices and timing decisions in patient management. Interview by Wayne Kuznar.
Topics: Age Factors; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Disease Progression; Drug Administration Schedule; Electric Stimulation Therapy; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease; Patient Selection; Selegiline; Time Factors; Tolcapone | 1999 |
The time course of metabolites in human plasma after 6-[(18)F]fluoro-l-m-tyrosine administration.
Topics: Antiparkinson Agents; Brain; Carbidopa; Dopamine; Fluorine Radioisotopes; Humans; Parkinson Disease; Time Factors; Tomography, Emission-Computed; Tyrosine | 1999 |
Successful orchestration of antiparkinsonian pharmacotherapy.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Comorbidity; Disease Progression; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pharmacists | 1999 |
Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study.
Topics: Adult; Aged; Antiparkinson Agents; Brain Mapping; Carbidopa; Carbon Radioisotopes; Corpus Striatum; Dihydroxyphenylalanine; Drug Combinations; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Raclopride; Receptors, Dopamine D2; Tomography, Emission-Computed | 1999 |
The reach-to-grasp movement in Parkinson's disease before and after dopaminergic medication.
Topics: Adult; Aged; Antiparkinson Agents; Basal Ganglia; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Reaction Time; Receptors, Dopamine | 2000 |
The effect of pregnancy in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Carbidopa; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Infant, Newborn; Levodopa; Neurologic Examination; Parkinson Disease; Pregnancy; Pregnancy Complications; Quality of Life | 2000 |
Parkinsonism, dystonia, and hemiatrophy.
Topics: Adolescent; Antiparkinson Agents; Carbidopa; Caudate Nucleus; Child; Child, Preschool; Dominance, Cerebral; Drug Therapy, Combination; Dystonia; Humans; Infant; Infant, Newborn; Levodopa; Magnetic Resonance Imaging; Muscular Atrophy; Neurologic Examination; Parkinson Disease; Putamen; Treatment Outcome | 2000 |
Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Humans; Levodopa; Multicenter Studies as Topic; Parkinson Disease; Randomized Controlled Trials as Topic | 2000 |
Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents.
Topics: Antipsychotic Agents; Carbidopa; Dopamine Agonists; Drug Therapy, Combination; Female; Gambling; Humans; Impulsive Behavior; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Risperidone; Treatment Outcome | 2000 |
Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls.
Topics: Aged; Antiparkinson Agents; Carbidopa; Case-Control Studies; Diagnosis, Computer-Assisted; Diagnosis, Differential; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinson Disease; Postural Balance; Posture; Severity of Illness Index; Supranuclear Palsy, Progressive | 2000 |
Dopa-induced blood flow responses in nonhuman primates.
Topics: Anesthetics, Dissociative; Animals; Antiparkinson Agents; Arousal; Carbidopa; Cerebrovascular Circulation; Dopamine; Frontal Lobe; Gyrus Cinguli; Ketamine; Levodopa; Macaca nemestrina; Male; Papio; Parkinson Disease; Putamen; Temporal Lobe; Tomography, Emission-Computed | 2000 |
Case report: successful use of rectally administered levodopa-carbidopa.
Topics: Administration, Oral; Administration, Rectal; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Deglutition Disorders; Female; Humans; Levodopa; Parkinson Disease; Patient Compliance | 2001 |
Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Carbidopa; Decarboxylation; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Extracellular Space; Levodopa; Male; Microdialysis; Neostriatum; Parkinson Disease; Rats; Rats, Wistar | 2001 |
Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase.
Topics: 5-Hydroxytryptophan; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Binding Sites; Carbidopa; Crystallography, X-Ray; Dopa Decarboxylase; Drug Design; Humans; Kidney; Levodopa; Ligands; Models, Molecular; Parkinson Disease; Pliability; Protein Structure, Secondary; Swine | 2001 |
Interactions between deep brain stimulation and levodopa in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electric Stimulation Therapy; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Reaction Time; Subthalamic Nucleus; Walking | 2001 |
[Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
Topics: Adult; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Circadian Rhythm; Drug Tolerance; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2002 |
Duodenal levodopa infusion in Parkinson's disease--long-term experience.
Topics: Adult; Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Administration Schedule; Drug Therapy, Combination; Duodenoscopy; Female; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Time | 2001 |
Bruxism as presenting feature of Parkinson's disease.
Topics: Antiparkinson Agents; Bruxism; Carbidopa; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2002 |
[Hallucinations caused by paroxetine taken together with a levodopa-carbidopa preparation].
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Interactions; Drug Therapy, Combination; Female; Hallucinations; Humans; Levodopa; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2002 |
[Hallucinations caused by paroxetine in combined usage of levodopa-carbidopa].
Topics: Antidepressive Agents, Second-Generation; Antiparkinson Agents; Carbidopa; Drug Interactions; Hallucinations; Levodopa; Parkinson Disease; Paroxetine | 2002 |
Drug therapy for Parkinsonism.
Topics: Carbidopa; Drug Combinations; Humans; Hydrazines; Levodopa; Parkinson Disease | 1976 |
How to achieve maximum benefit for the patient with Parkinson's disease.
Topics: Aged; Amantadine; Carbidopa; Diagnosis, Differential; Histamine H1 Antagonists; Humans; Levodopa; Nervous System Diseases; Occupational Therapy; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities; Psychotherapy; Trihexyphenidyl | 1976 |
[Therapy of Parkinson's disease. Practical criteria of treatment].
Topics: Amantadine; Antiparkinson Agents; Benserazide; Carbidopa; Cyproheptadine; Drug Therapy, Combination; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Piribedil; Pizotyline; Propranolol | 1976 |
Parkinson's disease.
Topics: Amantadine; Antidepressive Agents; Carbidopa; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities | 1977 |
Update on drug treatment of Parkinsonism.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1977 |
Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Circadian Rhythm; Drug Combinations; Drug Therapy, Combination; Ergolines; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Sleep | 1978 |
Letter: Psychosis in patient on bromocriptine and levodopa with carbidopa.
Topics: Bromocriptine; Carbidopa; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease; Schizophrenia, Paranoid | 1976 |
A pseudohemipharetic form of Parkinson's disease.
Topics: Aged; Amantadine; Carbidopa; Diagnosis, Differential; Drug Therapy, Combination; Female; Functional Laterality; Hemiplegia; Humans; Middle Aged; Parkinson Disease; Trihexyphenidyl | 1976 |
Dream phenomena induced by chronic levodopa therapy.
Topics: Adult; Aged; Carbidopa; Delusions; Dreams; Female; Hallucinations; Humans; Illusions; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced | 1978 |
Therapeutics of disordered movement.
Topics: Carbidopa; Chorea; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dystonia Musculorum Deformans; Hepatolenticular Degeneration; Humans; Huntington Disease; Levodopa; Movement Disorders; Parasympatholytics; Parkinson Disease; Receptors, Cholinergic; Receptors, Dopamine; Tremor | 1977 |
Cerebrospinal fluid cyclic AMP in parkinsonism [proceedings].
Topics: Adult; Carbidopa; Cyclic AMP; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Time Factors | 1979 |
Electroencephalographic change in Parkinsonian patients treated with levodopa-carbidopa.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Electroencephalography; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
Drugs for parkinsonism.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1979 |
Causes of pseudotumor cerebri and papilledema.
Topics: Aged; Carbidopa; Dose-Response Relationship, Drug; Female; Humans; Hydrazines; Levodopa; Papilledema; Parkinson Disease; Pseudotumor Cerebri | 1979 |
Reversible haemolytic anaemia after levodopa-carbidopa.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Carbidopa; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Male; Parkinson Disease | 1979 |
Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa.
Topics: Adolescent; Adult; Benserazide; Bromocriptine; Carbidopa; Female; Humans; Hydrazines; Levodopa; Male; Micrococcus; Middle Aged; Nicotinamidase; Nicotinic Acids; Parkinson Disease; Tryptophan | 1979 |
Conditioning of the H reflex by stimulation of the posterior tibial nerve in Parkinson's disease.
Topics: Aged; Carbidopa; Conditioning, Psychological; Drug Therapy, Combination; Electric Stimulation; Evoked Potentials; Female; H-Reflex; Humans; Levodopa; Male; Middle Aged; Motor Neurons; Parkinson Disease; Reflex, Monosynaptic; Tibial Nerve | 1979 |
Western equine encephalitis with rapid onset of parkinsonism.
Topics: Adult; Carbidopa; Encephalitis Virus, Western Equine; Encephalomyelitis, Equine; Female; Humans; Levodopa; Parkinson Disease; Trihexyphenidyl | 1977 |
Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Dihydroxyphenylalanine; Female; Humans; Hydrazines; Male; Middle Aged; Parkinson Disease | 1978 |
Normal pressure hydrocephalus, parkinsonism, and primary empty sella--coincidence or cause-effect?
Topics: Aged; Carbidopa; Cerebrospinal Fluid Shunts; Drug Therapy, Combination; Empty Sella Syndrome; Female; Humans; Hydrocephalus; Hydrocephalus, Normal Pressure; Jugular Veins; Levodopa; Parkinson Disease | 1978 |
Need for uncombined carbidopa to treat parkinsonism.
Topics: Carbidopa; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease | 1978 |
Plasma DOPA and growth hormone in parkinsonism: oscillations in symptoms.
Topics: Aged; Carbidopa; Dihydroxyphenylalanine; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
Bromocriptine in Parkinson disease: further studies.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
Sinemet and thyroid function in Parkinson disease.
Topics: Carbidopa; Drug Combinations; Humans; Hydrazines; Levodopa; Male; Parkinson Disease; Thyroid Function Tests; Thyroid Gland; Thyrotropin | 1979 |
Interaction between bromocriptine and levodopa. Biochemical basis for an improved treatment for parkinsonism.
Topics: Animals; Brain; Bromocriptine; Carbidopa; Dopamine; Drug Interactions; Ergolines; gamma-Aminobutyric Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Parkinson Disease; Rats; Serotonin | 1977 |
CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders.
Topics: Aged; Athetosis; Carbidopa; Chorea; Dihydroxyphenylalanine; Dopamine; Dystonia Musculorum Deformans; Hepatolenticular Degeneration; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methoxyhydroxyphenylglycol; Middle Aged; Movement Disorders; Parkinson Disease; Parkinson Disease, Postencephalitic; Serotonin; Tetrabenazine; Torticollis | 1977 |
Plasma O-methyldopa in levodopa-induced dyskinesias. A bioclinical investigation.
Topics: Aged; Benserazide; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 1977 |
Application of paired-ion high-pressure liquid column chromatography to the analysis of L-3,4-dihydroxyphenylalanine metabolites.
Topics: Carbidopa; Chromatography, High Pressure Liquid; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Parkinson Disease | 1978 |
Comparison between lergotrile and bromocriptine in parkinsonism.
Topics: Acetonitriles; Adult; Aged; Bromocriptine; Carbidopa; Chemical Phenomena; Chemistry; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1978 |
Paradoxial response to dopaminergic agents in parkinsonism.
Topics: Acetonitriles; Aged; Carbidopa; Ergolines; Homovanillic Acid; Humans; Hydrazines; Levodopa; Male; Parkinson Disease; Receptors, Dopamine | 1978 |
Bromocriptine in parkinsonism. A long-term study.
Topics: Anorexia; Bromocriptine; Carbidopa; Hallucinations; Humans; Levodopa; Middle Aged; Nausea; Parkinson Disease; Time Factors; Urinary Incontinence; Vasomotor System | 1978 |
Photic EEG-driving responses in thalamotomized and medicated cases of Parkinson's disease.
Topics: Adult; Aged; Alpha Rhythm; Beta Rhythm; Carbidopa; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Photic Stimulation; Spectrum Analysis; Thalamus; Theta Rhythm | 1978 |
Effects of levodopa alone and in combination with dopa-decarboxylase inhibitors on plasma renin activity in patients with Parkinson's disease.
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Drug Therapy, Combination; Furosemide; Humans; Hypotension, Orthostatic; Levodopa; Middle Aged; Parkinson Disease; Posture; Renin | 1978 |
Regional cerebral blood flow in parkinsonism. Measurement before and after levodopa.
Topics: Adult; Aged; Carbidopa; Cerebrovascular Circulation; Dopamine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Regional Blood Flow; Xenon Radioisotopes | 1978 |
Measurements of visual evoked potentials in Parkinson's disease.
Topics: Age Factors; Aged; Carbidopa; Dominance, Cerebral; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Photic Stimulation; Reaction Time; Visual Cortex; Visual Pathways; Visual Perception | 1978 |
Electrical properties of motor units in Parkinsonism and a possible relationship with bradykinesia.
Topics: Action Potentials; Adult; Aged; Carbidopa; Electromyography; Forearm; Gait; Hand; Humans; Levodopa; Male; Middle Aged; Motor Skills; Movement Disorders; Muscle Contraction; Muscles; Neuromuscular Junction; Parkinson Disease; Recruitment, Neurophysiological | 1979 |
[Therapy of Parkinson's syndrome].
Topics: Amantadine; Benserazide; Carbidopa; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities; Reserpine; Stereotaxic Techniques | 1976 |
[Effects of simultaneous administration of pyridoxine in the combined administration of L-dopa and peripheral decarboxylase inhibitors. Experimental and clinical studies].
Topics: Animals; Carbidopa; Carboxy-Lyases; Dogs; Drug Therapy, Combination; Female; Haplorhini; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pyridoxine; Rats; Tremor | 1976 |
The long-term effects of combining carbidopa with levodopa for Parkinson's disease.
Topics: Carbidopa; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Long-Term Care; Male; Parkinson Disease | 1976 |
Drug therapy of Parkinsonism dopaminergic drugs.
Topics: Carbidopa; Humans; Hydrazines; Levodopa; Parkinson Disease | 1977 |
The shaking patient. Diagnosis and management of tremor.
Topics: Amantadine; Carbidopa; Cerebellar Diseases; Humans; Levodopa; Parkinson Disease; Propranolol; Tremor | 1977 |
The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders. Treatment with levodopa and decarboxylase inhibitor.
Topics: Adult; Carbidopa; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
[Treatment of Parkinson's disease with the combination drug L-carbidopa/L-dopa. Report on a 2 years study].
Topics: Carbidopa; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Movement Disorders; Parkinson Disease; Psychoses, Substance-Induced | 1977 |
Effect of thalamotomy and levodopa therapy on the speech of Parkinson patients.
Topics: Aged; Aphasia; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Speech; Thalamus; Vital Capacity | 1977 |
Does O-methyl-dopa play a role in levodopa-induced dyskinesias?
Topics: Adult; Aged; Benserazide; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 1977 |
Hypertensive crisis in a patient given sinemet, metoclopramide, and amitriptyline.
Topics: Acute Disease; Amitriptyline; Carbidopa; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrazines; Hypertension; Levodopa; Metoclopramide; Middle Aged; Parkinson Disease | 1977 |
[Treatment of Parkinson's syndrome with a combination of levodopa and carbidopa].
Topics: Adult; Aged; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
Occurrence of a new class of tetrahydroisoquinoline alkaloids in L-dopa-treated parkinsonian patients.
Topics: Animals; Biotransformation; Brain; Carbidopa; Catechols; Humans; Levodopa; Mice; Papaverine; Parkinson Disease; Rats; Tetrahydropapaveroline | 1977 |
Problems in the treatment of Parkinsonism.
Topics: Antiparkinson Agents; Arteriosclerosis; Carbidopa; Diagnosis, Differential; Drug Combinations; Eye Manifestations; Humans; Levodopa; Mental Disorders; Movement Disorders; Parasympatholytics; Paresthesia; Parkinson Disease; Vision Disorders | 1977 |
Treatment of parkinsonism.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Carbidopa; Dopamine; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 1977 |
Psychiatric symptoms with initiation of carbidopa-levodopa treatment.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced | 1976 |
Letter: Carbidopa.
Topics: Carbidopa; Humans; Hydrazines; Parkinson Disease; United States | 1976 |
In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Dopamine; Drug Interactions; Humans; Hydrazines; Levodopa; Parkinson Disease; Pyridoxine; Rats | 1976 |
[Carbidopa-levodopa, growth hormone and parkinsonism].
Topics: Aged; Carbidopa; Female; Growth Hormone; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Pituitary Gland; Stimulation, Chemical | 1976 |
14C-homovanillic acid in the cerebrospinal fluid of parkinsonian patients after intravenous 14C-L-dopa.
Topics: Aged; Brain; Carbidopa; Carboxy-Lyases; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenylacetates; Probenecid; Sensory Receptor Cells | 1976 |
[Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
Topics: Adult; Aged; Benserazide; Carbidopa; Dihydroxyphenylalanine; Dopamine; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
New drugs for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Interactions; Drug Therapy, Combination; Food; Humans; Levodopa; Parkinson Disease | 1976 |
[Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
Topics: Adult; Aged; Carbidopa; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Tablets | 1976 |
[Effects and side effects to levodopa in parkinsonism- results of a collaborative study. (5) Combined therapy with a peripheral decarboxylase inhibitor].
Topics: Adult; Aged; Carbidopa; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease | 1976 |
Editorial: Long-term assessment of levodopa therapy in Parkinson's disease.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Drug Evaluation; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Postencephalitic | 1975 |
Effect of L-DOPA on endogenous histamine metabolism.
Topics: Acetates; Adult; Aged; Animals; Carbidopa; Depression, Chemical; Female; Guinea Pigs; Histamine; Humans; Imidazoles; Levodopa; Male; Methylation; Middle Aged; Parkinson Disease; Rats; Species Specificity | 1975 |
L-dopa therapy combined with peripheral decarboxylase inhibitor (MK-486) in Parkinsonism.
Topics: Adult; Aged; Animals; Carbidopa; Carboxy-Lyases; Cats; Dopamine; Drug Therapy, Combination; Female; Humans; Hydrazines; Injections, Intraperitoneal; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1975 |
Interactions of levodopa with inhibitors of monoamine oxidase and L-aromatic amino acid decarboxylase.
Topics: Adult; Amino Acids; Blood Pressure; Carbidopa; Carboxy-Lyases; Drug Interactions; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Stimulation, Chemical; Time Factors; Tranylcypromine | 1975 |
Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients.
Topics: Adult; Aged; Carbidopa; Female; Follow-Up Studies; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 1975 |
Patterns of clinical response and plasma dopa levels in Parkinson's disease.
Topics: Adult; Aged; Brain; Carbidopa; Dihydroxyphenylalanine; Disability Evaluation; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1975 |
Drug therapy for Parkinson's disease.
Topics: Carbidopa; Circadian Rhythm; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1975 |
[Treatment of Parkinson's syndromes by a combination of levodopa with decarboxylase inhibitors].
Topics: Adult; Aged; Carbidopa; Carboxy-Lyases; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1975 |
[Effect of carbidopa and L-dopa combination on the secretion of growth hormone in normal subjects and in patients with Parkinsonism].
Topics: Carbidopa; Growth Hormone; Humans; Hydrazines; Levodopa; Parkinson Disease; Pituitary Gland; Stimulation, Chemical | 1975 |
L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Drug Combinations; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
Gout induced by L-dopa and decarboxylase inhibitors.
Topics: Aged; Carbidopa; Carboxy-Lyases; Gout; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 1976 |
Letter: Alternatives to levodopa.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease | 1976 |
Phenelzine treatment of depression in Parkinson's disease.
Topics: Aged; Carbidopa; Depressive Disorder; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Male; Parkinson Disease; Phenelzine | 1992 |
ECT and delirium in Parkinson's disease.
Topics: Carbidopa; Combined Modality Therapy; Delirium; Depressive Disorder; Drug Combinations; Electroconvulsive Therapy; Humans; Levodopa; Parkinson Disease | 1992 |
The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease.
Topics: Benserazide; Carbidopa; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1992 |
Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Paranoid Disorders; Parkinson Disease; Psychoses, Substance-Induced | 1992 |
Juvenile parkinsonism: ventricular CSF biopterin levels and clinical features.
Topics: Adult; Age Factors; Benserazide; Biomarkers; Biopterins; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Motor Neurons; Parkinson Disease | 1992 |
Improvement of parkinsonian features correlate with high plasma levodopa values after broad bean (Vicia faba) consumption.
Topics: Aged; Bromocriptine; Carbidopa; Combined Modality Therapy; Fabaceae; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Plants, Medicinal | 1992 |
Lack of changes in ventricular cerebrospinal fluid concentrations of homovanillic acid following acute challenge with levodopa.
Topics: Aged; Carbidopa; Cerebral Ventricles; Drug Combinations; Female; Homovanillic Acid; Humans; Hydrocephalus, Normal Pressure; Levodopa; Male; Middle Aged; Parkinson Disease | 1992 |
Sensorimotor disinhibition in Parkinson's disease: effects of levodopa.
Topics: Carbidopa; Drug Combinations; Hand; Humans; Levodopa; Male; Motor Activity; Parkinson Disease; Psychomotor Performance; Reaction Time | 1992 |
Controlled-release carbidopa-levodopa: old drug--new drug. Introduction.
Topics: Carbidopa; Circadian Rhythm; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Evaluation Studies as Topic; Humans; Levodopa; Parkinson Disease | 1992 |
The use of Sinemet CR in the management of mild to moderate Parkinson's disease.
Topics: Carbidopa; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement; Parkinson Disease; Patient Compliance; Patient Education as Topic; Tissue Distribution | 1992 |
Hemiballism and chorea in a patient with parkinsonism due to a multisystem degeneration.
Topics: Aged; Antiparkinson Agents; Atrophy; Brain; Carbidopa; Central Nervous System Diseases; Chorea; Diagnosis, Differential; Drug Combinations; Female; Humans; Levodopa; Movement Disorders; Nerve Degeneration; Parkinson Disease; Spinal Cord | 1992 |
Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Carbidopa; Domperidone; Humans; Levodopa; Middle Aged; Parkinson Disease; Psychomotor Performance | 1992 |
Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide)
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Lactose; Levodopa; Male; Methylcellulose; Middle Aged; Oxazines; Parkinson Disease; Pergolide | 1992 |
Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.
Topics: Age Factors; Blood Glucose; Blood Platelets; Carbidopa; Drug Therapy, Combination; Energy Metabolism; Female; Humans; Lactates; Lactic Acid; Levodopa; Lisuride; Male; Middle Aged; Mitochondria; Oxygen Consumption; Parkinson Disease; Receptors, Dopamine; Selegiline | 1992 |
Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease.
Topics: Adult; Benserazide; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Reaction Time | 1992 |
Unforeseen beneficial effects of controlled-release levodopa-carbidopa (Sinemet CR)
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Depressive Disorder; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease | 1992 |
Protein redistribution diet remains effective in patients with fluctuating parkinsonism.
Topics: Adult; Aged; Amino Acids; Antiparkinson Agents; Brain; Carbidopa; Dietary Proteins; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1992 |
Levodopa-associated hemifacial dystonia.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dystonia; Facial Muscles; Female; Humans; Levodopa; Parkinson Disease; Putamen | 1991 |
Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa.
Topics: Administration, Oral; Aged; Carbidopa; Drug Therapy, Combination; Duodenum; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
Effect of duration of levodopa/decarboxylase inhibitor therapy on the pharmacokinetic handling of levodopa in elderly patients with idiopathic Parkinson's disease.
Topics: Age Factors; Aged; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Time Factors | 1991 |
The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease.
Topics: Biogenic Monoamines; Biomarkers; Carbidopa; Humans; Levodopa; Middle Aged; Parkinson Disease; Tyrosine | 1991 |
Autologous adrenal medullary transplants in advanced Parkinson's disease with particular attention to the selective improvement in symptoms.
Topics: Adrenal Medulla; Adult; Antiparkinson Agents; Carbidopa; Caudate Nucleus; Combined Modality Therapy; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Time Factors; Tomography, X-Ray Computed; Transplantation, Heterotopic | 1991 |
Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease.
Topics: Aged; Carbidopa; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1991 |
Sinemet (CR4): an open-label study in moderately severe Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
Dopaminergic induced changes in cognitive and motor processing in Parkinson's disease: an electrophysiological investigation.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Cerebral Cortex; Cognition Disorders; Dopamine; Dose-Response Relationship, Drug; Drug Combinations; Electroencephalography; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Psychomotor Performance; Reaction Time; Receptors, Dopamine | 1991 |
Sinemet CR for Parkinson's disease.
Topics: Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1991 |
Naloxone reverses L-dopa induced overstimulation effects in a Parkinson's disease animal model analogue.
Topics: Animals; Carbidopa; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Hydroxydopamines; Levodopa; Male; Mesencephalon; Naloxone; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Time Factors | 1991 |
The effect of chronic L-dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts.
Topics: Animals; Apomorphine; Body Weight; Carbidopa; Corpus Striatum; Drinking; Female; Fetal Tissue Transplantation; Hydroxydopamines; Levodopa; Mesencephalon; Motor Activity; Nervous System; Oxidopamine; Parkinson Disease; Rats; Rotation; Stereotyped Behavior; Time Factors | 1991 |
Treating the progressive stages of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Combinations; Electroconvulsive Therapy; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Pergolide; Selegiline | 1991 |
Decrease in blood histamine in drug-treated parkinsonian patients.
Topics: Adult; Aged; Amine Oxidase (Copper-Containing); Antiparkinson Agents; Carbidopa; Female; Histamine; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease | 1991 |
Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
Topics: 5-Hydroxytryptophan; Aged; Carbidopa; Chronic Disease; Depression; Drug Therapy, Combination; Eosinophilia-Myalgia Syndrome; Humans; Male; Parkinson Disease; Scleroderma, Localized | 1991 |
Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson's disease.
Topics: Carbidopa; Cerebral Ventricles; Dopamine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Movement; Parkinson Disease; Sulfates | 1991 |
New concepts in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Diet; Dopamine Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Intestinal Absorption; Levodopa; Parkinson Disease; Selegiline | 1990 |
Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation.
Topics: Activities of Daily Living; Antiparkinson Agents; Brain; Carbidopa; Delayed-Action Preparations; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Oxazines; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D2 | 1990 |
Inhibition of human benzylamine oxidase (BzAO) by analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Benzylamine Oxidase; Carbidopa; Dopamine Agents; Humans; Kinetics; Parkinson Disease; Selegiline | 1990 |
Off-period screaming accompanying motor fluctuations in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Crying; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1991 |
A 73-year-old woman with confusion, rigidity, and fever.
Topics: Aged; Carbidopa; Confusion; Drug Therapy, Combination; Female; Fever; Humans; Levodopa; Muscle Rigidity; Neuroleptic Malignant Syndrome; Parkinson Disease | 1991 |
Clinical experience with duodenal infusions of levodopa for the treatment of motor fluctuations in Parkinson's disease.
Topics: Carbidopa; Drug Administration Schedule; Drug Therapy, Combination; Duodenum; Dystonia; Humans; Infusion Pumps; Infusions, Parenteral; Levodopa; Long-Term Care; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
The effect of L-dopa and carbidopa on behavioural recovery produced by ventral mesencephalic grafts in rats.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Brain Tissue Transplantation; Carbidopa; Corpus Striatum; Female; Fetal Tissue Transplantation; Hydroxydopamines; Levodopa; Mesencephalon; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Stereotyped Behavior; Substantia Nigra | 1990 |
New drugs for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Quality of Life; Selegiline | 1990 |
Levodopa-responsive parkinsonism in a patient with Down's syndrome.
Topics: Activities of Daily Living; Carbidopa; Dose-Response Relationship, Drug; Down Syndrome; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Utilization of unilateral and bilateral stereotactically placed adrenomedullary-striatal autografts in parkinsonian humans: rationale, techniques, and observations.
Topics: Adrenal Medulla; Adult; Aged; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurosurgery; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques; Tomography, X-Ray Computed | 1990 |
A view from inside.
Topics: Accidental Falls; Antiparkinson Agents; Bromocriptine; Carbidopa; Dentists; Drug Combinations; Humans; Levodopa; Male; Northern Ireland; Parkinson Disease | 1990 |
Parkinsonism with neuroacanthocytosis.
Topics: Acanthocytes; Adult; Carbidopa; Erythrocytes; Humans; Levodopa; Lipids; Male; Middle Aged; Parkinson Disease; Tomography, Emission-Computed | 1990 |
Hypotensive effect of long-term levodopa in patients with Parkinson's disease.
Topics: Aged; Biogenic Monoamines; Blood Pressure; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 1990 |
Simultaneous measurement of L-dopa, its metabolites and carbidopa in plasma of parkinsonian patients by improved sample pretreatment and high-performance liquid chromatographic determination.
Topics: Carbidopa; Catecholamines; Catechols; Chromatography, High Pressure Liquid; Electrochemistry; Humans; Hydrogen-Ion Concentration; Indicators and Reagents; Levodopa; Parkinson Disease | 1990 |
Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients.
Topics: Carbidopa; Droxidopa; Humans; Levodopa; Middle Aged; Norepinephrine; Parkinson Disease | 1990 |
Comparison of motor response to apomorphine and levodopa in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Apomorphine; Carbidopa; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Neuroleptic malignant syndrome without neuroleptics.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Depressive Disorder; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome; Tranylcypromine; Tryptophan | 1990 |
The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Carbidopa; Corpus Striatum; Deoxyglucose; Flunitrazepam; gamma-Aminobutyric Acid; Globus Pallidus; Levodopa; Macaca fascicularis; Neurons; Organ Specificity; Parkinson Disease; Parkinson Disease, Secondary; Tritium | 1990 |
Preliminary report on adrenal medullary grafting and cografting with sural nerve in the treatment of hemiparkinson monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Apomorphine; Behavior, Animal; Carbidopa; Caudate Nucleus; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Macaca mulatta; Motor Activity; Parkinson Disease; Sural Nerve; Transplantation, Heterotopic | 1990 |
A year follow-up of autoimplants of perfused adrenal medulla into parkinsonian patients. CPH Neural Transplantation Group.
Topics: Adrenal Medulla; Carbidopa; Caudate Nucleus; Combined Modality Therapy; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Perfusion; Severity of Illness Index; Transplantation, Autologous; Transplantation, Heterotopic | 1990 |
Sinemet-ferrous sulphate interaction in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Drug Combinations; Drug Interactions; Female; Ferrous Compounds; Humans; Levodopa; Male; Middle Aged; Oxygen; Parkinson Disease | 1990 |
Pharmacodynamic modeling of concentration-effect relationships after controlled-release carbidopa/levodopa (Sinemet CR4) in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Models, Biological; Parkinson Disease | 1990 |
Treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Lisuride; Parkinson Disease | 1990 |
Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Carboxy-Lyases; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Hydrazines; Levodopa; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Steady plasma levodopa concentrations required for good clinical response to CR-4 in patients with 'on-off'.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
Marijuana for parkinsonian tremor.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Diazepam; Drug Combinations; Humans; Levodopa; Marijuana Smoking; Parkinson Disease; Tremor | 1990 |
MAO and L-dopa treatment of Parkinson's disease.
Topics: Aged; Carbidopa; Dopamine; Drug Combinations; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease | 1990 |
Respiratory dysfunction due to L-dopa therapy for parkinsonism: diagnosis using serial pulmonary function tests and respiratory inductive plethysmography.
Topics: Aged; Carbidopa; Dyspnea; Humans; Levodopa; Lung Volume Measurements; Male; Middle Aged; Parkinson Disease; Plethysmography; Pulmonary Ventilation; Respiration Disorders | 1990 |
Influence of L-DOPA/carbidopa on pattern reversal VEP: behavioural difference in primary and secondary parkinsonism.
Topics: Adult; Aged; Carbidopa; Drug Therapy, Combination; Electroencephalography; Evoked Potentials, Visual; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pattern Recognition, Visual | 1985 |
Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Long-Term Care; Male; Metabolic Clearance Rate; Middle Aged; Motor Skills; Parkinson Disease; Reaction Time | 1989 |
Selegiline in the treatment of Parkinson's disease--long term experience.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Dopamine and memory function in Parkinson's disease.
Topics: Aged; Attention; Brain; Carbidopa; Dopamine; Drug Combinations; Female; Humans; Levodopa; Male; Memory; Mental Recall; Middle Aged; Motor Skills; Neuropsychological Tests; Parkinson Disease; Pattern Recognition, Visual; Receptors, Dopamine; Synaptic Transmission; Verbal Learning | 1989 |
Clinical and pharmacokinetic evaluation of controlled-release levodopa/carbidopa (CR-4) in parkinsonian patients with severe motor fluctuations: a six month follow-up study.
Topics: Adult; Aged; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1989 |
New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation. London, England, April 28 and 29, 1989. Proceedings.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1989 |
A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1989 |
Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease; Psychomotor Performance | 1989 |
Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Tablets | 1989 |
Treatment of early Parkinson's disease with controlled-release levodopa preparations.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Parkinson Disease | 1989 |
Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Experiences with Sinemet CR in the Paracelsus-Elena-Klinik.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1989 |
Long-term clinical efficacy of Sinemet CR in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease | 1989 |
Darkening of white hair in Parkinson's disease.
Topics: Carbidopa; Hair Color; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Magnitude of response to levodopa in Parkinson disease as it relates to peripheral and central measurements of levodopa and associated metabolites.
Topics: Aged; Carbidopa; Drug Combinations; Homovanillic Acid; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 1989 |
Adrenal medullary autograft transplantation into the striatum of patients with Parkinson's disease.
Topics: Adrenal Medulla; Adult; Carbidopa; Caudate Nucleus; Drug Combinations; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques | 1989 |
Correlates of memory in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Memory; Memory Disorders; Middle Aged; Movement Disorders; Neuropsychological Tests; Parkinson Disease | 1989 |
Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations.
Topics: Adult; Aged; Carbidopa; Disability Evaluation; Dominance, Cerebral; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Nerve Degeneration; Parkinson Disease; Substantia Nigra | 1989 |
Efficacy of sinemet CR4 in subgroups of patients with Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Biological Availability; Carbidopa; Corpus Striatum; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease | 1989 |
Levodopa and 3-O-methyldopa plasma levels in parkinsonian patients with stable and fluctuating motor response.
Topics: Aged; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1989 |
Increased dosage of carbidopa in parkinsonian patients on low carbidopa-levodopa regimen. Effect on levodopa bioavailability.
Topics: Aged; Aged, 80 and over; Biological Availability; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1989 |
Disability profiles and objective quantitative assessment in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carbidopa; Disability Evaluation; Drug Combinations; Female; Humans; Levodopa; Locomotion; Male; Middle Aged; Parkinson Disease; Posture; Psychomotor Performance; Reaction Time | 1989 |
Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet.
Topics: Adult; Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Mathematics; Middle Aged; Models, Theoretical; Parkinson Disease | 1989 |
[The problems of L-dopa therapy in the course of Parkinson syndrome].
Topics: Adult; Aged; Benserazide; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 1989 |
An open trial of controlled release carbidopa/L-dopa (sinemet CR) for the treatment of mild-to-moderate Parkinson's disease.
Topics: Aged; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Oxazines; Parkinson Disease | 1989 |
Acute postoperative confusion and hallucinations in Parkinson disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Cognition Disorders; Confusion; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Retrospective Studies; Risk | 1989 |
Cerebrospinal fluid indices of blood-brain barrier permeability following adrenal-brain transplantation in patients with Parkinson's disease.
Topics: Adrenal Medulla; Adult; Blood-Brain Barrier; Brain; Capillary Permeability; Carbidopa; Caudate Nucleus; Humans; Immunoglobulin G; Male; Middle Aged; Osmolar Concentration; Parkinson Disease; Serum Albumin; Tomography, X-Ray Computed | 1989 |
Acetaminophen metabolism by cytochrome P450 monooxygenases in Parkinson's disease.
Topics: Acetaminophen; Carbidopa; Cytochrome P-450 Enzyme System; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Levodopa consumption reduces dopaminergic receptor responsiveness in Parkinson's disease.
Topics: Aged; Apomorphine; Carbidopa; Drug Resistance; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Receptors, Dopamine | 1989 |
Tremors in early Parkinson's disease.
Topics: Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Oxazines; Parkinson Disease; Tremor | 1989 |
ECT and Parkinson's disease revisited: a "naturalistic" study.
Topics: Aged; Carbidopa; Confusion; Depressive Disorder; Electroconvulsive Therapy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1989 |
Active and inactive L-prolyl-L-leucyl glycinamide synthetic analogs in rat models of levodopa-treated Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Carbidopa; Dipeptides; Drug Synergism; Drug Therapy, Combination; Levodopa; Motor Activity; MSH Release-Inhibiting Hormone; Neuropeptides; Parkinson Disease; Peptides, Cyclic; Rats; Structure-Activity Relationship | 1985 |
(+)-4-Propyl-9-hydroxynaphthoxazine in Parkinson's disease.
Topics: Animals; Callithrix; Carbidopa; Domperidone; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Oxazines; Parkinson Disease; Time Factors | 1986 |
Painful Parkinson's disease.
Topics: Acute Disease; Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Pain; Parkinson Disease; Time Factors | 1986 |
MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Dopamine Agents; Female; Humans; Hypromellose Derivatives; Lactose; Levodopa; Lisuride; Methylcellulose; Middle Aged; Nausea; Oxazines; Parkinson Disease; Pergolide; Psychomotor Performance; Receptors, Dopamine | 1988 |
Parkinson's disease, depression, and the on-off phenomenon.
Topics: Bromocriptine; Carbidopa; Depressive Disorder; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease | 1989 |
Dose-dependent memory impairment in Parkinson's disease.
Topics: Carbidopa; Dopamine; Drug Combinations; Humans; Levodopa; Memory Disorders; Parkinson Disease | 1989 |
Comprehensive care of the patient with Parkinson's disease.
Topics: Aged; Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Muscle Rigidity; Parasympatholytics; Parkinson Disease; Patient Care Planning; Patient Care Team; Tremor | 1986 |
Pharmacokinetics of L-dopa in patients with Parkinson's disease.
Topics: Biotransformation; Carbidopa; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Disability Evaluation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Kinetics; Levodopa; Methyldopa; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D2; Tiapamil Hydrochloride | 1987 |
Visual evoked potentials in parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans.
Topics: Adult; Aged; Brain; Carbidopa; Dopamine; Evoked Potentials, Visual; Female; Haloperidol; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Synaptic Transmission; Visual Pathways | 1986 |
Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Droxidopa; Drug Therapy, Combination; Glycols; Humans; Methoxyhydroxyphenylglycol; Middle Aged; Norepinephrine; Parkinson Disease; Serine | 1986 |
Effect of supplemental carbidopa on bioavailability of L-dopa.
Topics: Aged; Biological Availability; Carbidopa; Dihydroxyphenylalanine; Drug Administration Schedule; Humans; Levodopa; Parkinson Disease | 1986 |
Determination of plasma [18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Carbidopa; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Dystonia; Humans; Kinetics; Metabolic Clearance Rate; Parkinson Disease; Pyridines; Tomography, Emission-Computed | 1986 |
[Therapeutic strategies and tactics in parkinsonism].
Topics: Amantadine; Antidepressive Agents; Antiparkinson Agents; Benserazide; Carbidopa; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Motor Skills; Parkinson Disease; Selegiline; Sleep Initiation and Maintenance Disorders | 1986 |
The visual system in Parkinson's disease.
Topics: Animals; Carbidopa; Drug Therapy, Combination; Evoked Potentials, Visual; Haplorhini; Humans; Levodopa; Parkinson Disease; Rats; Reaction Time; Vision Disorders; Vision Tests; Visual Acuity | 1987 |
Current and future approaches to therapy.
Topics: Antiparkinson Agents; Benserazide; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Parkinson Disease; Selegiline | 1987 |
Drugs for parkinsonism.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1988 |
Acute exacerbation of Parkinson's disease with sulindac.
Topics: Back Pain; Carbidopa; Drug Combinations; Humans; Indenes; Levodopa; Male; Middle Aged; Parkinson Disease; Sulindac | 1985 |
Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease.
Topics: Animals; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Ketones; Levodopa; Male; Mice; Motor Activity; Parkinson Disease; Pentanones; Rats; Rats, Inbred Strains; Rotation | 1988 |
Treatment of Parkinson's disease.
Topics: Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pergolide | 1988 |
Improved high-performance liquid chromatographic analysis with double detection system for L-dopa, its metabolites and carbidopa in plasma of parkinsonian patients under L-dopa therapy.
Topics: Carbidopa; Catecholamines; Chromatography, High Pressure Liquid; Electrochemistry; Humans; Levodopa; Parkinson Disease; Spectrometry, Fluorescence | 1988 |
Cerebrospinal fluid amino compounds in Parkinson's disease. Alterations due to carbidopa/levodopa.
Topics: Adult; Aged; Amino Acids; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
International symposium on early dopamine agonist therapy of Parkinson's disease.
Topics: Animals; Bromocriptine; Carbidopa; Dopamine; Humans; Levodopa; Parkinson Disease; Pergolide; Time Factors | 1988 |
Drug-induced alzheimerism.
Topics: Aged; Alzheimer Disease; Biperiden; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Parkinson Disease; Piperidines | 1988 |
Lack of pharmacokinetic influence on levodopa by bromocriptine.
Topics: Bromocriptine; Carbidopa; Chromatography, High Pressure Liquid; Drug Interactions; Female; Humans; Levodopa; Middle Aged; Parkinson Disease | 1988 |
Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Evaluation; Humans; Levodopa; Parkinson Disease | 1988 |
Peripheral pharmacokinetic parameters of levodopa/carbidopa and the on-off phenomenon in parkinsonian patients.
Topics: Age Factors; Aged; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
False positive diagnosis of phaeochromocytoma in a patient with Parkinson's disease receiving levodopa.
Topics: Adrenal Gland Neoplasms; Aged; Carbidopa; Diagnostic Errors; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Pheochromocytoma; Vanilmandelic Acid | 1988 |
Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism.
Topics: Adult; Carbidopa; Drug Therapy, Combination; Duodenum; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
[Cholestasis caused by Nakom].
Topics: Antiparkinson Agents; Carbidopa; Cholestasis; Diagnosis, Differential; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
The adrenal medullary transplant operation for Parkinson's disease: clinical observations in five patients.
Topics: Adrenal Medulla; Adult; Carbidopa; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurosurgery; Parkinson Disease; Postoperative Complications | 1988 |
Mood swings associated with the 'on-off' phenomenon in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Depressive Disorder; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Mood Disorders; Parkinson Disease; Parkinson Disease, Secondary | 1987 |
Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Domperidone; Ergolines; Female; Humans; Infusions, Intravenous; Levodopa; Lisuride; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1986 |
Use of carbidopa as an adjuvant to levodopa/carbidopa therapy in patients with Parkinson's disease.
Topics: Aged; Carbidopa; Drug Antagonism; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease | 1986 |
Drug-induced myoclonus.
Topics: 5-Hydroxytryptophan; Anesthetics; Animals; Anti-Bacterial Agents; Antidepressive Agents; Bismuth; Carbidopa; Electroencephalography; Gasoline; Guinea Pigs; Humans; Hydrocarbons, Brominated; Imipramine; Levodopa; Methysergide; Models, Biological; Myoclonus; Parkinson Disease; Sleep | 1986 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Rats | 1986 |
Idiopathic Parkinson's disease in a chronic schizophrenic patient: long-term treatment with clozapine and L-dopa.
Topics: Adult; Carbidopa; Clozapine; Dibenzazepines; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Male; Parkinson Disease; Schizophrenia | 1987 |
Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period.
Topics: Aged; Carbidopa; Drug Combinations; Humans; Levodopa; Locus Coeruleus; Male; Parkinson Disease; Substantia Nigra | 1986 |
Levodopa-induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson's disease. Lack of correlation with clinical or neuropsychological improvements.
Topics: Administration, Oral; Aged; Bromocriptine; Carbidopa; Cerebrovascular Circulation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Regional Blood Flow; Tomography, Emission-Computed | 1987 |
Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 1987 |
A case of normal pressure hydrocephalus presenting as levodopa responsive parkinsonism.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Hydrocephalus; Hydrocephalus, Normal Pressure; Levodopa; Middle Aged; Parkinson Disease | 1987 |
Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet).
Topics: Adult; Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease | 1987 |
Stridor during dystonic phases of Parkinson's disease.
Topics: Adult; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Respiratory Sounds | 1987 |
Fluctuations in plasma dopamine level impair memory in Parkinson's disease.
Topics: Carbidopa; Dopamine; Humans; Levodopa; Memory; Parkinson Disease | 1987 |
Controlled-release Sinemet.
Topics: Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1987 |
Dietary influences on the antiparkinsonian response to levodopa.
Topics: Amino Acids; Carbidopa; Dietary Proteins; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1987 |
Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.
Topics: Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Paranoid Disorders; Parkinson Disease; Patient Acceptance of Health Care; Time Factors | 1987 |
Sinemet in Parkinson's disease: efficacy with and without food.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Diet; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1986 |
Pharmacotherapy: problems and practices.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1986 |
L-dopa induced "serotonin syndrome" in a parkinsonian patient on bromocriptine.
Topics: Aged; Bromocriptine; Carbidopa; Drug Combinations; Drug Interactions; Humans; Levodopa; Male; Myoclonus; Parkinson Disease; Serotonin | 1986 |
Drugs for parkinsonism.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1986 |
Akinetic parkinsonism and the catatonic syndrome: an overview.
Topics: Adult; Akinetic Mutism; Benztropine; Carbidopa; Catatonia; Humans; Levodopa; Male; Parasympatholytics; Parkinson Disease; Syndrome | 1986 |
Dystonia-Parkinson syndrome: differential effects of levodopa and dopamine agonists.
Topics: Adult; Bromocriptine; Carbidopa; Dystonia; Ergolines; Humans; Levodopa; Meige Syndrome; Middle Aged; Parkinson Disease; Pergolide; Torticollis | 1986 |
Management of Parkinson's disease in general practice.
Topics: Aged; Benserazide; Bromocriptine; Carbidopa; Drug Combinations; Family Practice; Humans; Levodopa; Medical Audit; Parkinson Disease | 1986 |
Clinical and biochemical studies with controlled-release levodopa/carbidopa.
Topics: Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1986 |
Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations.
Topics: Adult; Aged; Carbidopa; Drug Combinations; Duodenum; Female; Gastric Emptying; Humans; Intubation, Gastrointestinal; Levodopa; Male; Parkinson Disease | 1986 |
Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carbidopa; Domperidone; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1986 |
Effect of antacid on levodopa therapy.
Topics: Aluminum Hydroxide; Bromocriptine; Carbidopa; Double-Blind Method; Drug Combinations; Drug Interactions; Humans; Levodopa; Magnesium; Magnesium Hydroxide; Parkinson Disease | 1986 |
Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nervous System Diseases; Parkinson Disease | 1987 |
Alleviation of severe emotional symptoms by carbidopa-levodopa, MSD, in a Parkinson's patient: a personal report.
Topics: Affective Symptoms; Aged; Carbidopa; Dopamine; Drug Combinations; Emotions; Humans; Levodopa; Male; Parkinson Disease | 1987 |
Juvenile onset Parkinson's disease.
Topics: Adolescent; Adult; Carbidopa; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1987 |
Parkinson's disease: progression and mortality.
Topics: Carbidopa; Disability Evaluation; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Middle Aged; Parkinson Disease | 1987 |
Low-dosage treatment in de novo patients with Parkinson's disease: a prospective study.
Topics: Aged; Bromocriptine; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Orphenadrine; Parkinson Disease | 1987 |
Pergolide mesylate: four years experience in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1987 |
Controversies in the treatment of Parkinson's disease.
Topics: Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1985 |
Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Adult; Carbidopa; Chronic Disease; Drug Combinations; Female; Humans; Levodopa; Male; Parkinson Disease; Pyridines; Substance-Related Disorders; Substantia Nigra | 1985 |
Parkinson disease. Individualizing therapy.
Topics: Aged; Bromocriptine; Carbidopa; Central Nervous System Diseases; Diagnosis, Differential; Gait; Humans; Levodopa; Male; Motor Activity; Parkinson Disease; Psychoses, Substance-Induced; Tremor | 1985 |
[L-dopa therapy of parkinson syndrome].
Topics: Benserazide; Biotransformation; Carbidopa; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Parkinson Disease; Receptors, Dopamine | 1985 |
Deprenyl in Parkinson disease: personal experience.
Topics: Adult; Aged; Benserazide; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1985 |
Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators.
Topics: Aged; Carbidopa; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease | 1986 |
Pharmacologic treatment of parkinsonian tremor.
Topics: Amantadine; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tremor; Trihexyphenidyl | 1986 |
Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause.
Topics: Body Temperature Regulation; Bromocriptine; Carbidopa; Drug Combinations; Female; Fever; Humans; Levodopa; Malignant Hyperthermia; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Receptors, Dopamine | 1985 |
Autonomic cardiovascular responses in parkinsonism: effect of levodopa with dopa-decarboxylase inhibition.
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Autonomic Nervous System; Benserazide; Blood Pressure; Carbidopa; Drug Therapy, Combination; Female; Heart; Heart Rate; Humans; Hydrazines; Levodopa; Male; Middle Aged; Muscle Contraction; Parkinson Disease | 1985 |
Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy: a preliminary study.
Topics: Aged; Carbidopa; Drug Combinations; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Receptors, Dopamine; Sleep Wake Disorders; Sleep, REM | 1985 |
Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease | 1985 |
Inhibitory effect of drugs used in the treatment of Parkinson's disease on plasma monoamine oxidase activity.
Topics: Adult; Aged; Benserazide; Benzylamine Oxidase; Carbidopa; Female; Humans; Hydrazines; Isoenzymes; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease | 1985 |
Levodopa-induced dyskinesia: clinical observations.
Topics: Adult; Aged; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk | 1985 |
Audit of the drug treatment of Parkinson's disease in general practice.
Topics: Aged; Carbidopa; Family Practice; Humans; Levodopa; Medical Audit; Middle Aged; Parasympatholytics; Parkinson Disease | 1985 |
Auditory and somatosensory evoked potentials (AEPs and SEPs) and ballistic movements in Parkinson disease.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Electromyography; Evoked Potentials, Auditory; Evoked Potentials, Somatosensory; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1985 |
The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Drug Therapy, Combination; Female; Half-Life; Humans; Infusions, Parenteral; Kinetics; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Parkinson Disease | 1985 |
[Drug therapy of Parkinson's disease].
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1985 |
[Combined therapy of carbidopa and levodopa in Parkinson's disease].
Topics: Adult; Aged; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1985 |
[Clinical significance of cramps of the lower extremities in patients with parkinsonism].
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Leg; Levodopa; Male; Middle Aged; Muscle Cramp; Parkinson Disease | 1985 |
Carbidopa dosage modifies L-dopa induced side effects and blood levels of L-dopa and other amino acids in advanced parkinsonism.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease; Tryptophan; Tyrosine | 1985 |
[Sclerodermiform and poikilodermal syndrome observed during treatment with carbidopa and 5-hydroxytryptophan].
Topics: Aged; Carbidopa; Drug Therapy, Combination; Humans; Male; Parkinson Disease; Photosensitivity Disorders; Pigmentation Disorders; Scleroderma, Localized | 1985 |
M.I.F.: effect on levodopa dyskinesias in man.
Topics: Antiparkinson Agents; Carbidopa; Carboxy-Lyases; Decarboxylation; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Humans; Melanocyte-Stimulating Hormones; Methylation; Movement Disorders; Parkinson Disease | 1973 |
[Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzyl Compounds; Carbidopa; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease; Phenols | 1974 |
[Treatment of parkinsonism by L-dopa and dopa-decarboxylase inhibitor in a single tablet].
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Drug Combinations; Humans; Hydrazines; Levodopa; Parkinson Disease | 1974 |
Short- and long-term approaches to the "on-off" phenomenon.
Topics: Apomorphine; Carbidopa; Dietary Proteins; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Movement Disorders; Parkinson Disease; Time Factors | 1974 |
The "on-off" side effect of L-DOPA.
Topics: Age Factors; Amitriptyline; Aromatic Amino Acid Decarboxylase Inhibitors; Athetosis; Carbidopa; Catechol O-Methyltransferase Inhibitors; Chlordiazepoxide; Chorea; Desipramine; Diazepam; Dietary Proteins; Enzyme Inhibitors; Female; Humans; Imipramine; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Physical Exertion; Picolinic Acids; Prochlorperazine; Sex Factors; Stress, Psychological | 1974 |
[A year of treatment with carbidopa and levodopa in Parkinsonian patients].
Topics: Carbidopa; Drug Evaluation; Female; Humans; Levodopa; Male; Parkinson Disease; Tablets; Time Factors | 1974 |
Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.
Topics: Aged; Carbidopa; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1974 |
Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase.
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Dihydroxyphenylalanine; Evaluation Studies as Topic; Female; Humans; Hydrazines; Male; Middle Aged; Parkinson Disease | 1973 |
L-Dopa, B 6 , and alpha-methyldopa hydrazine.
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Carbidopa; Dihydroxyphenylalanine; Dopamine; Drug Synergism; Female; Humans; Hydrazines; Male; Middle Aged; Parkinson Disease; Pyridoxine | 1973 |
An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy.
Topics: Aged; Carbidopa; Diagnosis, Differential; Dihydroxyphenylalanine; Evaluation Studies as Topic; Female; Homovanillic Acid; Humans; Hydrazines; Male; Muscle Rigidity; Muscles; Neurologic Examination; Parkinson Disease; Tremor | 1973 |
Monitoring phenylalanine-tyrosine metabolism by high-resolution liquid chromatography of urine.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Autistic Disorder; Carbidopa; Catechols; Child; Chromatography, Gas; Chromatography, Ion Exchange; Dihydroxyphenylalanine; Hippurates; Homovanillic Acid; Humans; Hyperkinesis; Intellectual Disability; Lactates; Mandelic Acids; Mass Spectrometry; Methods; Nervous System Diseases; Parkinson Disease; Phenylacetates; Phenylalanine; Spectrophotometry, Ultraviolet; Tyrosine | 1973 |
Levodopa and dopamine in cerebrospinal fluid.
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benztropine; Carbidopa; Dihydroxyphenylalanine; Dopamine; Drug Synergism; Evaluation Studies as Topic; Female; Humans; Male; Middle Aged; Parkinson Disease; Pyridoxine; Spinal Puncture; Trihexyphenidyl | 1973 |
Levodopa-induced dyskinesias. Comparison in Parkinsonism-dementia and amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Carbidopa; Dementia; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1973 |
Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
Topics: Brain; Carbidopa; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Homovanillic Acid; Humans; Hydrazines; Parkinson Disease; Pyridoxine | 1973 |
Reversal of reserpine-induced bradykinesia by alpha-methyldopa--new light on its modus operandi.
Topics: Animals; Carbidopa; Chlorpromazine; Dihydroxyphenylalanine; Disease Models, Animal; Disulfiram; Dose-Response Relationship, Drug; Drug Synergism; Methyldopa; Mice; Movement Disorders; Parkinson Disease; Phenoxybenzamine; Pimozide; Reserpine | 1974 |
Levodopa, carbidopa, and pyridoxine in Parkinson disease. Metabolic interactions.
Topics: Carbidopa; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Drug Interactions; Drug Synergism; Homovanillic Acid; Humans; Hydrazines; Parkinson Disease; Pyridoxine | 1974 |
Carbidopa in Parkinson disease and in nausea and vomiting of levodopa.
Topics: Aged; Athetosis; Carbidopa; Chorea; Dihydroxyphenylalanine; Evaluation Studies as Topic; Female; Humans; Hydrazines; Male; Middle Aged; Nausea; Parkinson Disease; Vomiting | 1974 |
Parkinsonism-dementia of Guam: treatment with levodopa and L-alpha-methyldopahydrazine.
Topics: Adult; Aged; Carbidopa; Dementia; Dihydroxyphenylalanine; Drug Synergism; Evaluation Studies as Topic; Female; Humans; Hydrazines; Male; Middle Aged; Pacific Islands; Parkinson Disease | 1974 |
"On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine.
Topics: Adult; Carbidopa; Dihydroxyphenylalanine; Drug Synergism; Evaluation Studies as Topic; Female; Homovanillic Acid; Humans; Hydrazines; Injections, Intramuscular; Male; Methyldopa; Middle Aged; Movement Disorders; Parkinson Disease; Pyridoxine | 1974 |
Ro 4-4602 and levodopa in the treatment of Parkinsonism.
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Basal Ganglia Diseases; Carbidopa; Dihydroxyphenylalanine; Drug Synergism; Evaluation Studies as Topic; Female; Gastrointestinal Diseases; Humans; Hydrazines; Male; Middle Aged; Parkinson Disease | 1974 |
Coupling of hypotensive and anit-Parkinson effects with two dopaminergic drugs.
Topics: Apomorphine; Blood Pressure; Brain; Carbidopa; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Synergism; Humans; Hydrazines; Hypotension; Parkinson Disease; Time Factors | 1971 |